

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

Attorney Docket No.

240083.508D2

First Inventor or Application Identifier

Mary E. Brunkow

Title

COMPOSITIONS AND METHODS FOR
INCREASING BONE MINERALIZATION

Express Mail Label No.

EL615483938US

Only for nonprovisional applications under 37 CFR § 1.53(b)

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 202311. ☒ General Authorization Form & Fee Transmittal
(Submit an original and a duplicate for fee processing)2. ☒ Specification [Total Pages] **108**
(preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention

- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☒ Copy Drawing(s) (35 USC 113) [Total Sheets] **6**4. Oath or Declaration [Total Pages] **4**

- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior
application,
see 37 CFR 1.63(d)(2) and 1.33(b)

5. ☐ Incorporation By Reference (useable if box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer-Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8. ☐ Assignment Papers (cover sheet & document(s))
- 9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Copy of Power of Attorney
- 10. ☐ English Translation Document (if applicable)
- 11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- 12. ☒ Preliminary Amendment
- 13. ☒ Return Receipt Postcard
- 14. ☐ Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired
- 15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 16. ☒ Other: Certificate of Express Mail
Check No. 13127 for \$ 950

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment

☐ Continuation ☒ Divisional ☐ Continuation-In-Part (CIP) of prior Application No.: 09/449,218Prior application information: Examiner Kathleen M. KerrGroup / Art Unit 1652☒ Claims the benefit of Provisional Application No. 60/110,283, filed 11/27/98**CORRESPONDENCE ADDRESS**Gary M. Myles, Ph.D.
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900 Fax: (206) 682-6031

Respectfully submitted,

TYPED or PRINTED NAME Gary M. Myles, Ph.D.SIGNATURE Gary M. MylesREGISTRATION NO. 46,209Date September 21, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mary E. Brunkow, Seattle, Washington;
David J. Galas, Claremont, California;
Brian Kovacevich, Renton, Washington;
John T. Mulligan, Seattle, Washington;
Bryan W. Paper, Seattle, Washington;
Jeffrey Van Ness, Seattle, Washington; and
David G. Winkler, Seattle, Washington

Filed : September 21, 2000

For : COMPOSITIONS AND METHODS FOR INCREASING BONE
MINERALIZATION

Docket No. : 240083.508D2

Date : September 21, 2000

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Assistant Commissioner for Patents:

I hereby certify that the enclosures listed below are being deposited with the United States Postal Service "EXPRESS MAIL Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Certificate No. EL615483938US, on September 21, 2000, addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Stephen Plante / Jeanette West / Susan Johnson

GMM:cew

Enclosures:


Postcard
Check No. 13127 for \$ 950.00
Form PTO/SB/05
Preliminary Amendment
General Authorization (+ copy)
Copy of Specification, Claims, Abstract (108 pages)
Copy of Sequence Listing (29 pages)
Copy of 6 Sheets of Drawings (Figures 1-6)
Copy of Declaration and Power of Attorney

For	Number filed	Number extra		Rate		
Basic Fee						\$ 690.00
Total Claims	15	0	X	\$	=	\$ 0
Independent Claims	1	0	X	\$	=	\$ 0
Multiple Dependent Claim					+	\$ 260.00
Assignment Fee					+	\$
TOTAL FILING FEE						\$ 950.00
Extension-of-time fee (parent)					+	\$
TOTAL						\$ 950.00

A check in the amount of \$950.00 is enclosed to cover the filing fee.

The Assistant Commissioner is authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required, or credit any overpayment, to Deposit Account No. 19-1090. A duplicate copy of this request is enclosed.

Date September 21, 2000


 Gary M. Myles, Ph.D.
 Registration No. 46,209

GMM:cew

Seed Intellectual Property Law Group PLLC
 701 Fifth Avenue, Suite 6300
 Seattle, Washington 98104-7092
 Phone: (206) 622-4900
 Fax: (206) 682-6031

U:\ GaryM\client folders\Chiroscience\508D2\Divisional Application

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Present Application:

Applicants : Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, and David G. Winkler
Title : COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION
Docket No. : 240083.508D2
Date : September 21, 2000

Prior Application:

Examiner : Kathleen M. Kerr
Art Unit : 1652
Application No. : 09/449,218

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents:

Please amend the above-identified application as follows:

In the Specification:

Please amend the specification as follows:

On page 1, please delete lines 4-6 and replace therefor:

-- CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of pending United States Patent Application No. 09/449,218 filed November 24, 1999; which application claims priority from United States Provisional Patent Application No. 60/110,283, filed November 27, 1998. --

In the Claims:

Please cancel claims 1-17, 20-21 and 23-87 without prejudice.

Please amend the following claims 18 and 19:

18. (Amended) An antibody which specifically binds to [the protein according to claim 17] an isolated protein, comprising a TGF-beta binding-protein encoded by an isolated nucleic acid molecule selected from the group consisting of:

(a) an isolated nucleic acid molecule comprising sequence ID Nos., 1, 5, 9, 11, 13, or, 15, or complementary sequence thereof;

(b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and

(c) an isolated nucleic acid that encodes a TGF-beta binding-protein according to (a) or (b).

19. (Amended) The antibody according to [claim 18] any one of claims 18 and 88-93 wherein said antibody is a monoclonal antibody.

Please add the following new claims 88-93:

— 88. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 2.

89. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 6.

90. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 10.

91. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 12.

92. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 14.

93. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 16. --


REMARKS

With entry of this Preliminary Amendment, claims 18-19, 22 and 88-93 are pending in this application. By this Amendment, the specification is amended to add the section entitled "CROSS-REFERENCE TO RELATED APPLICATION" which section recites Applicants' claim to priority. Also by this Amendment, claims 18-19 are amended and new claims 88-93 are added to incorporate the subject matter of cancelled claims. None of these amendments add new matter to the application. Applicants respectfully request entry of this amendment and consideration of the present application.

Applicants believe that the application is in condition for allowance and respectfully request that the Examiner issue a Notice to that effect.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Gary M. Myles, Ph.D.

Registration No. 46,209

GMM:cew

Enclosures:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

U:\ GaryM\client folders\Chiroscience\240083\508D2 \Divisional application\Preliminary Amendment as filed.doc

COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application
5 No. 60/110,283 filed November 27, 1998, which application is incorporated by
reference in its entirety.

TECHNICAL FIELD

The present invention relates generally to pharmaceutical products and
methods and, more specifically, to methods and compositions suitable for increasing the
10 mineral content of bone. Such compositions and methods may be utilized to treat a
wide variety of conditions, including for example, osteopenia, osteoporosis, fractures
and other disorders in which low bone mineral density are a hallmark of the disease.

BACKGROUND OF THE INVENTION

Two or three distinct phases of changes to bone mass occur over the life
15 of an individual (see Riggs, *West J. Med.* 154:63-77, 1991). The first phase occurs in
both men and women, and proceeds to attainment of a peak bone mass. This first phase
is achieved through linear growth of the endochondral growth plates, and radial growth
due to a rate of periosteal apposition. The second phase begins around age 30 for
trabecular bone (flat bones such as the vertebrae and pelvis) and about age 40 for
20 cortical bone (e.g., long bones found in the limbs) and continues to old age. This phase
is characterized by slow bone loss, and occurs in both men and women. In women, a
third phase of bone loss also occurs, most likely due to postmenopausal estrogen
deficiencies. During this phase alone, women may lose an additional 10% of bone mass
from the cortical bone and 25% from the trabecular compartment (see Riggs, *supra*).

25 Loss of bone mineral content can be caused by a wide variety of
conditions, and may result in significant medical problems. For example, osteoporosis
is a debilitating disease in humans characterized by marked decreases in skeletal bone

mass and mineral density, structural deterioration of bone including degradation of bone microarchitecture and corresponding increases in bone fragility and susceptibility to fracture in afflicted individuals. Osteoporosis in humans is preceded by clinical osteopenia (bone mineral density that is greater than one standard deviation but less than 2.5 standard deviations below the mean value for young adult bone), a condition found in approximately 25 million people in the United States. Another 7-8 million patients in the United States have been diagnosed with clinical osteoporosis (defined as bone mineral content greater than 2.5 standard deviations below that of mature young adult bone). Osteoporosis is one of the most expensive diseases for the health care system, costing tens of billions of dollars annually in the United States. In addition to health care-related costs, long-term residential care and lost working days add to the financial and social costs of this disease. Worldwide approximately 75 million people are at risk for osteoporosis.

The frequency of osteoporosis in the human population increases with age, and among Caucasians is predominant in women (who comprise 80% of the osteoporosis patient pool in the United States). The increased fragility and susceptibility to fracture of skeletal bone in the aged is aggravated by the greater risk of accidental falls in this population. More than 1.5 million osteoporosis-related bone fractures are reported in the United States each year. Fractured hips, wrists, and vertebrae are among the most common injuries associated with osteoporosis. Hip fractures in particular are extremely uncomfortable and expensive for the patient, and for women correlate with high rates of mortality and morbidity.

Although osteoporosis has been defined as an increase in the risk of fracture due to decreased bone mass, none of the presently available treatments for skeletal disorders can substantially increase the bone density of adults. There is a strong perception among all physicians that drugs are needed which could increase bone density in adults, particularly in the bones of the wrist, spinal column and hip that are at risk in osteopenia and osteoporosis.

Current strategies for the prevention of osteoporosis may offer some benefit to individuals but cannot ensure resolution of the disease. These strategies

include moderating physical activity (particularly in weight-bearing activities) with the onset of advanced age, including adequate calcium in the diet, and avoiding consumption of products containing alcohol or tobacco. For patients presenting with clinical osteopenia or osteoporosis, all current therapeutic drugs and strategies are
5 directed to reducing further loss of bone mass by inhibiting the process of bone absorption, a natural component of the bone remodeling process that occurs constitutively.

For example, estrogen is now being prescribed to retard bone loss. There is, however, some controversy over whether there is any long term benefit to patients
10 and whether there is any effect at all on patients over 75 years old. Moreover, use of estrogen is believed to increase the risk of breast and endometrial cancer.

High doses of dietary calcium, with or without vitamin D has also been suggested for postmenopausal women. However, high doses of calcium can often have unpleasant gastrointestinal side effects, and serum and urinary calcium levels must be
15 continuously monitored (see Khosla and Riggs, *Mayo Clin. Proc.* 70:978-982, 1995).

Other therapeutics which have been suggested include calcitonin, bisphosphonates, anabolic steroids and sodium fluoride. Such therapeutics however, have undesirable side effects (e.g., calcitonin and steroids may cause nausea and provoke an immune reaction, bisphosphonates and sodium fluoride may inhibit repair
20 of fractures, even though bone density increases modestly) that may prevent their usage (see Khosla and Riggs, *supra*).

No currently practiced therapeutic strategy involves a drug that stimulates or enhances the growth of new bone mass. The present invention provides compositions and methods which can be utilized to increase bone mineralization, and
25 thus may be utilized to treat a wide variety of conditions where it is desired to increase bone mass. Further, the present invention provides other, related advantages.

SUMMARY OF THE INVENTION

As noted above, the present invention provides a novel class or family of TGF-beta binding-proteins, as well as assays for selecting compounds which increase

bone mineral content and bone mineral density, compounds which increase bone mineral content and bone mineral density and methods for utilizing such compounds in the treatment or prevention of a wide variety of conditions.

Within one aspect of the present invention, isolated nucleic acid molecules are provided, wherein said nucleic acid molecules are selected from the group consisting of: (a) an isolated nucleic acid molecule comprising sequence ID Nos. 1, 5, 7, 9, 11, 13, or, 15, or complementary sequence thereof; (b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and (c) an isolated nucleic acid that encodes a TGF-beta binding-protein according to (a) or (b). Within related aspects of the present invention, isolated nucleic acid molecules are provided based upon hybridization to only a portion of one of the above-identified sequences (e.g., for (a) hybridization may be to a probe of at least 20, 25, 50, or 100 nucleotides selected from nucleotides 156 to 539 or 555 to 687 of Sequence ID No. 1). As should be readily evident, the necessary stringency to be utilized for hybridization may vary based upon the size of the probe. For example, for a 25-mer probe high stringency conditions could include: 60 mM Tris pH 8.0, 2 mM EDTA, 5x Denhardt's, 6x SSC, 0.1% (w/v) N-laurylsarcosine, 0.5% (w/v) NP-40 (nonidet P-40) overnight at 45 degrees C, followed by two washes with 0.2x SSC / 0.1% SDS at 45-50 degrees. For a 100-mer probe under low stringency conditions, suitable conditions might include the following: 5x SSPE, 5x Denhardt's, and 0.5% SDS overnight at 42-50 degrees, followed by two washes with 2x SSPE (or 2x SSC) / 0.1% SDS at 42-50 degrees.

Within related aspects of the present invention, isolated nucleic acid molecules are provided which have homology to Sequence ID Nos. 1, 5, 7, 9, 11, 13, or 15, at a 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Wilbur-Lipman algorithm. Representative examples of such isolated molecules include, for example, nucleic acid molecules which encode a protein comprising Sequence ID NOs. 2, 6, 10, 12, 14, or 16, or have homology to these sequences at a level of 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Lipman-Pearson algorithm.

Isolated nucleic acid molecules are typically less than 100kb in size, and,

within certain embodiments, less than 50kb, 25kb, 10kb, or even 5kb in size. Further, isolated nucleic acid molecules, within other embodiments, do not exist in a "library" of other unrelated nucleic acid molecules (*e.g.*, a subclone BAC such as described in GenBank Accession No. AC003098 and EMB No. AQ171546). However, isolated
5 nucleic acid molecules can be found in libraries of related molecules (*e.g.*, for shuffling, such as is described in U.S. Patent Nos. 5,837,458; 5,830,721; and 5,811,238). Finally, isolated nucleic acid molecules as described herein do not include nucleic acid molecules which encode Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

10 Also provided by the present invention are cloning vectors which contain the above-noted nucleic acid molecules, and expression vectors which comprise a promoter (*e.g.*, a regulatory sequence) operably linked to one of the above-noted nucleic acid molecules. Representative examples of suitable promoters include tissue-specific promoters, and viral - based promoters (*e.g.*, CMV-based promoters such as CMV I-E,
15 SV40 early promoter, and MuLV LTR). Expression vectors may also be based upon, or derived from viruses (*e.g.*, a "viral vector"). Representative examples of viral vectors include herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors. Also provided are host cells containing or comprising any of above-noted vectors (including for example, host cells of human, monkey, dog, rat,
20 or mouse origin).

Within other aspects of the present invention, methods of producing TGF-beta binding-proteins are provided, comprising the step of culturing the aforementioned host cell containing vector under conditions and for a time sufficient to produce the TGF-beta binding protein. Within further embodiments, the protein
25 produced by this method may be further purified (*e.g.*, by column chromatography, affinity purification, and the like). Hence, isolated proteins which are encoded by the above-noted nucleic acid molecules (*e.g.*, Sequence ID NOs. 2, 4, 6, 8, 10, 12, 14, or 16) may be readily produced given the disclosure of the subject application.

It should also be noted that the aforementioned proteins, or fragments
30 thereof, may be produced as fusion proteins. For example, within one aspect fusion

proteins are provided comprising a first polypeptide segment comprising a TGF-beta binding-protein encoded by a nucleic acid molecule as described above, or a portion thereof of at least 10, 20, 30, 50, or 100 amino acids in length, and a second polypeptide segment comprising a non-TGF-beta binding-protein. Within certain embodiments, the
 5 second polypeptide may be a tag suitable for purification or recognition (*e.g.*, a polypeptide comprising multiple anionic amino acid residues – see U.S. Patent No. 4,851,341), a marker (*e.g.*, green fluorescent protein, or alkaline phosphatase), or a toxic molecule (*e.g.*, ricin).

Within another aspect of the present invention, antibodies are provided
 10 which are capable of specifically binding the above-described class of TGF-beta binding proteins (*e.g.*, human BEER). Within various embodiments, the antibody may be a polyclonal antibody, or a monoclonal antibody (*e.g.*, of human or murine origin). Within further embodiments, the antibody is a fragment of an antibody which retains the binding characteristics of a whole antibody (*e.g.*, an F(ab')₂, F(ab)₂, Fab', Fab, or Fv
 15 fragment, or even a CDR). Also provided are hybridomas and other cells which are capable of producing or expressing the aforementioned antibodies.

Within related aspects of the invention, methods are provided detecting a TGF-beta binding protein, comprising the steps of incubating an antibody as described above under conditions and for a time sufficient to permit said antibody to bind to a
 20 TGF-beta binding protein, and detecting the binding. Within various embodiments the antibody may be bound to a solid support to facilitate washing or separation, and/or labeled. (*e.g.*, with a marker selected from the group consisting of enzymes, fluorescent proteins, and radioisotopes).

Within other aspects of the present invention, isolated oligonucleotides
 25 are provided which hybridize to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, or 18 or the complement thereto, under conditions of high stringency. Within further embodiments, the oligonucleotide may be found in the sequence which encodes Sequence ID Nos. 2, 4, 6, 8, 10, 12, 14, or 16. Within certain embodiments, the oligonucleotide is at least 15, 20, 30, 50, or 100 nucleotides in length.
 30 Within further embodiments, the oligonucleotide is labeled with another molecule (*e.g.*,

an enzyme, fluorescent molecule, or radioisotope). Also provided are primers which are capable of specifically amplifying all or a portion of the above-mentioned nucleic acid molecules which encode TGF-beta binding-proteins. As utilized herein, the term "specifically amplifying" should be understood to refer to primers which amplify the
 5 aforementioned TGF-beta binding-proteins, and not other TGF-beta binding proteins such as Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

Within related aspects of the present invention, methods are provided for detecting a nucleic acid molecule which encodes a TGF-beta binding protein, comprising the steps of incubating an oligonucleotide as described above under
 10 conditions of high stringency, and detecting hybridization of said oligonucleotide. Within certain embodiments, the oligonucleotide may be labeled and/or bound to a solid support.

Within other aspects of the present invention, ribozymes are provided which are capable of cleaving RNA which encodes one of the above-mentioned TGF-
 15 beta binding-proteins (*e.g.*, Sequence ID NOs. 2, 6, 8, 10, 12, 14, or 16). Such ribozymes may be composed of DNA, RNA (including 2'-O-methyl ribonucleic acids), nucleic acid analogs (*e.g.*, nucleic acids having phosphorothioate linkages) or mixtures thereof. Also provided are nucleic acid molecules (*e.g.*, DNA or cDNA) which encode these ribozymes, and vectors which are capable of expressing or producing the
 20 ribozymes. Representative examples of vectors include plasmids, retrotransposons, cosmids, and viral-based vectors (*e.g.*, viral vectors generated at least in part from a retrovirus, adenovirus, or, adeno-associated virus). Also provided are host cells (*e.g.*, human, dog, rat, or mouse cells) which contain these vectors. In certain embodiments, the host cell may be stably transformed with the vector.

25 Within further aspects of the invention, methods are provided for producing ribozymes either synthetically, or by *in vitro* or *in vivo* transcription. Within further embodiments, the ribozymes so produced may be further purified and/or formulated into pharmaceutical compositions (*e.g.*, the ribozyme or nucleic acid molecule encoding the ribozyme along with a pharmaceutically acceptable carrier or
 30 diluent). Similarly, the antisense oligonucleotides and antibodies or other selected

molecules described herein may be formulated into pharmaceutical compositions.

Within other aspects of the present invention, antisense oligonucleotides are provided comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, and wherein said oligonucleotide inhibits the expression of TGF-beta binding protein as described herein (e.g., human BEER). Within various embodiments, the oligonucleotide is 15, 20, 25, 30, 35, 40, or 50 nucleotides in length. Preferably, the oligonucleotide is less than 100, 75, or 60 nucleotides in length. As should be readily evident, the oligonucleotide may be comprised of one or more nucleic acid analogs, ribonucleic acids, or deoxyribonucleic acids. Further, the oligonucleotide may be modified by one or more linkages, including for example, covalent linkage such as a phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene(methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage. One representative example of a chimeric oligonucleotide is provided in U.S. Patent No. 5,989,912.

Within yet another aspect of the present invention, methods are provided for increasing bone mineralization, comprising introducing into a warm-blooded animal an effective amount of the ribozyme as described above. Within related aspects, such methods comprise the step of introducing into a patient an effective amount of the nucleic acid molecule or vector as described herein which is capable of producing the desired ribozyme, under conditions favoring transcription of the nucleic acid molecule to produce the ribozyme.

Within other aspects of the invention transgenic, non-human animals are provided. Within one embodiment a transgenic animal is provided whose germ cells and somatic cells contain a nucleic acid molecule encoding a TGF-beta binding-protein as described above which is operably linked to a promoter effective for the expression of the gene, the gene being introduced into the animal, or an ancestor of the animal, at an embryonic stage, with the proviso that said animal is not a human. Within other

embodiments, transgenic knockout animals are provided, comprising an animal whose germ cells and somatic cells comprise a disruption of at least one allele of an endogenous nucleic acid molecule which hybridizes to a nucleic acid molecule which encodes a TGF-binding protein as described herein, wherein the disruption prevents
 5 transcription of messenger RNA from said allele as compared to an animal without the disruption, with the proviso that the animal is not a human. Within various embodiments, the disruption is a nucleic acid deletion, substitution, or, insertion. Within other embodiments the transgenic animal is a mouse, rat, sheep, pig, or dog.

Within further aspects of the invention, kits are provided for the
 10 detection of TGF-beta binding-protein gene expression, comprising a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; (b) a nucleic acid molecule comprising the complement of the nucleotide sequence of (a); (c) a nucleic acid molecule that is a
 15 fragment of (a) or (b) of at least 15, 20 30, 50, 75, or, 100 nucleotides in length. Also provided are kits for the detection of a TGF-beta binding-protein which comprise a container that comprise one of the TGF-beta binding protein antibodies described herein.

For example, within one aspect of the present invention methods are
 20 provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing one or more candidate molecules with TGF-beta-binding-protein encoded by the nucleic acid molecule according to claim 1 and a selected member of the TGF-beta family of proteins (*e.g.*, BMP 5 or 6), (b) determining whether the candidate molecule alters the signaling of the TGF-beta
 25 family member, or alters the binding of the TGF-beta binding-protein to the TGF-beta family member. Within certain embodiments, the molecule alters the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation. Within this aspect of the present invention, the candidate molecule(s) may alter signaling or binding by, for example, either decreasing (*e.g.*, inhibiting), or increasing (*e.g.*, enhancing)
 30 signaling or binding.

Within yet another aspect, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. Representative examples of bone or analogues thereof include hydroxyapatite and primary human bone samples obtained via biopsy.

Within certain embodiments of the above-recited methods, the selected molecule is contained within a mixture of molecules and the methods may further comprise the step of isolating one or more molecules which are functional within the assay. Within yet other embodiments, TGF-beta family of proteins is bound to a solid support and the binding of TGF-beta binding-protein is measured or TGF-beta binding-protein are bound to a solid support and the binding of TGF-beta proteins are measured.

Utilizing methods such as those described above, a wide variety of molecules may be assayed for their ability to increase bone mineral content by inhibiting the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Representative examples of such molecules include proteins or peptides, organic molecules, and nucleic acid molecules.

Within other related aspects of the invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule identified from the assays recited herein. Within another aspect, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins, including bone morphogenic proteins (BMPs). Representative examples of suitable molecules include antisense molecules, ribozymes, ribozyme genes, and antibodies (e.g., a humanized antibody) which specifically recognize and alter the activity of the TGF-beta binding-protein.

Within another aspect of the present invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the steps of (a) introducing into cells which home to the bone a vector which directs the expression

of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and (b) administering the vector-containing cells to a warm-blooded animal. As utilized herein, it should be understood that cells "home to bone" if they localize within the bone matrix after
 5 peripheral administration. Within one embodiment, such methods further comprise, prior to the step of introducing, isolating cells from the marrow of bone which home to the bone. Within a further embodiment, the cells which home to bone are selected from the group consisting of CD34+ cells and osteoblasts.

Within other aspects of the present invention, molecules are provided
 10 (preferably isolated) which inhibit the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins.

Within further embodiments, the molecules may be provided as a composition, and can further comprise an inhibitor of bone resorption. Representative examples of such inhibitors include calcitonin, estrogen, a bisphosphonate, a growth
 15 factor having anti-resorptive activity and tamoxifen.

Representative examples of molecules which may be utilized in the afore-mentioned therapeutic contexts include, e.g., ribozymes, ribozyme genes, antisense molecules, and/or antibodies (e.g., humanized antibodies). Such molecules may depending upon their selection, used to alter, antagonize, or agonize the signalling
 20 or binding of a TGF-beta binding-protein family member as described herein

Within various embodiments of the invention, the above-described molecules and methods of treatment or prevention may be utilized on conditions such as osteoporosis, osteomalasia, periodontal disease, scurvy, Cushing's Disease, bone fracture and conditions due to limb immobilization and steroid usage.

25 These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration comparing the amino acid sequence of Human Dan; Human Gremlin; Human Cerberus and Human Beer. Arrows indicate the Cysteine backbone.

5 Figure 2 summarizes the results obtained from surveying a variety of human tissues for the expression of a TGF-beta binding-protein gene, specifically, the Human Beer gene. A semi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) procedure was used to amplify a portion of the gene from first-strand cDNA synthesized from total RNA (described in more detail in EXAMPLE 2A).

10 Figure 3 summarizes the results obtained from RNA *in situ* hybridization of mouse embryo sections, using a cRNA probe that is complementary to the mouse Beer transcript (described in more detail in EXAMPLE 2B). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

15 Figure 4 illustrates, by western blot analysis, the specificity of three different polyclonal antibodies for their respective antigens (described in more detail in EXAMPLE 4). Figure 4A shows specific reactivity of an anti-H. Beer antibody for H. Beer antigen, but not H. Dan or H. Gremlin. Figure 4B shows reactivity of an anti-H. Gremlin antibody for H. Gremlin antigen, but not H. Beer or H. Dan. Figure 4C shows
20 reactivity of an anti-H. Dan antibody for H. Dan, but not H. Beer or H. Gremlin.

Figure 5 illustrates, by western blot analysis, the selectivity of the TGF-beta binding-protein, Beer, for BMP-5 and BMP-6, but not BMP-4 (described in more detail in EXAMPLE 5).

25 Figure 6 demonstrates that the ionic interaction between the TGF-beta binding-protein, Beer, and BMP-5 has a dissociation constant in the 15-30 nM range.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

Prior to setting forth the invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

“Molecule” should be understood to include proteins or peptides (e.g., antibodies, recombinant binding partners, peptides with a desired binding affinity), nucleic acids (e.g., DNA, RNA, chimeric nucleic acid molecules, and nucleic acid analogues such as PNA); and organic or inorganic compounds.

“TGF-beta” should be understood to include any known or novel member of the TGF-beta super-family, which also includes bone morphogenic proteins (BMPs).

“TGF-beta receptor” should be understood to refer to the receptor specific for a particular member of the TGF-beta super-family (including bone morphogenic proteins (BMPs)).

“TGF-beta binding-protein” should be understood to refer to a protein with specific binding affinity for a particular member or subset of members of the TGF-beta super-family (including bone morphogenic proteins (BMPs)). Specific examples of TGF-beta binding-proteins include proteins encoded by Sequence ID Nos. 1, 5, 7, 9, 11, 13, and 15.

Inhibiting the “binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs)” should be understood to refer to molecules which allow the activation of TGF-beta or bone morphogenic proteins (BMPs), or allow the binding of TGF-beta family members including bone morphogenic proteins (BMPs) to their respective receptors, by removing or preventing TGF-beta from binding to TGF-binding-protein. Such inhibition may be accomplished, for example, by molecules which inhibit the binding of the TGF-beta binding-protein to specific members of the TGF-beta super-family.

“Vector” refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter

elements which are operably linked to the gene(s) of interest. The vector may be composed of either deoxyribonucleic acids ("DNA"), ribonucleic acids ("RNA"), or a combination of the two (e.g., a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more

5 selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

10 An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a TGF-binding protein that has been separated from the genomic DNA of a eukaryotic cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the

15 genome of an organism. The isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.

An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Within certain embodiments, a

20 particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining. "Isolated" when referring to organic molecules means that the compounds are greater than 90 percent pure utilizing methods which are well known in the art (e.g., NMR, melting point).

"Sclerosteosis" Sclerosteosis is a term that was applied by Hansen

25 (1967) (Hansen, H. G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases. The jaw has an unusually

30 square appearance in this condition.

"Humanized antibodies" are recombinant proteins in which murine complementary determining regions of monoclonal antibodies have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

5 As used herein, an "antibody fragment" is a portion of an antibody such as F(ab')₂, F(ab)₂, Fab', Fab, and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an anti-TGF-beta binding-protein monoclonal antibody fragment binds with an epitope of TGF-beta binding-protein.

10 The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light
15 and heavy variable regions are connected by a peptide linker ("sFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable
20 labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, enzymes, and other marker moieties.

As used herein, an "immunoconjugate" is a molecule comprising an anti-TGF-beta binding-protein antibody, or an antibody fragment, and a detectable label. An immunoconjugate has roughly the same, or only slightly reduced, ability to bind TGF-
25 beta binding-protein after conjugation as before conjugation.

Abbreviations: TGF-beta - "Transforming Growth Factor-beta"; TGF-bBP - "Transforming Growth Factor-beta binding-protein" (one representative TGF-bBP is designated "H. Beer"); BMP - "bone morphogenic protein"; PCR - "polymerase chain reaction"; RT-PCR - PCR process in which RNA is first transcribed

into DNA at the first step using reverse transcriptase (RT); cDNA - any DNA made by copying an RNA sequence into DNA form.

As noted above, the present invention provides a novel class of TGF-beta
 5 binding-proteins, as well as methods and compositions for increasing bone mineral
 content in warm-blooded animals. Briefly, the present inventions are based upon the
 unexpected discovery that a mutation in the gene which encodes a novel member of the
 TGF-beta binding-protein family results in a rare condition (sclerosteosis) characterized
 by bone mineral contents which are one- to four-fold higher than in normal individuals.
 10 Thus, as discussed in more detail below this discovery has led to the development of
 assays which may be utilized to select molecules which inhibit the binding of the TGF-
 beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins
 (BMPs), and methods of utilizing such molecules for increasing the bone mineral
 content of warm-blooded animals (including for example, humans).

15 DISCUSSION OF THE DISEASE KNOWN AS SCLEROSTEOSIS

Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H.
 G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin:
 Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis
 corticalis generalisata but possibly differing in radiologic appearance of the bone
 20 changes and in the presence of asymmetric cutaneous syndactyly of the index and
 middle fingers in many cases.

Sclerosteosis is now known to be an autosomal semi-dominant disorder
 which is characterized by widely disseminated sclerotic lesions of the bone in the adult.
 The condition is progressive. Sclerosteosis also has a developmental aspect which is
 25 associated with syndactyly (two or more fingers are fused together). The Sclerosteosis
 Syndrome is associated with large stature and many affected individuals attain a height
 of six feet or more. The bone mineral content of homozygotes can be 1 to 6 fold over
 normal individuals and bone mineral density can be 1 to 4 fold above normal values
 (e.g., from unaffected siblings).

The Sclerosteosis Syndrome occurs primarily in Afrikaaners of Dutch descent in South Africa. Approximately 1/140 individuals in the Afrikaaner population are carriers of the mutated gene (heterozygotes). The mutation shows 100% penetrance. There are anecdotal reports of increased of bone mineral density in heterozygotes with
 5 no associated pathologies (syndactyly or skull overgrowth).

It appears at the present time that there is no abnormality of the pituitary-hypothalamus axis in Sclerosteosis. In particular, there appears to be no over-production of growth hormone and cortisone. In addition, sex hormone levels are normal in affected individuals. However, bone turnover markers (osteoblast specific
 10 alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; (see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995) indicate that there is hyperosteoblastic activity associated with the disease but that there is normal to slightly decreased osteoclast activity as measured by markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma
 15 tartrate-resistant acid phosphatases and galactosyl hydroxylysine (see Comier, *supra*)).

Sclerosteosis is characterized by the continual deposition of bone throughout the skeleton during the lifetime of the affected individuals. In homozygotes the continual deposition of bone mineral leads to an overgrowth of bone in areas of the skeleton where there is an absence of mechanoreceptors (skull, jaw, cranium). In
 20 homozygotes with Sclerosteosis, the overgrowth of the bones of the skull leads to cranial compression and eventually to death due to excessive hydrostatic pressure on the brain stem. In all other parts of the skeleton there is a generalized and diffuse sclerosis. Cortical areas of the long bones are greatly thickened resulting in a substantial increase in bone strength. Trabecular connections are increased in thickness which in turn
 25 increases the strength of the trabecular bone. Sclerotic bones appear unusually opaque to x-rays.

As described in more detail in Example 1, the rare genetic mutation that is responsible for the Sclerosteosis syndrome has been localized to the region of human chromosome 17 that encodes a novel member of the TGF-beta binding-protein family
 30 (one representative example of which is designated "H. Beer"). As described in more

detail below, based upon this discovery, the mechanism of bone mineralization is more fully understood, allowing the development of assays for molecules which increase bone mineralization, and use of such molecules to increase bone mineral content, and in the treatment or prevention of a wide number of diseases.

5

TGF-BETA SUPER-FAMILY

The Transforming Growth Factor-beta (TGF-beta) super-family contains a variety of growth factors that share common sequence elements and structural motifs (at both the secondary and tertiary levels). This protein family is known to exert a wide spectrum of biological responses on a large variety of cell types. Many of them have important functions during the embryonal development in pattern formation and tissue specification; in adults they are involved, *e.g.*, in wound healing and bone repair and bone remodeling, and in the modulation of the immune system. In addition to the three TGF-beta's, the super-family includes the Bone Morphogenic Proteins (BMPs), Activins, Inhibins, Growth and Differentiation Factors (GDFs), and Glial-Derived Neurotrophic Factors (GDNFs). Primary classification is established through general sequence features that bin a specific protein into a general sub-family. Additional stratification within the sub-family is possible due to stricter sequence conservation between members of the smaller group. In certain instances, such as with BMP-5, BMP-6 and BMP-7, this can be as high as 75 percent amino acid homology between members of the smaller group. This level of identity enables a single representative sequence to illustrate the key biochemical elements of the sub-group that separates it from other members of the larger family.

TGF-beta signals by inducing the formation of hetero-oligomeric complexes of type I and type II receptors. The crystal structure of TGF-beta2 has been determined. The general fold of the TGF-beta2 monomer contains a stable, compact, cysteine knotlike structure formed by three disulphide bridges. Dimerization, stabilized by one disulphide bridge, is antiparallel.

TGF-beta family members initiate their cellular action by binding to receptors with intrinsic serine/threonine kinase activity. This receptor family consists of two subfamilies, denoted type I and type II receptors. Each member of the TGF-beta

family binds to a characteristic combination of type I and type II receptors, both of which are needed for signaling. In the current model for TGF-beta receptor activation, TGF-beta first binds to the type II receptor (TbR-II), which occurs in the cell membrane in an oligomeric form with activated kinase. Thereafter, the type I receptor (TbR-I), which can not bind ligand in the absence of TbR-II, is recruited into the complex. TbR-II then phosphorylates TbR-I predominantly in a domain rich in glycine and serine residues (GS domain) in the juxtamembrane region, and thereby activates TbR-I.

Thus far seven type I receptors and five type II receptors have been identified.

10 BONE MORPHOGENIC PROTEINS (BMPs) ARE KEY REGULATORY PROTEINS IN DETERMINING BONE MINERAL DENSITY IN HUMANS

A major advance in the understanding of bone formation was the identification of the bone morphogenic proteins (BMPs), also known as osteogenic proteins (OPs), which regulate cartilage and bone differentiation in vivo. BMPs/OPs induce endochondral bone differentiation through a cascade of events which include formation of cartilage, hypertrophy and calcification of the cartilage, vascular invasion, differentiation of osteoblasts, and formation of bone. As described above, the BMPs/OPs (BMP 2-14, and osteogenic protein 1 and -2, OP-1 and OP-2) are members of the TGF-beta super-family. The striking evolutionary conservation between members the BMP/OP sub-family suggests that they are critical in the normal development and function of animals. Moreover, the presence of multiple forms of BMPs/OPs raises an important question about the biological relevance of this apparent redundancy. In addition to postfetal chondrogenesis and osteogenesis, the BMPs/OPs play multiple roles in skeletogenesis (including the development of craniofacial and dental tissues) and in embryonic development and organogenesis of parenchymatous organs, including the kidney. It is now understood that nature relies on common (and few) molecular mechanisms tailored to provide the emergence of specialized tissues and organs. The BMP/OP super-family is an elegant example of nature parsimony in programming multiple specialized functions deploying molecular isoforms with minor variation in amino acid motifs within highly conserved carboxy-terminal regions.

BMP ANTAGONISM

The BMP and Activin sub-families are subject to significant post-translational regulation. An intricate extracellular control system exists, whereby a high affinity antagonist is synthesized and exported, and subsequently complexes selectively
 5 with BMPs or activins to disrupt their biological activity (W.C. Smith (1999) *TIG 15*(1) 3-6). A number of these natural antagonists have been identified, and based on sequence divergence appear to have evolved independently due to the lack of primary sequence conservation. There has been no structural work to date on this class of proteins. Studies of these antagonists has highlighted a distinct preference for
 10 interacting and neutralizing BMP-2 and BMP-4. Furthermore, the mechanism of inhibition seems to differ for the different antagonists (S. Iemura et al. (1998) *Proc Natl Acad Sci USA* 95 9337-9342).

NOVEL TGF-BETA BINDING-PROTEINS

1. Background re: TGF-beta binding-proteins

15 As noted above, the present invention provides a novel class of TGF-beta binding-proteins that possess a nearly identical cysteine (disulfide) scaffold when compared to Human DAN, Human Gremlin, and Human Cerberus, and SCGF (U.S. Patent No. 5,780,263) but almost no homology at the nucleotide level (for background information, see generally Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M.,
 20 Harland, R.M., "The *Xenopus* Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities," *Molecular Cell* 1:673-683, 1998).

One representative example of the novel class of TGF-beta binding-proteins is disclosed in Sequence ID Nos. 1, 5, 9, 11, 13, and 15. Representative members of this class of binding proteins should also be understood to include variants
 25 of the TGF-beta binding-protein (e.g., Sequence ID Nos. 5 and 7). As utilized herein, a "TGF-beta binding-protein variant gene" refers to nucleic acid molecules that encode a polypeptide having an amino acid sequence that is a modification of SEQ ID Nos: 2, 10, 12, 14 or 16. Such variants include naturally-occurring polymorphisms or allelic variants of TGF-beta binding-protein genes, as well as synthetic genes that contain

conservative amino acid substitutions of these amino acid sequences. Additional variant forms of a TGF-beta binding-protein gene are nucleic acid molecules that contain insertions or deletions of the nucleotide sequences described herein. TGF-beta binding-protein variant genes can be identified by determining whether the genes
 5 hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 7, 9, 11, 13, or 15 under stringent conditions. In addition, TGF-beta binding-protein variant genes should encode a protein having a cysteine backbone.

As an alternative, TGF-beta binding-protein variant genes can be identified by sequence comparison. As used herein, two amino acid sequences have
 10 "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software
 15 programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc.
 20 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic Acids and Proteins," in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)).

A variant TGF-beta binding-protein should have at least a 50% amino
 25 acid sequence identity to SEQ ID NOS: 2, 6, 10, 12, 14 or 16 and preferably, greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity. Alternatively, TGF-beta binding-protein variants can be identified by having at least a 70% nucleotide sequence identity to SEQ ID NOS: 1, 5, 9, 11, 13 or 15. Moreover, the present invention contemplates TGF-beta binding-protein gene variants having greater than 75%, 80%,
 30 85%, 90%, or 95% identity to SEQ ID NO:1. Regardless of the particular method used

to identify a TGF-beta binding-protein variant gene or variant TGF-beta binding-protein, a variant TGF-beta binding-protein or a polypeptide encoded by a variant TGF-beta binding-protein gene can be functionally characterized by, for example, its ability to bind to and/or inhibit the signaling of a selected member of the TGF-beta family of proteins, or by its ability to bind specifically to an anti-TGF-beta binding-protein antibody.

The present invention includes functional fragments of TGF-beta binding-protein genes. Within the context of this invention, a "functional fragment" of a TGF-beta binding-protein gene refers to a nucleic acid molecule that encodes a portion of a TGF-beta binding-protein polypeptide which either (1) possesses the above-noted function activity, or (2) specifically binds with an anti-TGF-beta binding-protein antibody. For example, a functional fragment of a TGF-beta binding-protein gene described herein comprises a portion of the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or 15.

2. Isolation of the TGF-beta binding-protein gene

DNA molecules encoding a binding-protein gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon, for example, SEQ ID NO:1.

For example, the first step in the preparation of a cDNA library is to isolate RNA using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel et al. (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu et al., *Methods in Gene Biotechnology*, pages 33-41 (CRC Press, Inc. 1997)

["Wu (1997)"].

Alternatively, total RNA can be isolated by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Ausubel (1995) at pages 4-1 to 4-6; Wu (1997) at pages 33-41).

In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA by using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Ausubel (1995) at pages 4-11 to 4-12).

Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life Technologies, Inc. (Gaithersburg, Maryland), CLONTECH Laboratories, Inc. (Palo Alto, California), Promega Corporation (Madison, Wisconsin) and Stratagene Cloning Systems (La Jolla, California).

The basic approach for obtaining TGF-beta binding-protein cDNA clones can be modified by constructing a subtracted cDNA library which is enriched in TGF-binding-protein-specific cDNA molecules. Techniques for constructing subtracted libraries are well-known to those of skill in the art (see, for example, Sargent, "Isolation of Differentially Expressed Genes," in *Meth. Enzymol.* 152:423, 1987, and Wu et al. (eds.), "Construction and Screening of Subtracted and Complete Expression cDNA Libraries," in *Methods in Gene Biotechnology*, pages 29-65 (CRC Press, Inc. 1997)).

Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector (see, for example, Huynh et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52).

Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a pBluescript vector (Stratagene Cloning Systems; La Jolla.

California), a LambdaGEM-4 (Promega Corp.; Madison, Wisconsin) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Rockville, Maryland).

In order to amplify the cloned cDNA molecules, the cDNA library is
5 inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 cells, which can be obtained from Life Technologies, Inc. (Gaithersburg, Maryland).

A human genomic DNA library can be prepared by means well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-
10 327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

DNA fragments that are suitable for the production of a genomic library
15 can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules,
20 and ligation with appropriate ligases. Techniques for such manipulation are well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

Nucleic acid molecules that encode a TGF-beta binding-protein gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide
25 primers having nucleotide sequences that are based upon the nucleotide sequences of the human TGF-beta binding-protein gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu et al., "Use of the Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.),
30 pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to

isolate related genes are described by, for example, Preston, "Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

5 Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture Collection (Rockville, Maryland).

A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (*see, for*
10 *example*, Ausubel (1995) at pages 6-1 to 6-11).

Anti-TGF-beta binding-protein antibodies, produced as described below, can also be used to isolate DNA sequences that encode TGF-beta binding-protein genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries; or the antibodies can be used for immunoscreening following
15 hybrid selection and translation (*see, for example*, Ausubel (1995) at pages 6-12 to 6-16; Margolis et al., "Screening λ expression libraries with antibody and protein probes," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 1-14 (Oxford University Press 1995)).

The sequence of a TGF-beta binding-protein cDNA or TGF-beta
20 binding-protein genomic fragment can be determined using standard methods. Moreover, the identification of genomic fragments containing a TGF-beta binding-protein promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (*see, generally*, Ausubel (1995)).

As an alternative, a TGF-beta binding-protein gene can be obtained by
25 synthesizing DNA molecules using mutually priming long oligonucleotides and the nucleotide sequences described herein (*see, for example*, Ausubel (1995) at pages 8-8 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang et al., *Plant Molec. Biol.* 21:1131, 1993; Bambot et al., *PCR Methods and Applications* 2:266, 1993; Dillon
30 et al., "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic

Genes," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 263-268, (Humana Press, Inc. 1993); Holowachuk et al., *PCR Methods Appl.* 4:299, 1995).

3. Production of TGF-beta binding-protein genes

5 Nucleic acid molecules encoding variant TGF-beta binding-protein genes can be obtained by screening various cDNA or genomic libraries with polynucleotide probes having nucleotide sequences based upon SEQ ID NO:1, 5, 9, 11, 13, or 15, using procedures described above. TGF-beta binding-protein gene variants can also be constructed synthetically. For example, a nucleic acid molecule can be
10 devised that encodes a polypeptide having a conservative amino acid change, compared with the amino acid sequence of SEQ ID NOs: 2, 6, 8, 10, 12, 14, or 16. That is, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NOs: 2, 6, 8, 10, 12, 14 or 16, in which an alkyl amino acid is substituted for an alkyl amino acid in a TGF-beta binding-protein amino acid sequence, an aromatic amino acid
15 is substituted for an aromatic amino acid in a TGF-beta binding-protein amino acid sequence, a sulfur-containing amino acid is substituted for a sulfur-containing amino acid in a TGF-beta binding-protein amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a TGF-beta binding-protein amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a
20 TGF-beta binding-protein amino acid sequence, a basic amino acid is substituted for a basic amino acid in a TGF-beta binding-protein amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a TGF-beta binding-protein amino acid sequence.

Among the common amino acids, for example, a "conservative amino
25 acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. In making such substitutions, it is important to, where possible, maintain the cysteine

backbone outlined in Figure 1.

Conservative amino acid changes in a TGF-beta binding-protein gene can be introduced by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained, for example, by
 5 oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed Mutagenesis: A Practical Approach* (IRL Press 1991)). The functional ability of such variants can be determined using a standard method, such as the assay described herein. Alternatively, a variant TGF-beta binding-protein
 10 polypeptide can be identified by the ability to specifically bind anti-TGF-beta binding-protein antibodies.

Routine deletion analyses of nucleic acid molecules can be performed to obtain "functional fragments" of a nucleic acid molecule that encodes a TGF-beta binding-protein polypeptide. As an illustration, DNA molecules having the nucleotide
 15 sequence of SEQ ID NO:1 can be digested with *Bal31* nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for activity, or for the ability to bind anti-TGF-beta binding-protein antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce
 20 deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a TGF-beta binding-protein gene can be synthesized using the polymerase chain reaction.

Standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113, 1993; Content et al.,
 25 "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation, Vol. 1*, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., *J. Biol. Chem.*
 30 270:29270, 1995; Fukunaga et al., *J. Biol. Chem.* 270:25291, 1995; Yamaguchi et al.,

Biochem. Pharmacol. 50:1295, 1995; and Meisel et al., *Plant Molec. Biol.* 30:1, 1996.

The present invention also contemplates functional fragments of a TGF-beta binding-protein gene that have conservative amino acid changes.

A TGF-beta binding-protein variant gene can be identified on the basis
 5 of structure by determining the level of identity with nucleotide and amino acid sequences of SEQ ID NOs: 1, 5, 9, 11, 13, or, 15 and 2, 6, 10, 12, 14, or 16, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant TGF-beta binding-protein gene can hybridize under stringent conditions to a nucleic
 10 acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or, 15, or a portion thereof of at least 15 or 20 nucleotides in length. As an illustration of stringent hybridization conditions, a nucleic acid molecule having a variant TGF-beta binding-protein sequence can bind with a fragment of a nucleic acid molecule having a sequence from SEQ ID NO:1 in a buffer containing, for example, 5xSSPE (1xSSPE =
 15 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7), 5xDenhardt's solution (100xDenhardt's = 2% (w/v) bovine serum albumin, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5% SDS incubated overnight at 55-60°C. Post-hybridization washes at high stringency are typically performed in 0.5xSSC (1xSSC = 150 mM sodium chloride, 15 mM trisodium citrate) or in 0.5xSSPE at 55-60°
 20 C.

Regardless of the particular nucleotide sequence of a variant TGF-beta binding-protein gene, the gene encodes a polypeptide that can be characterized by its functional activity, or by the ability to bind specifically to an anti-TGF-beta binding-protein antibody. More specifically, variant TGF-beta binding-protein genes encode
 25 polypeptides which exhibit at least 50%, and preferably, greater than 60, 70, 80 or 90%, of the activity of polypeptides encoded by the human TGF-beta binding-protein gene described herein.

4. Production of TGF-beta binding-protein in Cultured Cells

To express a TGF-beta binding-protein gene, a nucleic acid molecule

encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene
 5 which is suitable for selection of cells that carry the expression vector.

Expression vectors that are suitable for production of a foreign protein in eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that
 10 control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence.

TGF-beta binding-proteins of the present invention are preferably expressed in mammalian cells. Examples of mammalian host cells include African green
 15 monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21; ATCC CRL 8544), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells
 20 (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

For a mammalian host, the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, in which the regulatory signals are associated with a particular gene which has a high level of expression. Suitable transcriptional and translational
 25 regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

Transcriptional regulatory sequences include a promoter region sufficient to direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse metallothionein I gene [Hamer et al., *J. Molec. Appl. Genet.* 1:273,
 30 1982], the *TK* promoter of *Herpes* virus [McKnight, *Cell* 31:355, 1982], the *SV40* early

promoter [Benoist et al., *Nature* 290:304, 1981], the Rous sarcoma virus promoter [Gorman et al., *Proc. Nat'l Acad. Sci. USA* 79:6777, 1982], the cytomegalovirus promoter [Foecking et al., *Gene* 45:101, 1980], and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

Alternatively, a prokaryotic promoter, such as the bacteriophage T3 RNA polymerase promoter, can be used to control TGF-beta binding-protein gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou et al., *Mol. Cell. Biol.* 10:4529, 1990; Kaufman et al., *Nucl. Acids Res.* 19:4485, 1991).

TGF-beta binding-protein genes may also be expressed in bacterial, yeast, insect, or plant cells. Suitable promoters that can be used to express TGF-beta binding-protein polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*, promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacteriophage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, *J. Ind. Microbiol.* 1:277, 1987, Watson et al., *Molecular Biology of the Gene*, 4th Ed. (Benjamin Cummins 1987), and by Ausubel et al. (1995).

Preferred prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (Ed.), *Molecular Biology Labfax* (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119, MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in *DNA Cloning: A Practical Approach*, Glover (Ed.) (IRL Press 1985)).

Methods for expressing proteins in prokaryotic hosts are well-known to

those of skill in the art (see, for example, Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995); Ward et al., "Genetic Manipulation and
 5 Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, page 137 (Wiley-Liss, Inc. 1995); and Georgiou, "Expression of Proteins in Bacteria," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

The baculovirus system provides an efficient means to introduce cloned
 10 *TGF-beta binding-protein* genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila* heat shock protein (hsp) 70 promoter, *Autographa californica* nuclear polyhedrosis virus immediate-early gene promoter (*ie-1*) and the delayed early 39K promoter, baculovirus p10 promoter, and the
 15 *Drosophila* metallothionein promoter. Suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL 1711), Sf21AE, and Sf21 (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells. Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey et al.,
 20 "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel et al., "The baculovirus expression system," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson
 25 (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

Promoters for expression in yeast include promoters from *GAL1* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOX1*
 30 (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning

vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YE_p vectors such as YE_p13 and YC_p vectors, such as YC_p19. One skilled in the art will appreciate that there are a wide variety of suitable vectors for expression in yeast cells.

5 Expression vectors can also be introduced into plant protoplasts, intact plant tissues, or isolated plant cells. General methods of culturing plant tissues are provided, for example, by Miki et al., "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), pages 67-88 (CRC Press, 1993).

10 An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, electroporation, and the like. Preferably, the transfected cells are selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for
15 introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel (1995) and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991). Methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are also provided by Ausubel (1995).

20 General methods for expressing and recovering foreign protein produced by a mammalian cell system is provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example,
25 Grisshammer *et al.*, "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc., 1995).

30 More generally, TGF-beta binding-protein can be isolated by standard

techniques, such as affinity chromatography, size exclusion chromatography, ion exchange chromatography, HPLC and the like. Additional variations in TGF-beta binding-protein isolation and purification can be devised by those of skill in the art. For example, anti-TGF-beta binding-protein antibodies, obtained as described below, can be
 5 used to isolate large quantities of protein by immunoaffinity purification.

5. Production of Antibodies to TGF-beta binding-proteins

Antibodies to TGF-beta binding-protein can be obtained, for example, using the product of an expression vector as an antigen. Particularly useful anti-TGF-beta binding-protein antibodies "bind specifically" with TGF-beta binding-protein of
 10 Sequence ID Nos. 2, 6, 10, 12, 14, or 16, but not to other TGF-beta binding-proteins such as Dan, Cerberus, SCGF, or Gremlin. Antibodies of the present invention (including fragments and derivatives thereof) may be a polyclonal or, especially a monoclonal antibody. The antibody may belong to any immunoglobulin class, and may be for example an IgG, for example IgG₁, IgG₂, IgG₃, IgG₄; IgE; IgM; or IgA antibody. It
 15 may be of animal, for example mammalian origin, and may be for example a murine, rat, human or other primate antibody. Where desired the antibody may be an internalising antibody.

Polyclonal antibodies to recombinant TGF-beta binding-protein can be prepared using methods well-known to those of skill in the art (see, for example, Green
 20 et al., "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992); Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995)). Although polyclonal antibodies are typically raised in animals
 25 such as rats, mice, rabbits, goats, or sheep, an anti-TGF-beta binding-protein antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46:310,

1990.

The antibody should comprise at least a variable region domain. The variable region domain may be of any size or amino acid composition and will generally comprise at least one hypervariable amino acid sequence responsible for antigen binding
 5 embedded in a framework sequence. In general terms the variable (V) region domain may be any suitable arrangement of immunoglobulin heavy (V_H) and/or light (V_L) chain variable domains. Thus for example the V region domain may be monomeric and be a V_H or V_L domain where these are capable of independently binding antigen with
 = acceptable affinity. Alternatively the V region domain may be dimeric and contain V_H -
 10 V_H , V_H - V_L , or V_L - V_L dimers in which the V_H and V_L chains are non-covalently associated (abbreviated hereinafter as F_v). Where desired, however, the chains may be covalently coupled either directly, for example via a disulphide bond between the two variable domains, or through a linker, for example a peptide linker, to form a single chain domain (abbreviated hereinafter as scF_v).

15 The variable region domain may be any naturally occurring variable domain or an engineered version thereof. By engineered version is meant a variable region domain which has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of
 20 the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.

The variable region domain may be covalently attached at a C-terminal
 25 amino acid to at least one other antibody domain or a fragment thereof. Thus, for example where a V_H domain is present in the variable region domain this may be linked to an immunoglobulin C_{H1} domain or a fragment thereof. Similarly a V_L domain may be

linked to a C_K domain or a fragment thereof. In this way for example the antibody may be a Fab fragment wherein the antigen binding domain contains associated V_H and V_L domains covalently linked at their C-termini to a CH1 and C_K domain respectively. The CH1 domain may be extended with further amino acids, for example to provide a hinge region domain as found in a Fab' fragment, or to provide further domains, such as antibody CH2 and CH3 domains.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., *Methods: A Companion to Methods in Enzymology* 2:106, 1991; Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter et al. (eds.), page 166 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch et al. (eds.), page 137 (Wiley-Liss, Inc. 1995)).

Antibodies for use in the invention may in general be monoclonal (prepared by conventional immunisation and cell fusion procedures) or in the case of fragments, derived therefrom using any suitable standard chemical e.g. reduction or enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin.

More specifically, monoclonal anti-TGF-beta binding-protein antibodies can be generated utilizing a variety of techniques. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., *Nature* 256:495, 1975; and Coligan et al. (eds.), *Current Protocols in Immunology*, 1:2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"]; Picksley et al., "Production of monoclonal antibodies against proteins expressed in *E. coli*," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a TGF-beta binding-protein gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce
 5 hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

In addition, an anti-TGF-beta binding-protein antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal
 10 antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for
 15 human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., *Nature Genet.* 7:13, 1994; Lonberg et al., *Nature* 368:856, 1994; and Taylor et al., *Int. Immun.* 6:579, 1994.

Monoclonal antibodies can be isolated and purified from hybridoma
 20 cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology, Vol. 10*, pages 79-104 (The Humana Press, Inc. 1992)).

25 For particular uses, it may be desirable to prepare fragments of anti-TGF-beta binding-protein antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of
 30 antibodies with pepsin to provide a 5S fragment denoted F(ab')₂. This fragment can be

further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab
 5 fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., *Arch Biochem. Biophys.* 89:230, 1960, Porter, *Biochem. J.* 73:119, 1959, Edelman et al., in *Methods in Enzymology* 1:422 (Academic Press 1967), and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains
 10 to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Alternatively, the antibody may be a recombinant or engineered antibody obtained by the use of recombinant DNA techniques involving the manipulation and re-
 15 expression of DNA encoding antibody variable and/or constant regions. Such DNA is known and/or is readily available from DNA libraries including for example phage-antibody libraries (see Chiswell, D J and McCafferty, J. *Tibtech.* 10 80-84 (1992)) or where desired can be synthesised. Standard molecular biology and/or chemistry procedures may be used to sequence and manipulate the DNA, for example, to introduce
 20 codons to create cysteine residues, to modify, add or delete other amino acids or domains as desired.

From here, one or more replicable expression vectors containing the DNA may be prepared and used to transform an appropriate cell line, e.g. a non-producing myeloma cell line, such as a mouse NSO line or a bacterial, e.g. *E.coli* line, in which
 25 production of the antibody will occur. In order to obtain efficient transcription and translation, the DNA sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence. Particular methods for producing antibodies in this way are generally well known and routinely used. For example, basic molecular biology procedures are
 30 described by Maniatis *et al* (Molecular Cloning, Cold Spring Harbor Laboratory, New

York, 1989); DNA sequencing can be performed as described in Sanger *et al* (PNAS 74, 5463, (1977)) and the Amersham International plc sequencing handbook; and site directed mutagenesis can be carried out according to the method of Kramer *et al* (Nucl. Acids Res. 12, 9441, (1984)) and the Anglian-Biotechnology Ltd handbook. Additionally, there are numerous publications, detailing techniques suitable for the preparation of antibodies by manipulation of DNA, creation of expression vectors and transformation of appropriate cells, for example as reviewed by Mountain A and Adair, J R in Biotechnology and Genetic Engineering Reviews (ed. Tombs, M P, 10, Chapter 1, 1992, Intercept, Andover, UK) and in International Patent Specification No. WO 91/09967.

Where desired, the antibody according to the invention may have one or more effector or reporter molecules attached to it and the invention extends to such modified proteins. The effector or reporter molecules may be attached to the antibody through any available amino acid side-chain, terminal amino acid or, where present carbohydrate functional group located in the antibody, always provided of course that this does not adversely affect the binding properties and eventual usefulness of the molecule. Particular functional groups include, for example any free amino, imino, thiol, hydroxyl, carboxyl or aldehyde group. Attachment of the antibody and the effector and/or reporter molecule(s) may be achieved via such groups and an appropriate functional group in the effector or reporter molecules. The linkage may be direct or indirect, through spacing or bridging groups.

Effector molecules include, for example, antineoplastic agents, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, nucleic acids and fragments thereof, e.g. DNA, RNA and fragments thereof, naturally occurring and synthetic polymers e.g. polysaccharides and polyalkylene polymers such as poly(ethylene glycol) and derivatives thereof, radionuclides, particularly radioiodide, and chelated metals. Suitable reporter groups include chelated metals, fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

Particular antineoplastic agents include cytotoxic and cytostatic agents, for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan,

mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramide, triethylenethiophosphoramide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid or fluorocitric acid, antibiotics, such as

5 bleomycins (e.g. bleomycin sulphate), doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calichaemicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids, such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone

10 or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

15 Particularly useful effector groups are calichaemicin and derivatives thereof (see for example South African Patent Specifications Nos. 85/8794, 88/8127 and 90/2839).

Chelated metals include chelates of di- or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include

20 technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc , ^{186}Re , ^{188}Re , ^{58}Co , ^{60}Co , ^{67}Cu , ^{195}Au , ^{199}Au , ^{110}Ag , ^{203}Pb , ^{206}Bi , ^{207}Bi , ^{111}In , ^{67}Ga , ^{68}Ga , ^{88}Y , ^{90}Y , ^{160}Tb , ^{153}Gd and ^{47}Sc .

25 The chelated metal may be for example one of the above types of metal chelated with any suitable polydentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

In general, the type of chelating agent will depend on the metal in use.

30 One particularly useful group of chelating agents in conjugates according to the invention,

however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No. WO 92/22583); and polyamides, especially
 5 desferrioxamine and derivatives thereof.

Thus for example when it is desired to use a thiol group in the antibody as the point of attachment this may be achieved through reaction with a thiol reactive group present in the effector or reporter molecule. Examples of such groups include an α -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl
 10 sulphone, or a disulphide. These and other suitable linking procedures are generally and more particularly described in International Patent Specifications Nos. WO 93/06231, WO 92/22583, WO 90/091195 and WO 89/01476.

ASSAYS FOR SELECTING MOLECULES WHICH INCREASE BONE DENSITY

As discussed above, the present invention provides methods for selecting
 15 and/or isolating compounds which are capable of increasing bone density. For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta binding protein and a selected member of the TGF-beta family of proteins, (b) determining whether the
 20 selected molecule stimulates signaling by the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding protein to the TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation.

Within other aspects of the invention, methods are provided for
 25 determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta binding-protein and (b) determining whether the expression (or activity) of TGF-beta binding-protein from said exposed cells decreases, and therefrom determining whether the compound is capable of increasing bone mineral content. Within one
 30 embodiment, the cells are selected from the group consisting of the spontaneously

transformed or untransformed normal human bone from bone biopsies and rat parietal bone osteoblasts. Such methods may be accomplished in a wide variety of assay formats including, for example, Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual, supra*).

Representative embodiments of such assays are provided below in Examples 5 and 6. Briefly, a family member of the TGF-beta super-family or a TGF-beta binding protein is first bound to a solid phase, followed by addition of a candidate molecule. The labeled family member of the TGF-beta super-family or a TGF-beta binding protein is then added to the assay, the solid phase washed, and the quantity of bound or labeled TGF-beta super-family member or TGF-beta binding protein on the solid support determined. Molecules which are suitable for use in increasing bone mineral content as described herein are those molecules which decrease the binding of TGF-beta binding protein to a member or members of the TGF-beta super-family in a statistically significant manner. Obviously, assays suitable for use within the present invention should not be limited to the embodiments described within Examples 2 and 3. In particular, numerous parameters may be altered, such as by binding TGF-beta to a solid phase, or by elimination of a solid phase entirely.

Within other aspects of the invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta and (b) determining whether the activity of TGF-beta from said exposed cells is altered, and therefrom determining whether the compound is capable of increasing bone mineral content. Similar to the above described methods, a wide variety of methods may be utilized to assess the changes of TGF-beta binding-protein expression due to a selected test compound.

For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone

mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta-binding-protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule up-regulates the signaling of the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding-protein to the

5 TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mechanochemical cell differentiation.

Similar to the above described methods, a wide variety of methods may be utilized to assess stimulation of TGF-beta due to a selected test compound. One

10 such representative method is provided below in Example 6 (see also Durham et al., *Endo.* 136:1374-1380).

Within yet other aspects of the present invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the

15 binding of TGF-beta binding-protein to bone, or an analogue thereof. As utilized herein, it should be understood that bone or analogues thereof refers to hydroxyapatite, or a surface composed of a powdered form of bone, crushed bone or intact bone. Similar to the above described methods, a wide variety of methods may be utilized to assess the inhibition of TGF-beta binding-protein localization to bone matrix. One such

20 representative method is provided below in Example 7.

It should be noted that while the methods recited herein may refer to the analysis of an individual test molecule, that the present invention should not be so limited. In particular, the selected molecule may be contained within a mixture of compounds. Hence, the recited methods may further comprise the step of isolating a

25 molecule which inhibits the binding of TGF-beta binding-protein to a TGF-beta family member.

CANDIDATE MOLECULES

A wide variety of molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member. Representative

30 examples which are discussed in more detail below include organic molecules, proteins

or peptides, and nucleic acid molecules. Although it should be evident from the discussion below that the candidate molecules described herein may be utilized in the assays described herein, it should also be readily apparent that such molecules can also be utilized in a variety of diagnostic and therapeutic settings.

5 1. Organic Molecules

Numerous organic molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

For example, within one embodiment of the invention suitable organic molecules may be selected from either a chemical library, wherein chemicals are
10 assayed individually, or from combinatorial chemical libraries where multiple compounds are assayed at once, then deconvoluted to determine and isolate the most active compounds.

Representative examples of such combinatorial chemical libraries include those described by Agrafiotis et al., "System and method of automatically
15 generating chemical compounds with desired properties," U.S. Patent No. 5,463,564; Armstrong, R.W., "Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses," WO 95/02566; Baldwin, J.J. et al., "Sulfonamide derivatives and their use," WO 95/24186; Baldwin, J.J. et al., "Combinatorial dihydrobenzopyran library," WO 95/30642; Brenner, S., "New kit for
20 preparing combinatorial libraries," WO 95/16918; Chenera, B. et al., "Preparation of library of resin-bound aromatic carbocyclic compounds," WO 95/16712; Ellman, J.A., "Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support," U.S. Patent No. 5,288,514; Felder, E. et al., "Novel combinatorial compound libraries," WO 95/16209; Lerner, R. et al., "Encoded combinatorial chemical libraries,"
25 WO 93/20242; Pavia, M.R. et al., "A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library," WO 95/04277; Summerton, J.E. and D.D. Weller, "Morpholino-subunit combinatorial library and method," U.S. Patent No. 5,506,337; Holmes, C., "Methods for the Solid Phase Synthesis of Thiazolidinones, Metathiazanones, and Derivatives

thereof," WO 96/00148; Phillips, G.B. and G.P. Wei, "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters* 37:4887-90, 1996; Ruhland, B. et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse β -Lactams," *J. Amer. Chem. Soc.* 111:253-4, 1996; Look, G.C. et al., "The Identification of Cyclooxygenase-1
 5 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters* 6:707-12, 1996.

2. Proteins and Peptides

A wide range of proteins and peptides may likewise be utilized as candidate molecules for inhibitors of the binding of TGF-beta binding-protein to a
 10 TGF-beta family member.

a. Combinatorial Peptide Libraries

Peptide molecules which are putative inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member may be obtained through the screening of combinatorial peptide libraries. Such libraries may either be prepared by
 15 one of skill in the art (*see e.g.*, U.S. Patent Nos. 4,528,266 and 4,359,535, and Patent Cooperation Treaty Publication Nos. WO 92/15679, WO 92/15677, WO 90/07862, WO 90/02809, or purchased from commercially available sources (*e.g.*, New England Biolabs Ph.D.TM Phage Display Peptide Library Kit).

b. Antibodies

20 Antibodies which inhibit the binding of TGF-beta binding-protein to a TGF-beta family member may readily be prepared given the disclosure provided herein. Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (*e.g.*, Fab, and F(ab')₂, F_V variable regions, or complementarity determining
 25 regions). As discussed above, antibodies are understood to be specific against TGF-beta binding-protein, or against a specific TGF-beta family member, if they bind with a K_a of greater than or equal to 10⁷M, preferably greater than or equal to 10⁸M, and do not bind to other TGF-beta binding-proteins, or, bind with a K_a of less than or equal to

10⁶M. Furthermore, antibodies of the present invention should block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

The affinity of a monoclonal antibody or binding partner, as well as inhibition of binding can be readily determined by one of ordinary skill in the art (*see*
 5 Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Briefly, polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, various fowl, rabbits, mice, or rats. Typically, the TGF-beta binding-protein or unique peptide thereof of 13-20 amino acids (preferably conjugated to keyhole limpet
 10 hemocyanin by cross-linking with glutaraldehyde) is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections, along with an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, samples of serum are collected and tested for reactivity to the protein or peptide. Particularly preferred polyclonal antisera will give a signal on one
 15 of these assays that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

Monoclonal antibodies may also be readily generated using conventional
 20 techniques (*see* U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; *see also Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated
 25 herein by reference).

Briefly, within one embodiment a subject animal such as a rat or mouse is immunized with TGF-beta binding-protein or portion thereof as described above. The protein may be admixed with an adjuvant such as Freund's complete or incomplete adjuvant in order to increase the resultant immune response. Between one and three
 30 weeks after the initial immunization the animal may be reimmunized with another

booster immunization, and tested for reactivity to the protein utilizing assays described above. Once the animal has reached a plateau in its reactivity to the injected protein, it is sacrificed, and organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested.

5 Cells which are obtained from the immunized animal may be immortalized by infection with a virus such as the Epstein-Barr virus (EBV) (see Glasky and Reading, *Hybridoma* 8(4):377-389, 1989). Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal
10 antibody. Suitable myeloma lines include, for example, NS-1 (ATCC No. TIB 18), and P3X63 - Ag 8.653 (ATCC No. CRL 1580).

Following the fusion, the cells may be placed into culture plates containing a suitable medium, such as RPMI 1640, or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, Kansas), as well as additional ingredients,
15 such as fetal bovine serum (FBS, *i.e.*, from Hyclone, Logan, Utah, or JRH Biosciences). Additionally, the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells such as HAT (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, Missouri). After about seven days, the resulting fused cells or hybridomas may be screened in order to determine the presence
20 of antibodies which are reactive against TGF-beta binding-protein (depending on the antigen used), and which block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

A wide variety of assays may be utilized to determine the presence of antibodies which are reactive against the proteins of the present invention, including for
25 example countercurrent immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, inhibition or competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press,

1988). Following several clonal dilutions and reassays, a hybridoma producing antibodies reactive against the desired protein may be isolated.

Other techniques may also be utilized to construct monoclonal antibodies (see William D. Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, December 1989; see also L. Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA* 86:5728-5732, August 1989; see also Michelle Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, January 1990). These references describe a commercial system available from Stratagene (La Jolla, California) which enables the production of antibodies through recombinant techniques. Briefly, mRNA is isolated from a B cell population, and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the λ ImmunoZap(H) and λ ImmunoZap(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., *supra*; see also Sastry et al., *supra*). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from *E. coli*.

Similarly, portions or fragments, such as Fab and Fv fragments, of antibodies may also be constructed utilizing conventional enzymatic digestion or recombinant DNA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody. Within one embodiment, the genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. Stratagene (La Jolla, California) sells primers for mouse and human variable regions including, among others, primers for V_{Ha} , V_{Hb} , V_{Hc} , V_{Hd} , C_{H1} , V_L and C_L regions. These primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as

ImmunoZAP™ H or ImmunoZAP™ L (Stratagene), respectively. These vectors may then be introduced into *E. coli*, yeast, or mammalian-based systems for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V_H and V_L domains may be produced (see Bird et al., *Science* 242:423-426, 5 1988). In addition, such techniques may be utilized to change a "murine" antibody to a "human" antibody, without altering the binding specificity of the antibody.

Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor 10 Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.

c. Mutant TGF-beta binding-proteins

As described herein and below in the Examples (e.g., Examples 8 and 9), 15 altered versions of TGF-beta binding-protein which compete with native TGF-beta binding-protein's ability to block the activity of a particular TGF-beta family member should lead to increased bone density. Thus, mutants of TGF-beta binding-protein which bind to the TGF-beta family member but do not inhibit the function of the TGF-beta family member would meet the criteria. The mutant versions must effectively 20 compete with the endogenous inhibitory functions of TGF-beta binding-protein.

d. Production of proteins

Although various genes (or portions thereof) have been provided herein, it should be understood that within the context of the present invention, reference to one or more of these genes includes derivatives of the genes that are substantially similar to 25 the genes (and, where appropriate, the proteins (including peptides and polypeptides) that are encoded by the genes and their derivatives). As used herein, a nucleotide sequence is deemed to be "substantially similar" if: (a) the nucleotide sequence is derived from the coding region of the above-described genes and includes, for example, portions of the sequence or allelic variations of the sequences discussed above, or

alternatively, encodes a molecule which inhibits the binding of TGF-beta binding-protein to a member of the TGF-beta family, (b) the nucleotide sequence is capable of hybridization to nucleotide sequences of the present invention under moderate, high or very high stringency (*see* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 5 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) the DNA sequences are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b). Further, the nucleic acid molecule disclosed herein includes both complementary and non-complementary sequences, provided the sequences otherwise meet the criteria set forth herein. Within the context of the present invention, high stringency means 10 standard hybridization conditions (*e.g.*, 5XSSPE, 0.5% SDS at 65°C, or the equivalent).

The structure of the proteins encoded by the nucleic acid molecules described herein may be predicted from the primary translation products using the hydrophobicity plot function of, for example, P/C Gene or Intelligenetics Suite (Intelligenetics, Mountain View, California), or according to the methods described by 15 Kyte and Doolittle (*J. Mol. Biol.* 157:105-132, 1982).

Proteins of the present invention may be prepared in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or nucleic acid sequences, the net effect of 20 which is to retain or further enhance or decrease the biological activity of the mutant or wild-type protein. Moreover, due to degeneracy in the genetic code, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

Other derivatives of the proteins disclosed herein include conjugates of 25 the proteins along with other proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins which may be added to facilitate purification or identification of proteins (*see* U.S. Patent No. 4,851,341, *see also*, Hopp et al., *Bio/Technology* 6:1204, 1988.) Alternatively, fusion proteins such as Flag/TGF-beta binding-protein be constructed in order to assist in the 30 identification, expression, and analysis of the protein.

Proteins of the present invention may be constructed using a wide variety of techniques described herein. Further, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the
5 resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary
10 methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and Sambrook et al. (*supra*). Deletion or truncation derivatives of proteins (e.g., a soluble extracellular portion) may also be constructed by utilizing convenient
15 restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, 1989).

Mutations which are made in the nucleic acid molecules of the present
20 invention preferably preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect translation of the mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in
25 order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for indicative biological activity. Alternatively, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following

ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Nucleic acid molecules which encode proteins of the present invention may also be constructed utilizing techniques of PCR mutagenesis, chemical
5 mutagenesis (Drinkwater and Klinedinst, *PNAS* 83:3402-3406, 1986), by forced nucleotide misincorporation (*e.g.*, Liao and Wise *Gene* 88:107-111, 1990), or by use of randomly mutagenized oligonucleotides (Horwitz et al., *Genome* 3:112-117, 1989).

The present invention also provides for the manipulation and expression of the above described genes by culturing host cells containing a vector capable of
10 expressing the above-described genes. Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules encoding the desired protein, which are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate
15 regulatory elements is dependent on the host cell chosen and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.

20 Nucleic acid molecules that encode any of the proteins described above may be readily expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, or plant cells. Methods for transforming or transfecting such cells to express foreign DNA are well known in the art (see, *e.g.*, Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., *Proc.*
25 *Natl. Acad. Sci. USA* 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; for plant cells see Czako and Marton, *Plant Physiol.*
30 104:1067-1071, 1994; and Paszkowski et al., *Biotech.* 24:387-392, 1992).

Bacterial host cells suitable for carrying out the present invention include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art. Representative examples of
5 bacterial host cells include DH5 α (Stratagene, LaJolla, California).

Bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase) and lactose promoter system (see Chang et al., *Nature* 275:615, 1978), the T7 RNA
10 polymerase promoter (Studier et al., *Meth. Enzymol.* 185:60-89, 1990), the lambda promoter (Elvin et al., *Gene* 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, *Meth. in Enzymology* 101:155, 1983) and the *tac* promoter (Russell et al., *Gene* 20:231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Many
15 plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., *Gene* 2:95, 1977), the pUC plasmids pUC18, pUC19, pUC118, pUC119 (see Messing, *Meth. in Enzymology* 101:20-77, 1983 and Vieira and Messing, *Gene* 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, California).

20 Yeast and fungi host cells suitable for carrying out the present invention include, among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3
25 (Turnbull, *Bio/Technology* 7:169, 1989), YRp7 (Struhl et al., *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEp13 (Broach et al., *Gene* 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof.

Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., *J. Biol. Chem.* 255:12073-12080, 1980; Alber and
30 Kawasaki, *J. Mol. Appl. Genet.* 1:419-434, 1982) or alcohol dehydrogenase genes

(Young et al., in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, *Meth. Enzymol.* 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al., 5 *EMBO J.* 4:2093-2099, 1985). The expression units may also include a transcriptional terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al., *ibid.*, 1985).

As with bacterial vectors, the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant 10 phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., *Gene* 8:17, 1979), or *his3* (Struhl et al., *ibid.*). Another suitable selectable marker is the *cat* gene, which confers 15 chloramphenicol resistance on yeast cells.

Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (*Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978), Yelton et al. (*Proc. Natl. Acad. Sci. USA* 81:1740-1747, 1984), and Russell (*Nature* 301:167-169, 1983). The genotype of the host cell may 20 contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.

Protocols for the transformation of yeast are also well known to those of ordinary skill in the art. For example, transformation may be readily accomplished 25 either by preparation of spheroplasts of yeast with DNA (see Hinnen et al., *PNAS USA* 75:1929, 1978) or by treatment with alkaline salts such as LiCl (see Itoh et al., *J. Bacteriology* 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (*Bio/Technology* 5:369, 1987).

Viral vectors include those which comprise a promoter that directs the 30 expression of an isolated nucleic acid molecule that encodes a desired protein as

described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., *Science* 265:781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), Herpes TK promoter, SV40 promoter, metallothionein IIa gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. Within particularly preferred embodiments of the invention, the promoter is a tissue-specific promoter (see e.g., WO 91/02805; EP 0,415,731; and WO 90/07936). Representative examples of suitable tissue specific promoters include neural specific enolase promoter, platelet derived growth factor beta promoter, bone morphogenic protein promoter, human alphas-1-acid glycoprotein promoter, synapsin I promoter and synapsin II promoter. In addition to the above-noted promoters, other viral-specific promoters (e.g., retroviral promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (e.g., EBV), and bacterial, fungal or parasitic (e.g., malarial) -specific promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

Mammalian cells suitable for carrying out the present invention include, among others COS, CHO, SaOS, osteosarcomas, KS483, MG-63, primary osteoblasts, and human or mammalian bone marrow stroma. Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Bone specific promoters include the bone sialo-protein and the promoter for osteocalcin. Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., *Cell* 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse V_K promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al., *Nucl. Acids Res.* 15:5496, 1987) and a mouse V_H promoter (Loh et al., *Cell*

33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., *Nuc. Acids Res.* 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (e.g., Stratagene, La Jolla, California).

Vector constructs comprising cloned DNA sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (*Mammalian Cell Technology*, Butterworth Publishers, Stoneham, Massachusetts, which is incorporated herein by reference).

Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable, selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production.

10 Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated transfection, electroporation, lipofection, retroviral, adenoviral and protoplast fusion-mediated transfection (*see* Sambrook et al., *supra*). Naked vector constructs can also be taken up by muscular cells or other suitable cells subsequent to injection into the muscle of a mammal (or other animals).

Numerous insect host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (*Pestic. Sci.* 28:215-224,1990).

20 Numerous plant host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (*J. Biosci. (Bangalore)* 11:47-58, 1987).

Within related aspects of the present invention, proteins of the present invention may be expressed in a transgenic animal whose germ cells and somatic cells contain a gene which encodes the desired protein and which is operably linked to a promoter effective for the expression of the gene. Alternatively, in a similar manner transgenic animals may be prepared that lack the desired gene (*e.g.*, "knock-out" mice). Such transgenics may be prepared in a variety of non-human animals, including mice, rats, rabbits, sheep, dogs, goats and pigs (*see* Hammer et al., *Nature* 315:680-683, 1985,

Palmiter et al., *Science* 222:809-814, 1983, Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985, Palmiter and Brinster, *Cell* 41:343-345, 1985, and U.S. Patent Nos. 5,175,383, 5,087,571, 4,736,866, 5,387,742, 5,347,075, 5,221,778, and 5,175,384). Briefly, an expression vector, including a nucleic acid molecule to be
5 expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs, for example, by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed on to the animal's progeny. Tissue-specific expression may be
10 achieved through the use of a tissue-specific promoter, or through the use of an inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene.

Proteins can be isolated by, among other methods, culturing suitable host and vector systems to produce the recombinant translation products of the present
15 invention. Supernatants from such cell lines, or protein inclusions or whole cells where the protein is not excreted into the supernatant, can then be treated by a variety of purification procedures in order to isolate the desired proteins. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit.
20 Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, an anti-protein antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the protein. As a further alternative, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the protein.
25 Other methods of isolating the proteins of the present invention are well known in the skill of the art.

A protein is deemed to be "isolated" within the context of the present invention if no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by Coomassie blue staining. Within other embodiments, the desired protein

can be isolated such that no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by silver staining.

3. Nucleic Acid Molecules

Within other aspects of the invention, nucleic acid molecules are provided which are capable of inhibiting TGF-beta binding-protein binding to a member of the TGF-beta family. For example, within one embodiment antisense oligonucleotide molecules are provided which specifically inhibit expression of TGF-beta binding-protein nucleic acid sequences (*see generally*, Hirashima et al. in *Molecular Biology of RNA: New Perspectives* (M. Inouye and B. S. Dudock, eds., 1987 Academic Press, San Diego, p. 401); *Oligonucleotides: Antisense Inhibitors of Gene Expression* (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, *Science* 261:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051; WO 92/06693; and EP-A2-612844). Briefly, such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed TGF-beta binding-protein mRNA sequence. The resultant double-stranded nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (see Example 10).

Within other aspects of the invention, ribozymes are provided which are capable of inhibiting the TGF-beta binding-protein binding to a member of the TGF-beta family. As used herein, "ribozymes" are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990);

and *Tetrahymena* ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present invention typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

5 4. Labels

The gene product or any of the candidate molecules described above and below, may be labeled with a variety of compounds, including for example, fluorescent molecules, toxins, and radionuclides. Representative examples of fluorescent molecules include fluorescein, *Phycobili* proteins, such as phycoerythrin, rhodamine, Texas red
10 and luciferase. Representative examples of toxins include ricin, abrin diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, *Shigella* toxin, and *Pseudomonas* exotoxin A. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. In addition, the
15 antibodies described above may also be labeled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein.

Methods for conjugating or labeling the molecules described herein with the representative labels set forth above may be readily accomplished by one of
20 ordinary skill in the art (see Trichothecene Antibody Conjugate, U.S. Patent No. 4,744,981; Antibody Conjugate, U.S. Patent No. 5,106,951; Fluorogenic Materials and Labeling Techniques, U.S. Patent No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Patent No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Patent No. 4,988,496; see
25 also Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; see also Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988).

PHARMACEUTICAL COMPOSITIONS

As noted above, the present invention also provides a variety of pharmaceutical compositions, comprising one of the above-described molecules which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.

In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes. In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (*e.g.*, water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition.

METHODS OF TREATMENT

The present invention also provides methods for increasing the mineral content and mineral density of bone. Briefly, numerous conditions result in the loss of bone mineral content, including for example, disease, genetic predisposition, accidents which result in the lack of use of bone (*e.g.*, due to fracture), therapeutics which effect bone resorption, or which kill bone forming cells and normal aging. Through use of the molecules described herein which inhibit the TGF-beta binding-protein binding to a TGF-beta family member such conditions may be treated or prevented. As utilized herein, it should be understood that bone mineral content has been increased, if bone

mineral content has been increased in a statistically significant manner (e.g., greater than one-half standard deviation), at a selected site.

A wide variety of conditions which result in loss of bone mineral content may be treated with the molecules described herein. Patients with such conditions may be identified through clinical diagnosis utilizing well known techniques (see, 5 e.g., Harrison's Principles of Internal Medicine, McGraw-Hill, Inc.). Representative examples of diseases that may be treated included dysplasias, wherein there is abnormal growth or development of bone. Representative examples of such conditions include achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, 10 Gaucher's, hypophosphatemic rickets, Marfan's, multiple hereditary exotoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, fractures, periodontal disease, pseudoarthrosis and pyogenic osteomyelitis.

Other conditions which may be treated or prevented include a wide variety of causes of osteopenia (i.e., a condition that causes greater than one standard 15 deviation of bone mineral content or density below peak skeletal mineral content at youth). Representative examples of such conditions include anemic states, conditions caused steroids, conditions caused by heparin, bone marrow disorders, scurvy, malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, postmenopausal state, 20 oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis and osteomalacia.

Within one aspect of the present invention, bone mineral content or density may be increased by administering to a warm-blooded animal a therapeutically 25 effective amount of a molecule which inhibits the TGF-beta binding-protein binding to a TGF-beta family member. Examples of warm-blooded animals that may be treated include both vertebrates and mammals, including for example horses, cows, pigs, sheep, dogs, cats, rats and mice. Representative examples of therapeutic molecules include ribozymes, ribozyme genes, antisense oligonucleotides and antibodies (e.g., humanized 30 antibodies).

Within other aspects of the present invention, methods are provided for increasing bone density, comprising the step of introducing into cells which home to bone a vector which directs the expression of a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family, and administering the vector containing cells to a warm-blooded animal. Briefly, cells which home to bone may be obtained directly from the bone of patients (e.g., cells obtained from the bone marrow such as CD34+, osteoblasts, osteocytes, and the like), from peripheral blood, or from cultures.

A vector which directs the expression of a molecule that inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family is introduced into the cells. Representative examples of suitable vectors include viral vectors such as herpes viral vectors (e.g., U.S. Patent No. 5,288,641), adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Kolls et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent et al., *Nat. Genet.* 5(2):130-134, 1993; Jaffe et al., *Nat. Genet.* 1(5):372-378, 1992; and Levrero et al., *Gene* 101(2):195-202, 1991), adeno-associated viral vectors (WO 95/13365; Flotte et al., *PNAS* 90(22):10613-10617, 1993), baculovirus vectors, parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), pox virus vectors (Panicali and Paoletti, *PNAS* 79:4927-4931, 1982; and Ozaki et al., *Biochem. Biophys. Res. Comm.* 193(2):653-660, 1993), and retroviruses (e.g., EP 0,415,731; WO 90/07936; WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218). Viral vectors may likewise be constructed which contain a mixture of different elements (e.g., promoters, envelope sequences and the like) from different viruses, or non-viral sources. Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

Within other embodiments of the invention, nucleic acid molecules which encode a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family themselves may be administered by a variety of techniques, including, for example, administration of asialosomucoid (ASOR) conjugated with poly-L-lysine DNA complexes (Cristano et al., *PNAS* 92:122-92:126, 1993), DNA linked to killed adenovirus (Curiel et al., *Hum. Gene Ther.* 3(2):147-154, 1992), cytofectin-mediated introduction (DMRIE-DOPE, Vical, California), direct DNA injection (Acsadi et al., *Nature* 352:815-818, 1991); DNA ligand (Wu et al., *J. of Biol. Chem.* 264:16985-16987, 1989); lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989); liposomes (Pickering et al., *Circ.* 89(1):13-21, 1994; and Wang et al., *PNAS* 84:7851-7855, 1987); microprojectile bombardment (Williams et al., *PNAS* 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the protein itself either alone (Vile and Hart, *Cancer Res.* 53: 3860-3864, 1993), or utilizing PEG-nucleic acid complexes.

Representative examples of molecules which may be expressed by the vectors of present invention include ribozymes and antisense molecules, each of which are discussed in more detail above.

Determination of increased bone mineral content may be determined directly through the use of X-rays (e.g., Dual Energy X-ray Absorptometry or "DEXA"), or by inference through bone turnover markers (osteoblast specific alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995), or markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine; see Comier, *supra*). The amount of bone mass may also be calculated from body weights, or utilizing other methods (see Guinness-Hey, *Metab. Bone Dis. and Rel. Res.* 5:177-181, 1984).

As will be evident to one of skill in the art, the amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.

Typically, the compositions may be administered by a variety of techniques, as noted above.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

SCLEROSTEOSIS MAPS TO THE LONG ARM OF HUMAN CHROMOSOME 17

Genetic mapping of the defect responsible for sclerosteosis in humans localized the gene responsible for this disorder to the region of human chromosome 17 that encodes a novel TGF-beta binding-protein family member. In sclerosteosis, skeletal bone displays a substantial increase in mineral density relative to that of unaffected individuals. Bone in the head displays overgrowth as well. Sclerosteosis patients are generally healthy although they may exhibit variable degrees of syndactyly at birth and variable degrees of cranial compression and nerve compression in the skull.

Linkage analysis of the gene defect associated with sclerosteosis was conducted by applying the homozygosity mapping method to DNA samples collected from 24 South African Afrikaaner families in which the disease occurred. (Sheffield et al., 1994, *Human Molecular Genetics* 3:1331-1335. "Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping"). The Afrikaaner population of South Africa is genetically homogeneous; the population is descended from a small number of founders who colonized the area several centuries ago, and it has been isolated by geographic and social barriers since the founding. Sclerosteosis is rare everywhere in the world outside the Afrikaaner community, which suggests that a mutation in the gene was present in the founding population and has since increased in numbers along with the increase in the population. The use of homozygosity mapping is based on the assumption that DNA mapping markers adjacent to a recessive mutation are likely to be homozygous in affected individuals from consanguineous families and isolated populations.

A set of 371 microsatellite markers (Research Genetics, Set 6) from the autosomal chromosomes was selected to type pools of DNA from sclerosteosis patient samples. The DNA samples for this analysis came from 29 sclerosteosis patients in 24 families, 59 unaffected family members and a set of unrelated control individuals from the same population. The pools consisted of 4-6 individuals, either affected individuals, affected individuals from consanguineous families, parents and unaffected siblings, or

unrelated controls. In the pools of unrelated individuals and in most of the pools with affected individuals or family members analysis of the markers showed several allele sizes for each marker. One marker, D17S1299, showed an indication of homozygosity: one band in several of the pools of affected individuals.

5 All 24 sclerosteosis families were typed with a total of 19 markers in the region of D17S1299 (at 17q12-q21). Affected individuals from every family were shown to be homozygous in this region, and 25 of the 29 individuals were homozygous for a core haplotype; they each had the same alleles between D17S1787 and D17S930. The other four individuals had one chromosome which matched this haplotype and a
10 second which did not. In sum, the data compellingly suggested that this 3 megabase region contained the sclerosteosis mutation. Sequence analysis of most of the exons in this 3 megabase region identified a nonsense mutation in the novel TGF-beta binding-protein coding sequence (C>T mutation at position 117 of Sequence ID No. 1 results in a stop codon). This mutation was shown to be unique to sclerosteosis patients and
15 carriers of Afrikaaner descent. The identity of the gene was further confirmed by identifying a mutation in its intron (A>T mutation at position +3 of the intron) which results in improper mRNA processing in a single, unrelated patient with diagnosed sclerosteosis.

20

EXAMPLE 2

TISSUE-SPECIFICITY OF TGF-BETA BINDING-PROTEIN GENE EXPRESSION

A. Human Bone Gene Expression by RT-PCR:

First-strand cDNA was prepared from the following total RNA samples
25 using a commercially available kit ("Superscript Preamplification System for First-Strand cDNA Synthesis", Life Technologies, Rockville, MD): human brain, human liver, human spleen, human thymus, human placenta, human skeletal muscle, human thyroid, human pituitary, human osteoblast (NHOst from Clonetics Corp., San Diego, CA), human osteosarcoma cell line (Saos-2, ATCC# HTB-85), human bone, human
30 bone marrow, human cartilage, vervet monkey bone, saccharomyces cerevisiae, and

human peripheral blood monocytes. All RNA samples were purchased from a commercial source (Clontech, Palo Alto, CA), except the following which were prepared in-house: human osteoblast, human osteosarcoma cell line, human bone, human cartilage and vervet monkey bone. These in-house RNA samples were prepared
 5 using a commercially available kit ("TRI Reagent", Molecular Research Center, Inc., Cincinnati, OH).

PCR was performed on these samples, and additionally on a human genomic sample as a control. The sense *Beer* oligonucleotide primer had the sequence 5'-CCGGAGCTGGAGAACAACAAG-3' (SEQ ID NO:19). The antisense *Beer*
 10 oligonucleotide primer had the sequence 5'-GCACTGGCCGGAGCACACC-3' (SEQ ID NO:20). In addition, PCR was performed using primers for the human beta-actin gene, as a control. The sense beta-actin oligonucleotide primer had the sequence 5'-AGGCCAACCGCGAGAAGATGA CC -3' (SEQ ID NO:21). The antisense beta-actin
 15 oligonucleotide primer had the sequence 5'-GAAGT CCAGGGCGACGTAGCA-3' (SEQ ID NO:22). PCR was performed using standard conditions in 25 ul reactions, with an annealing temperature of 61 degrees Celsius. Thirty-two cycles of PCR were performed with the *Beer* primers and twenty-four cycles were performed with the beta-actin primers.

Following amplification, 12 ul from each reaction were analyzed by
 20 agarose gel electrophoresis and ethidium bromide staining. See Figure 2A.

B. RNA In-situ Hybridization of Mouse Embryo Sections:

The full length mouse *Beer* cDNA (Sequence ID No. 11) was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) in the antisense and sense direction using
 25 the manufacturer's protocol. ³⁵S-alpha-GTP-labeled cRNA sense and antisense transcripts were synthesized using in-vitro transcription reagents supplied by Ambion, Inc (Austin, TX). In-situ hybridization was performed according to the protocols of Lyons et al. (*J. Cell Biol.* 111:2427-2436, 1990).

The mouse *Beer* cRNA probe detected a specific message expressed in
 30 the neural tube, limb buds, blood vessels and ossifying cartilages of developing mouse

embryos. Panel A in Figure 3 shows expression in the apical ectodermal ridge (aer) of the limb (l) bud, blood vessels (bv) and the neural tube (nt). Panel B shows expression in the 4th ventricle of the brain (4). Panel C shows expression in the mandible (ma) cervical vertebrae (cv), occipital bone (oc), palate (pa) and a blood vessel (bv). Panel D shows expression in the ribs (r) and a heart valve (va). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

ba=branchial arch, h=heart, te=telencephalon (forebrain), b=brain, f=frontonasal mass, g=gut, h=heart, j=jaw, li=liver, lu=lung, ot=otic vesicle, ao=, sc=spinal cord, skm=skeletal muscle, ns=nasal sinus, th=thymus, to=tongue, fl=forelimb, di=diaphragm

EXAMPLE 3

15 EXPRESSION AND PURIFICATION OF RECOMBINANT BEER PROTEIN

A. Expression in COS-1 Cells:

The DNA sequence encoding the full length human Beer protein was amplified using the following PCR oligonucleotide primers: The 5' oligonucleotide primer had the sequence 5'-AAGCTTGGTACCATGCAGCTCCCAC-3' (SEQ ID NO:23) and contained a HindIII restriction enzyme site (in bold) followed by 19 nucleotides of the *Beer* gene starting 6 base pairs prior to the presumed amino terminal start codon (ATG). The 3' oligonucleotide primer had the sequence 5'-AAGCTTCTACTTGTTCATCGTCGTCCT TGTAGTCGTAGGCGTTCTCCAGCT-3' (SEQ ID NO:24) and contained a HindIII restriction enzyme site (in bold) followed by a reverse complement stop codon (CTA) followed by the reverse complement of the FLAG epitope (underlined, Sigma-Aldrich Co., St. Louis, MO) flanked by the reverse complement of nucleotides coding for the carboxy terminal 5 amino acids of the Beer. The PCR product was TA cloned ("Original TA Cloning Kit", Invitrogen, Carlsbad, CA) and individual clones were screened by DNA sequencing. A sequence-verified clone was then digested by HindIII and purified on a 1.5% agarose gel using a

commercially available reagents ("QIAquick Gel Extraction Kit", Qiagen Inc., Valencia, CA). This fragment was then ligated to HindIII digested, phosphatase-treated pcDNA3.1 (Invitrogen, Carlsbad, CA) plasmid with T4 DNA ligase. DH10B *E. coli* were transformed and plated on LB, 100 µg/ml ampicillin plates. Colonies bearing the
 5 desired recombinant in the proper orientation were identified by a PCR-based screen, using a 5' primer corresponding to the T7 promoter/priming site in pcDNA3.1 and a 3' primer with the sequence 5'- GCACTGGCCGGAGCACACC-3' (SEQ ID NO:25) that corresponds to the reverse complement of internal BEER sequence. The sequence of the cloned fragment was confirmed by DNA sequencing.

10 COS-1 cells (ATCC# CRL-1650) were used for transfection. 50 µg of the expression plasmid pcDNA-Beer-Flag was transfected using a commercially available kit following protocols supplied by the manufacturer ("DEAE-Dextran Transfection Kit", Sigma Chemical Co., St. Louis, MO). The final media following transfection was DMEM (Life Technologies, Rockville, MD) containing 0.1% Fetal
 15 Bovine Serum. After 4 days in culture, the media was removed. Expression of recombinant BEER was analyzed by SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO). Purification of recombinant BEER protein was performed using an anti-FLAG M2 affinity column ("Mammalian Transient Expression System", Sigma-Aldrich Co., St. Louis, MO). The
 20 column profile was analyzed via SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody.

B. Expression in SF9 insect cells:

The human *Beer* gene sequence was amplified using PCR with standard
 25 conditions and the following primers:

Sense primer: 5'-GTCGTCGGATCCATGGGGTGGCAGGCGTTCAAGAATGAT-3'
 (SEQ ID NO:26)

Antisense primer: 5'-GTCGTCAAGCTTCTACTTGTCATCGTCCTTGTAGTCGTA
 GCGTTCTCCAGCTCGGC-3' (SEQ ID NO:27)

30 The resulting cDNA contained the coding region of Beer with two

modifications. The N-terminal secretion signal was removed and a FLAG epitope tag (Sigma) was fused in frame to the C-terminal end of the insert. BamHI and HindIII cloning sites were added and the gene was subcloned into pMelBac vector (Invitrogen) for transfer into a baculoviral expression vector using standard methods.

5 Recombinant baculoviruses expressing Beer protein were made using the Bac-N-Blue transfection kit (Invitrogen) and purified according to the manufacturers instructions.

SF9 cells (Invitrogen) were maintained in TNM_FH media (Invitrogen) containing 10% fetal calf serum. For protein expression, SF9 cultures in spinner flasks
10 were infected at an MOI of greater than 10. Samples of the media and cells were taken daily for five days, and Beer expression monitored by western blot using an anti-FLAG M2 monoclonal antibody (Sigma) or an anti-Beer rabbit polyclonal antiserum.

After five days the baculovirus-infected SF9 cells were harvested by centrifugation and cell associated protein was extracted from the cell pellet using a high
15 salt extraction buffer (1.5 M NaCl, 50 mM Tris pH 7.5). The extract (20 ml per 300 ml culture) was clarified by centrifugation, dialyzed three times against four liters of Tris buffered saline (150 mM NaCl, 50 mM Tris pH 7.5), and clarified by centrifugation again. This high salt fraction was applied to Hitrap Heparin (Pharmacia; 5 ml bed volume), washed extensively with HEPES buffered saline (25 mM HEPES
20 7.5, 150 mM NaCl) and bound proteins were eluted with a gradient from 150 mM NaCl to 1200 mM NaCl. Beer elution was observed at approximately 800 mM NaCl. Beer containing fractions were supplemented to 10% glycerol and 1 mM DTT and frozen at -80 degrees C.

25

EXAMPLE 4

PREPARATION AND TESTING OF POLYCLONAL ANTIBODIES TO BEER, GREMLIN, AND DAN

A. Preparation of antigen:

The DNA sequences of Human *Beer*, Human *Gremlin*, and Human *Dan*

were amplified using standard PCR methods with the following oligonucleotide primers:

H. Beer

Sense: 5' -GACTTGGATCCCAGGGGTGGCAGGCGTTC- 3' (SEQ ID NO:28)

5 Antisense 5' -AGCATAAGCTTCTAGTAGGCGTTCTCCAG- 3' (SEQ ID NO:29)

H. Gremlin

Sense: 5' -GACTTGGATCCGAAGGGAAAAAGAAAGGG- 3' (SEQ ID NO:30)

Antisense: 5' -AGCATAAGCTTTTAATCCAAATCGATGGA- 3' (SEQ ID NO:31)

H. Dan

10 Sense: 5' -ACTACGAGCTCGGCCCCACCACCCATCAACAAG- 3' (SEQ ID NO:32)

Antisense: 5' -ACTTAGAAGCTTTCAGTCCTCAGCCCCCTCTTCC-3' (SEQ ID NO:33)

In each case the listed primers amplified the entire coding region minus the secretion signal sequence. These include restriction sites for subcloning into the
15 bacterial expression vector pQE-30 (Qiagen Inc., Valencia, CA) at sites BamHI/HindIII for Beer and Gremlin, and sites SacI/HindIII for Dan. pQE30 contains a coding sequence for a 6x His tag at the 5' end of the cloning region. The completed constructs were transformed into *E. coli* strain M-15/pRep (Qiagen Inc) and individual clones verified by sequencing. Protein expression in M-15/pRep and purification (6xHis
20 affinity tag binding to Ni-NTA coupled to Sepharose) were performed as described by the manufacturer (Qiagen, The QIAexpressionist).

The *E. coli*-derived Beer protein was recovered in significant quantity using solubilization in 6M guanidine and dialyzed to 2-4M to prevent precipitation during storage. Gremlin and Dan protein were recovered in higher quantity with
25 solubilization in 6M guanidine and a post purification guanidine concentration of 0.5M.

B. Production and testing of polyclonal antibodies:

Polyclonal antibodies to each of the three antigens were produced in rabbit and in chicken hosts using standard protocols (R & R Antibody, Stanwood, WA;
30 standard protocol for rabbit immunization and antisera recovery; Short Protocols in

Molecular Biology. 2nd edition. 1992. 11.37- 11.41. Contributors Helen M. Cooper and Yvonne Paterson; chicken antisera was generated with Strategic Biosolutions, Ramona, CA).

Rabbit antisera and chicken egg IgY fraction were screened for activity
 5 via Western blot. Each of the three antigens was separated by PAGE and transferred to 0.45um nitrocellulose (Novex, San Diego, CA). The membrane was cut into strips with each strip containing approximately 75 ng of antigen. The strips were blocked in 3% Blotting Grade Block (Bio-Rad Laboratories, Hercules, CA) and washed 3 times in 1X Tris buffer saline (TBS) /0.02% TWEEN buffer. The primary antibody
 10 (preimmunization bleeds, rabbit antisera or chicken egg IgY in dilutions ranging from 1:100 to 1:10,000 in blocking buffer) was incubated with the strips for one hour with gentle rocking. A second series of three washes 1X TBS/0.02%TWEEN was followed by an one hour incubation with the secondary antibody (peroxidase conjugated donkey anti-rabbit, Amersham Life Science, Piscataway, NJ; or peroxidase conjugated donkey
 15 anti-chicken, Jackson ImmunoResearch, West Grove, PA). A final cycle of 3X washes of 1X TBS/0.02%TWEEN was performed and the strips were developed with Lumi-Light Western Blotting Substrate (Roche Molecular Biochemicals, Mannheim, Germany).

20 C. Antibody cross-reactivity test:

Following the protocol described in the previous section, nitrocellulose strips of Beer, Gremlin or Dan were incubated with dilutions (1:5000 and 1:10,000) of their respective rabbit antisera or chicken egg IgY as well as to antisera or chicken egg IgY (dilutions 1:1000 and 1:5000) made to the remaining two antigens. The increased
 25 levels of nonmatching antibodies was performed to detect low affinity binding by those antibodies that may be seen only at increased concentration. The protocol and duration of development is the same for all three binding events using the protocol described above. There was no antigen cross-reactivity observed for any of the antigens tested.

EXAMPLE 5

INTERACTION OF BEER WITH TGF-BETA SUPER-FAMILY PROTEINS

The interaction of Beer with proteins from different phylogenetic arms of the TGF- β superfamily were studied using immunoprecipitation methods. Purified

5 TGF β -1, TGF β -2, TGF β -3, BMP-4, BMP-5, BMP-6 and GDNF were obtained from commercial sources (R&D systems; Minneapolis, MN). A representative protocol is as follows. Partially purified Beer was dialyzed into HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl). Immunoprecipitations were done in 300 μ l of IP buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1mM EDTA, 1.4 mM β -mercaptoethanol, 0.5 %

10 triton X 100, and 10% glycerol). 30 ng recombinant human BMP-5 protein (R&D systems) was applied to 15 μ l of FLAG affinity matrix (Sigma; St Louis MO)) in the presence and absence of 500 ng FLAG epitope-tagged Beer. The proteins were incubated for 4 hours @ 4°C and then the affinity matrix-associated proteins were washed 5 times in IP buffer (1 ml per wash). The bound proteins were eluted from the

15 affinity matrix in 60 microliters of 1X SDS PAGE sample buffer. The proteins were resolved by SDS PAGE and Beer associated BMP-5 was detected by western blot using anti-BMP-5 antiserum (Research Diagnostics, Inc) (see Figure 5).

BEER Ligand Binding Assay:

20 FLAG-Beer protein (20 ng) is added to 100 μ l PBS/0.2% BSA and adsorbed into each well of 96 well microtiter plate previously coated with anti-FLAG monoclonal antibody (Sigma; St Louis MO) and blocked with 10% BSA in PBS. This is conducted at room temperature for 60 minutes. This protein solution is removed and the wells are washed to remove unbound protein. BMP-5 is added to each well in

25 concentrations ranging from 10 pM to 500 nM in PBS/0.2% BSA and incubated for 2 hours at room temperature. The binding solution is removed and the plate washed with three times with 200 μ l volumes of PBS/0.2% BSA. BMP-5 levels are then detected using BMP-5 anti-serum via ELISA (F.M. Ausubel et al (1998) Current Protocols in Mol Biol. Vol 2 11.2.1-11.2.22). Specific binding is calculated by subtracting non-

30 specific binding from total binding and analyzed by the LIGAND program (Munson

and Podbard, Anal. Biochem., 107, p220-239, (1980).

In a variation of this method, Beer is engineered and expressed as a human Fc fusion protein. Likewise the ligand BMP is engineered and expressed as mouse Fc fusion. These proteins are incubated together and the assay conducted as described by Mellor et al using homogeneous time resolved fluorescence detection (G.W. Mellor et al., *J of Biomol Screening*, 3(2) 91-99, 1998).

EXAMPLE 6

10 SCREENING ASSAY FOR INHIBITION OF TGF-BETA BINDING-PROTEIN BINDING TO TGF-BETA FAMILY MEMBERS

The assay described above is replicated with two exceptions. First, BMP concentration is held fixed at the Kd determined previously. Second, a collection of antagonist candidates is added at a fixed concentration (20 uM in the case of the small organic molecule collections and 1 uM in antibody studies). These candidate molecules (antagonists) of TGF-beta binding-protein binding include organic compounds derived from commercial or internal collections representing diverse chemical structures. These compounds are prepared as stock solutions in DMSO and are added to assay wells at ≤ 1% of final volume under the standard assay conditions. These are incubated for 2 hours at room temperature with the BMP and Beer, the solution removed and the bound BMP is quantitated as described. Agents that inhibit 40% of the BMP binding observed in the absence of compound or antibody are considered antagonists of this interaction. These are further evaluated as potential inhibitors based on titration studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity. Comparable specificity control assays may also be conducted to establish the selectivity profile for the identified antagonist through studies using assays dependent on the BMP ligand action (e.g. BMP/BMP receptor competition study).

EXAMPLE 7

INHIBITION OF TGF-BETA BINDING-PROTEIN LOCALIZATION TO BONE MATRIX

Evaluation of inhibition of localization to bone matrix (hydroxyapatite) is conducted using modifications to the method of Nicolas (Nicolas, V. *Calcif Tissue Int* 5 57:206, 1995). Briefly, ¹²⁵I-labelled TGF-beta binding-protein is prepared as described by Nicolas (*supra*). Hydroxyapatite is added to each well of a 96 well microtiter plate equipped with a polypropylene filtration membrane (Polyfritroninc, Weymouth MA). TGF-beta binding-protein is added to 0.2% albumin in PBS buffer. The wells containing matrix are washed 3 times with this buffer. Adsorbed TGF-beta binding- 10 protein is eluted using 0.3M NaOH and quantitated.

Inhibitor identification is conducted via incubation of TGF-beta binding-protein with test molecules and applying the mixture to the matrix as described above. The matrix is washed 3 times with 0.2% albumin in PBS buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3 M NaOH and quantitated. Agents that inhibit 40% 15 of the TGF-beta binding-protein binding observed in the absence of compound or antibody are considered bone localization inhibitors. These inhibitors are further characterized through dose response studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity.

20

EXAMPLE 8

CONSTRUCTION OF TGF-BETA BINDING-PROTEIN MUTANT

A. Mutagenesis:

A full-length TGF-beta binding-protein cDNA in pBluescript SK serves 25 as a template for mutagenesis. Briefly, appropriate primers (see the discussion provided above) are utilized to generate the DNA fragment by polymerase chain reaction using Vent DNA polymerase (New England Biolabs, Beverly, MA). The polymerase chain reaction is run for 23 cycles in buffers provided by the manufacturer using a 57°C annealing temperature. The product is then exposed to two restriction enzymes and 30 after isolation using agarose gel electrophoresis, ligated back into pRBP4-503 from

which the matching sequence has been removed by enzymatic digestion. Integrity of the mutant is verified by DNA sequencing.

B. Mammalian Cell Expression and Isolation of Mutant TGF-beta binding-protein:

5 The mutant TGF-beta binding-protein cDNAs are transferred into the pcDNA3.1 mammalian expression vector described in EXAMPLE 3. After verifying the sequence, the resultant constructs are transfected into COS-1 cells, and secreted protein is purified as described in EXAMPLE 3.

10

EXAMPLE 9

ANIMAL MODELS -I

GENERATION OF TRANSGENIC MICE OVEREXPRESSING THE *BEER* GENE

The ~200 kilobase (kb) BAC clone 15G5, isolated from the CITB mouse
 15 genomic DNA library (distributed by Research Genetics, Huntsville, AL) was used to determine the complete sequence of the mouse *Beer* gene and its 5' and 3' flanking regions. A 41 kb SalI fragment, containing the entire gene body, plus ~17 kb of 5' flanking and ~20 kb of 3' flanking sequence was sub-cloned into the BamHI site of the SuperCosI cosmid vector (Stratagene, La Jolla, CA) and propagated in the *E. coli* strain
 20 DH10B. From this cosmid construct, a 35 kb MluI - AvuII restriction fragment (Sequence No. 6), including the entire mouse *Beer* gene, as well as 17 kb and 14 kb of 5' and 3' flanking sequence, respectively, was then gel purified, using conventional means, and used for microinjection of mouse zygotes (DNX Transgenics; US Patent No. 4,873,191). Founder animals in which the cloned DNA fragment was integrated
 25 randomly into the genome were obtained at a frequency of 5-30% of live-born pups. The presence of the transgene was ascertained by performing Southern blot analysis of genomic DNA extracted from a small amount of mouse tissue, such as the tip of a tail. DNA was extracted using the following protocol: tissue was digested overnight at 55°C in a lysis buffer containing 200 mM NaCl, 100 mM Tris pH8.5, 5 mM EDTA, 0.2%
 30 SDS and 0.5 mg/ml Proteinase K. The following day, the DNA was extracted once

with phenol/chloroform (50:50), once with chloroform/isoamylalcohol (24:1) and precipitated with ethanol. Upon resuspension in TE (10mM Tris pH7.5, 1 mM EDTA) 8-10 ug of each DNA sample were digested with a restriction endonuclease, such as EcoRI, subjected to gel electrophoresis and transferred to a charged nylon membrane, such as HyBondN+ (Amersham, Arlington Heights, IL). The resulting filter was then hybridized with a radioactively labelled fragment of DNA deriving from the mouse *Beer* gene locus, and able to recognize both a fragment from the endogenous gene locus and a fragment of a different size deriving from the transgene. Founder animals were bred to normal non-transgenic mice to generate sufficient numbers of transgenic and non-transgenic progeny in which to determine the effects of *Beer* gene overexpression. For these studies, animals at various ages (for example, 1 day, 3 weeks, 6 weeks, 4 months) are subjected to a number of different assays designed to ascertain gross skeletal formation, bone mineral density, bone mineral content, osteoclast and osteoblast activity, extent of endochondral ossification, cartilage formation, etc. The transcriptional activity from the transgene may be determined by extracting RNA from various tissues, and using an RT-PCR assay which takes advantage of single nucleotide polymorphisms between the mouse strain from which the transgene is derived (129Sv/J) and the strain of mice used for DNA microinjection [(C57BL5/J x SJL/J)F2].

ANIMAL MODELS -- II

DISRUPTION OF THE MOUSE BEER GENE BY HOMOLOGOUS RECOMBINATION

Homologous recombination in embryonic stem (ES) cells can be used to inactivate the endogenous mouse *Beer* gene and subsequently generate animals carrying the loss-of-function mutation. A reporter gene, such as the *E. coli* β -galactosidase gene, was engineered into the targeting vector so that its expression is controlled by the endogenous *Beer* gene's promoter and translational initiation signal. In this way, the spatial and temporal patterns of *Beer* gene expression can be determined in animals carrying a targeted allele.

The targeting vector was constructed by first cloning the drug-selectable phosphoglycerate kinase (PGK) promoter driven *neomycin-resistance* gene (*neo*)

cassette from pGT-N29 (New England Biolabs, Beverly, MA) into the cloning vector pSP72 (Promega, Madison, WI). PCR was used to flank the PGKneo cassette with bacteriophage P1 loxP sites, which are recognition sites for the P1 Cre recombinase (Hoess et al., PNAS USA, 79:3398, 1982). This allows subsequent removal of the neo-resistance marker in targeted ES cells or ES cell-derived animals (US Patent 4,959,317). The PCR primers were comprised of the 34 nucleotide (ntd) loxP sequence, 15-25 ntd complementary to the 5' and 3' ends of the PGKneo cassette, as well as restriction enzyme recognition sites (BamHI in the sense primer and EcoRI in the anti-sense primer) for cloning into pSP72. The sequence of the sense primer was 5'-AATCTGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATCTGCAG . GATTCGAGGGCCCCT-3' (SEQ ID NO:34); sequence of the anti-sense primer was 5'-AATCTGAATTCCACCGGTGTTAATTAAATAACTTCGT ATAATGTATGCTATACGAAGTTATAGATCTAGAG TCAGCTTCTGA-3' (SEQ ID NO:35).

The next step was to clone a 3.6 kb XhoI-HindIII fragment, containing the *E. coli* β -galactosidase gene and SV40 polyadenylation signal from pSV β (Clontech, Palo Alto, CA) into the pSP72-PGKneo plasmid. The "short arm" of homology from the mouse *Beer* gene locus was generated by amplifying a 2.4 kb fragment from the BAC clone 15G5. The 3' end of the fragment coincided with the translational initiation site of the *Beer* gene, and the anti-sense primer used in the PCR also included 30 ntd complementary to the 5' end of the β -galactosidase gene so that its coding region could be fused to the Beer initiation site in-frame. The approach taken for introducing the "short arm" into the pSP72- β gal-PGKneo plasmid was to linearize the plasmid at a site upstream of the β -gal gene and then to co-transform this fragment with the "short arm" PCR product and to select for plasmids in which the PCR product was integrated by homologous recombination. The sense primer for the "short arm" amplification included 30 ntd complementary to the pSP72 vector to allow for this recombination event. The sequence of the sense primer was 5'-ATTAGGTGACACT ATAGAACTCGAGCAGCTGAAGCTTAACCACATGGTGGCTCACAACCAT-3' (SEQ ID NO:36) and the sequence of the anti-sense primer was 5'-

AACGACGGCCAGTGAATCCGTA

ATCATGGTCAATGCTGCCAGGTGGAGGAGGGCA-3' (SEQ ID NO:37).

The "long arm" from the *Beer* gene locus was generated by amplifying a 6.1 kb fragment from BAC clone 15G5 with primers which also introduce the rare-cutting restriction enzyme sites SgrAI, FseI, AscI and PacI. Specifically, the sequence of the sense primer was 5'-ATTACCACCGGTGACACCCGCTTCCTGACAG-3' (SEQ ID NO:38); the sequence of the anti-sense primer was 5'-ATTACTTAATTAAACATGGCGCGCCAT ATGGCCGGCCCCTAATTGCGGCGCATCGTTAATT-3' (SEQ ID NO:39). The resulting PCR product was cloned into the TA vector (Invitrogen, Carlsbad, CA) as an intermediate step.

The mouse *Beer* gene targeting construct also included a second selectable marker, the *herpes simplex virus 1 thymidine kinase* gene (HSVTK) under the control of rous sarcoma virus long terminal repeat element (RSV LTR). Expression of this gene renders mammalian cells sensitive (and inviable) to gancyclovir; it is therefore a convenient way to select against neomycin-resistant cells in which the construct has integrated by a non-homologous event (US Patent 5,464,764). The RSVLTR-HSVTK cassette was amplified from pPS1337 using primers that allow subsequent cloning into the FseI and AscI sites of the "long arm"-TA vector plasmid. For this PCR, the sequence of the sense primer was 5'-ATTACGGCCGGCCGCAAAGGAATTCAAGATCTGA-3' (SEQ ID NO:40); the sequence of the anti-sense primer was 5'-ATTACGGCGCGCCCCTC ACAGGCCGCGACCCAGCT-3' (SEQ ID NO:41).

The final step in the construction of the targeting vector involved cloning the 8.8 kb SgrAI-AscI fragment containing the "long arm" and RSVLTR-HSVTK gene into the SgrAI and AscI sites of the pSP72-"short arm"-βgal-PGKneo plasmid. This targeting vector was linearized by digestion with either AscI or PacI before electroporation into ES cells.

EXAMPLE 10

ANTISENSE-MEDIATED BEER INACTIVATION

17-nucleotide antisense oligonucleotides are prepared in an overlapping format, in such a way that the 5' end of the first oligonucleotide overlaps the translation
5 initiating AUG of the Beer transcript, and the 5' ends of successive oligonucleotides occur in 5 nucleotide increments moving in the 5' direction (up to 50 nucleotides away), relative to the Beer AUG. Corresponding control oligonucleotides are designed and prepared using equivalent base composition but redistributed in sequence to inhibit any significant hybridization to the coding mRNA. Reagent delivery to the test cellular
10 system is conducted through cationic lipid delivery (P.L. Felgner, *Proc. Natl. Acad. Sci. USA* 84:7413, 1987). 2 ug of antisense oligonucleotide is added to 100 ul of reduced serum media (Opti-MEM I reduced serum media; Life Technologies, Gaithersburg MD) and this is mixed with Lipofectin reagent (6 ul) (Life Technologies, Gaithersburg MD) in the 100 ul of reduced serum media. These are mixed, allowed to complex for 30
15 minutes at room temperature and the mixture is added to previously seeded MC3T3E21 or KS483 cells. These cells are cultured and the mRNA recovered. Beer mRNA is monitored using RT-PCR in conjunction with Beer specific primers. In addition, separate experimental wells are collected and protein levels characterized through western blot methods described in Example 4. The cells are harvested, resuspended in
20 lysis buffer (50 mM Tris pH 7.5, 20 mM NaCl, 1mM EDTA, 1% SDS) and the soluble protein collected. This material is applied to 10-20 % gradient denaturing SDS PAGE. The separated proteins are transferred to nitrocellulose and the western blot conducted as above using the antibody reagents described. In parallel, the control oligonucleotides are added to identical cultures and experimental operations are repeated. Decrease in
25 Beer mRNA or protein levels are considered significant if the treatment with the antisense oligonucleotide results in a 50% change in either instance compared to the control scrambled oligonucleotide. This methodology enables selective gene inactivation and subsequent phenotype characterization of the mineralized nodules in the tissue culture model.

SEQUENCES

Sequence ID No. 1: Human BEER cDNA (complete coding region plus 5' and 3' UTRs)

5
AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAATCATCCC
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACAAACAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCAACCGCTACGTGACCGAT
10 GGGCCGTGCGCAGCGCCAAGCCGGTCAACGAGCTGGTGTGCTCCGGCCAGTGCAGGCCCGCGCGCTGTGCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCAGCGCGTGC
AGCTGCTGTGTCCCGGTGGTGAAGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGAAGCGCTCACC
CGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGACCGAGGCGCTCGGCCGAGAGGGCCGAAGCCGCGGCCCG
CGCCCCGAGCGCCAAGCCAACAGGCCGAGCTGGAGAACCCCTACTAGAGCCCGCCCGCGCCCTCCCCACCGCGGGC
15 GCCCCGGCCCTGAACCCGCGCCCACTTTCTGTCTCTGCGCGTGGTTTGAATTGTTTATATTTATTGTAAATGCCTGC
AACCCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCCCTCAGCCCGCCAGCTG
AGGGGTCCCAAGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCAACGAGCCCGCCCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
20 GAAAGTCCAGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAAGTGTGTGTAACCTTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
CAGTTGCATTGATTAGTCCCAAGGTCACTTCCAGAATTCAGAGTTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAAA
CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAGCTATGCTG
25 CTTCCAGCCTGGCTTCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGTGGTGGGAGGATAGAAATCACATCCGCCCACTTCCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAAGTGAAGGTTCAAGGACACTGGCCTTGACGGCCGAGGGAGC
AGCCATCAAACTCACAGACCAGCACATCCCTTTGAGACACCGCCTTCTGCCACCACTCACGGACACATTTCTGCCT
AGAAAAAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAAATATTATTGGGGGAAAACTACAAGT
30 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAATCTTTTGAATATCATTTCCAGACAACCTC
TTACTTTCTGTGTAGTTTTTAATGTTTAAAAAALAAAGTTTAAACAGAGCAGATGACATATGAAGCCTGCGGACT
GGTGGTTTTTTTGGCAATTTCCACGTGGGACTTGTCCACAAGATGAAGTAGTGGTTTTAAAGAGTTAAGTTACAT
ATTTATTTCTCACTTAAGTTATTATGCAAAAGTTTTCTGTAGAGAAATGCAATGTTAATATTGCTTTATGAATTA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 2: Human BEER protein (complete sequence)

40 MQLPLALCLVCLLVHTAFRVVEGQGWQAFKNDATETIPELGEYPEPPPELENNKTMNRAENGRRPPHPHFETKDVSEYSC
RELHFTRYVTDGPRCSAKPVTELVCSGQCGPARLLPNAIGRKWWRPSGPDFRCIPDRYRAQRVQLLCPGGEAPRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

45 Sequence ID No. 3: Human Beer cDNA containing Sclerosteosis nonsense mutation

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCTAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAATCATCCC
50 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACAAACAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCAACCGCTACGTGACCGAT
GGGCGGTGCCGAGCGCCAAGCCGGTCAACGAGCTGGTGTGCTCCGGCCAGTGCAGGCCCGCGCGCTGCTGCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGGTGC
AGCTGCTGTGTCCCGGTGGTGAAGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGAAGCGCTCACC
55 CGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGAGAGGGCCGGAAGCCGCGGCCCG
CGCCCCGAGCGCCAAGCCAACAGGCCGAGCTGGAGAACCCCTACTAGAGCCCGCCCGCGCCCTCCCCACCGCGGGC
GCCCCGGCCCTGAACCCGCGCCCACTTTCTGTCTGCGCGTGGTTTGAATTGTTTATATTTATTGTAAATGCTGC
AACCCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCGGGGCGCGGCAAGGCCCCCTCAGCCCGCAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGACGCCCGCCCTCTGGGGCGCCTACCT
60 TTGCTGGTCCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
GAAAGTCCAGGAGTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAAAGTGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAAGTGTGTGTAACCTTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
65 CAGTTGCATTGATTAGTCCCAAGGTCACTTCCAGAATTCAGAGTTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAAA

CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
CTTCCCAGCCTGGCTTCCCAGGATGTTTGGCTACCTCCACCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCACTTCCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAAGTGAAAGGTTCAAGGACACTGGCCTTGACAGGCCGAGGGAGC
5 AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCACCCTACCGGACACATTCTGCCT
AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGAAAACTACAAGT
GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAATCTTTTGAAATCATTTCCAGACAACTC
TTACTTTCTGTAGTTTTTAATTGTTAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
GGTCGTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAAGTAGTGGTTTTTAAGAGTTAAGTTACAT
10 ATTTATTTCTCACTTAAGTTATTATGCAAAAGTTTTCTTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTTCTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 4: Truncated Human Beer protein from Sclerosteosis
15 MQLPLALCLVCLLVHTAFRVVEG*

Sequence ID No. 5: Human BEER cDNA encoding protein variant (V10I)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCATCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCG
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
25 CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTTCAACCCGCTACGTGACCGAT
GGGCGGTGCCGAGCGCAAGCCGGTCAACGAGCTGGTGTCTCCGGCCAGTGGCGGCCGCGCTGCTGCCCAACGC
CATCGGCGCGGCAAGTGGTGGCGACTTAGTGGGCGGACTTCCGCTGCATCCCGGACCGCTACCECGCGCAGCGGTGC
AGCTGCTGTGTCCCGTGGTGGGCGCGCGCGCAAGGTGGCGCTGGTGGCCTCGTGCAAGTGAAGCGCCTCACC
CGCTTCCACAACCACTGGAGCTCAAGGACTTCCGGACCGAGGCGCTCGGCGCAGAAAGGCGGAAGCCGCGGCCCCG
30 CGCCCCGAGCGCAAGGCCAACCAGGCGAGCTGGAGAACGCTTACTAGAGCCCGCGCGCCCTCCACCGCGGGC
GCCCCGGCCTGAACCGCGCCCCACATTTCTGCTCTGCGCGTGGTTTIGATTGTTTATTTTCAATTGTAATGCCTGC
AACCAGGGCAGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGCGCGCAAGGCCCCCTCAGCCCGCAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTACAGACACTGAGCCACGAGCCCGCCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCCAGAGGAGCAGAAATGGAAGCATTTTACCGCCCTGGGGTTTAAAGGAGCGGTGTGGAGTGG
35 GAAAGTCCAGGACTGGTTAAGAAAGTTGATAAGATTCCCCCTTGCACTCGCTGCGCCATCAGAAAGCCTGAGGGTGC
CCAGAGCACAAGACTGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATTGCTGTGTAACTTGAAC
TACAAATTTCTCTTCCGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCGAGGTGAGAGAGAGAGAGAAGAGAGAAATGAATG
40 CAGTTGCATTGATTCAAGTCCCAAGTCACTTCCAGAATTCAGAGTTGTGATGCTCTCTTGCAGCCAAAGATGAAAAA
CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
CTTCCCAGCCTGGCTTCCCAGGATGTTTGGCTACCTCCACCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCACTTCCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAAGTGAAGGTTCAAGGACACTGGCCTTGACGSCCGGAGGAGC
AGCCATCACAACTCACAGACCAGCACATCCCTTTGAGACACCGCCTTCTGCCACCACCTACCGGACACATTCTGCTCT
45 AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGAAAACTACAAGT
GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAATCTTTTGAAATCATTTCCAGACAACTC
TTACTTTCTGTAGTTTTTAATTGTTAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
GGTCGTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAAGTAGTGGTTTTTAAGAGTTAAGTTACAT
ATTTATTTCTCACTTAAGTTATTATGCAAAAGTTTTCTTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
50 CAGTCTGTTCTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 6: Human BEER protein variant (V10I)

55 MQLPLALCLICLLVHTAFRVVEGQWQAFKNDATBIIRELGEYPEPPPELENNKTMNRAENGRRPPHPFETKDVSEYSC
RELHFTRYVTDGPRSAKPVTELVCSGQCGRLLPNAIGRGKWRPSGPDFRCIPDRYRAQRVQLCPGGEAPRARKVR
LVASCKKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

60 Sequence ID No. 7: Human Beer cDNA encoding protein variant (P38R)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTGTCTGCTG
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCG
65 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTTCAACCCGCTACGTGACCGAT
GGGCGGTGCCGAGCGCAAGCCGGTCCGAGCTGGTGTGCTCCGGCCAGTGGCGGCCGCGCGCTGCTGCCAAACGC

CATCGGCCGCGGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCCGACCCTACCGCGCGCAGCGGTGC
 AGCTGCTGTGTCCCGTGGTGGAGGCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGAAGCGCCTCACC
 CGCTTCCACAACCAAGTCGGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGAGAAAGGCCGGAAGCCCGGCCCGC
 CGCCCGGAGCGCCAAAGCTAACAGGCCGAGCTGGAGAAGCCTACTAGAGCCCGCCCGCGCCCTCCCCACCGCGGGC
 5 GCCC CGCCCTGAACCCGCGCCCACTTCTGTCTCTGCGCGTGGTTGATTGTTTATATTTCATTGTAAATGCCTGC
 AACCCAGGCGAGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCGCAAGGCCCTCCAGCCGCGCAGCTG
 AGGGGTCCACCGGGCAGGGGAGGAATTGAGAGTCAAGACACTGAGCCACGAGCCCGCCTCTGGGGCCGCTACCT
 TTGCTGGTCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTACCGCCTGGGGTTTAAAGGAGCGGTGTGGGAGTGG
 10 GAAAGTCCAGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAAGACTGGGGCAACTGTAGATGTGGTTCTAGTCTGGCTCTGCCACTAATCTGTGTGAACCTTGAAC
 TACACAATTCTCTTCCGGACCTCAATTTCEACTTTGTAAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGGACTCCAGTGCTTTTGAATGGGCGAGAGGTGAGAGAGAGAGAGAAAGAGAGAGAATGAATG
 CAGTTGCATTGATTCAAGGCTCACTTCCAGAATTGAGAGTTGTGATGCTCTCTTGACAGCCAAAGATGAAAAA
 15 CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAAACTCCTGGGAAGAGCTATGCTG
 CTTCACGCTGGCTTCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCAACTTCCCAAAGAGCAGCATCCTCCCCCG
 ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAAAGTAAAGGTTCAAGGACACTGGCCTTGACGAGCCCGAGGGAGC
 AGCCATCACAACTCACAGACCAGCATCCCTTTTGGAGACACCGCCTTCTGCCCACTCAGGCACACATTTCTGCT
 20 AGAAAACAGCTTCTTACTGCTTACATGTGTGATGGCATATCTTACACTAAAAGAATATTATGGGGGAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAATCATTTCCAGACAACCTC
 TTACTTTCTGTGTAGTTTAAATGTTTAAAAAAGTTTAAACAGAAAGCATGACATATGAAAGCCTGCAGGAGCT
 GGTGCTTTTGGCAATTCTCCAGTGGGACTGTGCCAAGAAAGTAAAGTAGTGGTTTAAAGAGTTAAGTTACAT
 ATTTATTTCTCACTTAAGTTATTTATGCAAAAGTTTCTGTGTAGAGAAATGCAATGTTAATATTGCTTTATGAATTA
 25 CAGTCTGTTCTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 8: Human Beer protein variant (P38R)

30 MQLPLALCLVCLLVHTAFRVVEGGQWQAFKNDATETIIRELGEYPEPPPELENNKTMNRAENGGRPPHPFETKDVSEYSC
 RELHFTRYVTDGPRCAKPVTELCSGQCGPARLLPNAIGRGKWRPSPGDFRCIPDRYRAQRVQLLCPGGGAAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGTEAARPOKGRKPRPRARSAKANQAELENAY

35 Sequence ID No. 9: Vervet BEER cDNA (complete coding region)

ATGCAGCTCCCACTGGCCCTGTGTCTGTCTGCTGCTGTTACACGACGCTTCCGTGTAGTGGAGGGCCAGGGGTGGCA
 GGCCTTCAAGAAATGATGCCACGGAATCATCCCGAGCTCGGAGAGTACCCGAGCCTCCACCGAGCTGGAGAACAACA
 40 AGACCATGAACCGGGCGGAGAATGGAGGGCGGCTCCCCACCACTTGTAGACCAAGACGTGTCGAGTACAGCTGC
 CGAGAGCTGCACTTCAACCGCTACGTGACCGAAGGGCCGTGCCGCGAGCGCCAAAGCCAGTCAACGAGTTGGTGTGCTCCG
 CCAGTGGGCGCGGCAAGCCTGTGCCCCAACGCCATCGGCGCGGCAAGTGGTGGCGCCGAGTGGGCGGCACTTCCGCT
 GCATCCCGACCGCTACCGCGCGAGCGTGTGAGCTGCTGTCTCCCGTGGTGGCGCGCGCGCGCAAGGTGCGC
 CTGGTGGCTCGTGCAAGTGAAGCGCTCACCCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGTCCCGAGGCGGC
 45 TCGGCGCGAGAAGGGCGGAGCCGCGCGCCCGCGCGCGGGGGCCAAAGCCAATCAGGCCGAGCTGGAGAAGCGCTACT
 AG

Sequence ID No. 10: Vervet BEER protein (complete sequence)

50 MQLPLALCLVCLLVHAAFRVVEGGQWQAFKNDATETIIRELGEYPEPPPELENNKTMNRAENGGRPPHPFETKDVSEYSC
 RELHFTRYVTDGPRCAKPVTELCSGQCGPARLLPNAIGRGKWRPSPGDFRCIPDRYRAQRVQLLCPGGGAAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGPEAARPOKGRKPRPRARSAKANQAELENAY

55 **Sequence ID No. 11: Mouse BEER cDNA (coding region only)**

ATGCAGCCCTCACTAGCCCCGTGCTCATCTGCTACTTGTGCACGCTGCCTTCTGTGCTGTGGAGGGCCAGGGGTGGCA
 AGCCTTCAGGAATGATGCCACAGAGGTCACTCCAGGGCTTGGAGAGTACCCGAGCCTCCTCTGAGAACCAACAGACCA
 60 TGAACCGGGCGGAGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAAGGTGTGTCGAGTACAGCTGCCGCGAG
 CTGCACTACACCGCTTCTGACAGACGCCCATGCCGCGAGCGCCAAAGCGGTCAACGAGTTGGTGTGCTCCGGCCAGTG
 CGGCCCGCGCGGCTGCTGCCCAACGCCATCGGGCGCGTGAAGTGGTGGCGCCGAAACGGACCGGATTTCCGCTGCATCC
 CGATTCGCTACCGCGCGAGCGGTGAGCTGTGCTGCCCGGGGCGCGCGCGCGCTCGCGCAAGGTGCTGCTGGT
 65 GCCTCGTGAAGTGAAGCGCTCACCCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCGGAGACCGCGCGGCC
 GCAGAAGGGTCAAGCCGCGCCCGGCGCCCGGGGAGCCAAAGCCAACAGGCGGAGCTGGAGAAGCGCTACTAGAG

MQPSLAPCLICLLVHAACFAVEGGQGWQAFRNDATEVPIGLGEYPEPPENNQTMMNRAENGGRPPHHPYDAKDVSEYSCRE
LHYTRFLTDGPCRSAPVTELVCSGQCGPARILLPNAIGRVKWWRPNGDFFRCIPDRYRAQRVQLLCPGGAAPRSRKVRLV
ASCCKRLTRFHNOSELKDFGPETARPOKGRKPRPGARGAKANOAELENAY

GAGGACCGAGTGCCCTTCTCTCTTCTGGCACCATTGCAGCTCTCACTAGCCCCCTTGCCCTTGCCCTGCCTGCTTGTACATGCA
GCCTTCGTTGCTGTGGAGAGCCAGGGGTGGCAAGCETTCAAGATATGATGCCACAGAAATCATCCCGGGA CT CAGAGAGTA
CCCAGAGCCTCTCTCAGGAAGTCTAGAGAAACCAACGACCATGAACCGGGCCGGAAGCGGAGGACGACCCCCCAGCTCTT
ATGACACCAAGAGCTGTCCGATACAGCTGCCGCGAGTGCCTACTACACCGCTTCGTCGAGACGAGCGGCCGCTGCGCGACT
CCCAAGCCCGTCAACGAGTTGGTGTGCTCGGGCCAGTGCGGCCCCGCGCGSCTGCTGCCAACGCCATCGGGCGGTGAA
GTGGTGGCGCCCCAACGGACCGACTTCCGCTGCATCCCGGATCGCTACCGCGCGCAGCGGGTGCAGCTGCTGTGCCCCG
GCGGCGCGCGCGCGCTCGCGCAAGGTGCGTCTGGTGGCCTCGTCAAGTGC AAGCGCTCACCCGCTTCCACACCAG
TCGGAGCTCAAGGACTTCGGACCTGAGACCTCGCGCGCCGCGCAGAAAGGTCGCAAGCCGCGGCCCGCGCCCGGGAGCCAA
AGCCAAACAGGCGGAGCTGGAGAACGCGCTACTAG

Sequence ID No. 14: Rat BEER protein (complete sequence)

25

MQLSLAPLACLCLLVAAAFVAVESQGWQAFKNDATETIIPGLREYPEPPQLENNQTMNRAENGGRPPHPYDTKDVSEYSC
RELHYTRFVTDGPFCSAKPVTELVCSSGQCPGARLLPNAIGRVKWWRPNGPDFRCIPDRYRAQRVQLLCPGGAAPRSRKVR
LVASCKCKRLTRFHNQSELKDFGEPATPQGRKPRPRARGAKANQAELENAY

30

Sequence ID No. 15: Bovine BEER cDNA (partial coding sequence)

35 AGAATGATGCCACAGAAATCATCCCGAGCTGGGCGAGTACCCCGAGCCTCTGCCAGAGCTGAACAACAGACCATGAAC
CGGGCGGAGAACGGGAGGGAGAGCTCCCCACCAACCCCTTTGAGACCAAGACGCCTCCGAGTACAGCTGCCGGGAGCTGCA
CTTCACCCGCTACGTGACCGATGGGCGGCGCGACGCCAAGCCGGTACCGAGCTGGTGTGCTCGGGCGATGTGCGGCC
CGGCGCGCTCTGTGCCAACCGCATCGCGCGCGGCAAGTGGTGGCGCCCAAGCGGCGCCGACTCTCCGCTGCATCCCCGAC
CGCTACCGCGCGCAGCGGGTGCAGCTGTTGTGTCTCGGCGGCGCGGCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTC
40 GTGCAAGTGCAGAGCCCTCACTCGCTTCCCAACCAACGACTCCGAGCTCAAGGACTTCGGGCCCGAGGCCCGCGCGCAAA
CGGGCCGAAGCTGCGGGCCCGCGCCCGGCGGCCAACAAGCCAGCCGGGCGCA

Sequence ID No. 16: Bovine BEER protein (partial sequence -- missing signal sequence and last 6 residues)

NDATEIIPELGEYPELPPELNNTMNAENGRRPPHPHFFETKDASEYSCRELHFTRYVTDGPCRSAKPVTELCSGQCGP
ARLLPNAIGRGKWRPSGPDFRCIPDRYARQVRQLCPGGAAPRARKVRLVASCKKRLTRFHNQSELKDFGPEAAPQT
GKLEPRARGTKASRA

Sequence ID No. 17: MluI - AviII restriction fragment used to make mouse Beer transgene

55 CGCGTTTTGGTGAGCAGCAATATTGCGCTTCGATGAGCCTTGGCGTTGAGATTGATACCTCTGCTGCACAAAAGGCAATC
GACCGAGCTGGACCAGCGCATTTCGTGACACCGTCTCCTTCGAACCTATTTCGAATGGAGTGTCAATTCATCAAGGACNCCC
TGATCGCAAAATGGTGCTATCCACGCGAGCGCAATCGAAACCCCTCAGCCGGTGACCAATATCTACAACCTTGACCTTCGGT
ATCTCGCTGATGAGCCAGCGCAGAACGTAACCGTCAGTCCGCGTAAAGTTCAAAAGTTAAACCTGGTGTGATACCA
60 CATTGAACCGTTGATCGAAACAGCGCTCGTGAATGTCGGGCTGGATGTGCACAAAGCAAAATGGCAGCAG
ACAAGAAAGCGATGGATGAACTGGCTTCCTATGTCCGACAGGCCATCATGATGGAATGTTTCCCGGTGGTGTATTCTGG
CAGCAGTCCCGTCGATAGTATGCAATTGATAATTATTATCATTTCGGGTCCTTTCCGCGGATCCGCTTGTTCAGGGGG
GGCGACCTTCGCGGGTTTTCGCTATTTATGAAATTTTCGGTTTAAAGCGTTTCGGTTCTTCTTCGTGATCAACTTAATGT
TTTTATTTAAAATACCTCTGAAAGAAAGAAACGACAGGTGCTGAAAGCGAGCTTTTGGCCTCTGTCTGTTCTCTTCT
TCTGTTTTTGTCCGTGGAATGAAACATGGAAGTCAACAAAAGCAGAGCTTATCGATGATAAGCGGTGCAACATGAGAAAT

AATACTCTTAAATCTGGGTGGGAGAGTGGCCTGCTGTAATCCAGAACTCGGGAGGGGAGACAGGGAATCATCAGA
 GCAAACTGGCTAACAGAAATAGCAAAACACTGAGCTCTGGGCTCTGTGAGAGATCTGCGCTTAACATATAAGAGAGAGAA
 TAAACATTGAAGAAGACAGTAGATGCCAATTTTAAAGCCCCACATGCACATGGACAAGTGTGCGTTTGAACACACATAT
 GCACCTCATGTGAACAGGCATGCACACTCGGGCTTATCACACACATAATTTGAAAGAGAGAGTGTGAGAGAGGAGAGTGCAC
 5 ATTAGAGTTTACAGGAAAGTGTGAGTGAGCACACCCATGCACACAGACATGTGTGCCAGGAGTAGGAAAGGAGCCTGGG
 TTTGTGTATAAGAGGGAGCCATCATGTGTTTCTAAGGAGGGCGTGTGAAGGAGGCGTGTGTGGCTGGGACTGGAGCAT
 GGTGTAACTGAGCATGCTCCCTGTGGGAAACAGGAGGGTGGCCACCCTGCAGAGGGTCCCACTGTCCAGCGGGATCAGT
 AAAAGCCCCTGCTGAGAACTTTAGGTAATAGCCAGAGAGAGAAAGGTAGGAAAGTGGGGGACTCCCATCTCTGATGTAG
 GAGGATCTGGGCAAGTAGAGGTGCGTTTGTAGGTAGAAAGAGGGGTGCAGAGGAGATGCTCTTAATTCTGGGTGAGCAGTT
 10 TCTTTCCAAATAATGCCCTGTGAGGAGGTGTAGGTGGTGGCCATTCACTCACTCAGCAGAGGAGATGATGATGCCCGTGGGA
 TGCTGGAAATGGCCGAGCATCAACCCCTGGCTCTGGAAGAATCCATCTTTCAGAGGAGAGTGGATCTGTGTATGCCAG
 CGGGGTGCAGAGTGCTTGGGGCCCTGGGGGACTCCTAGCACTGGGTGATGTTTATCGAGTGTCTTGTGTGCCAGGCAC
 TGGCCTGGGGCTTGTGTTCTGTCTCTGTTTGTGTTTGTGTTTGTGAGACAGACTCTTGCTATGTATCCGTGTCAATCTTGG
 AATCTCACTGCATAGCCAGGCTGCGGAGAGAGGGGAGGGCAATAGGCCTTGAAGCAAGCCACTTCAGAGACTAGAC
 15 TCCACCTGCGAATGATGACAGGTGAGAGCTGAGTTCGGAAGATTTTTTTTCCAGTGCAGGTGGAGTGTGGAGTGGC
 AGCTAGCGGCAAGGTAGAGGGCGAGCTCCCTGTGAGGAGAAATGCAAGCAAGAGATGGCAAGCCAGTGTAGTTAAGCAT
 TCTGTGTGGGAGCAGGTGGATGAAGAGAGAGGCTGGGCTTTCGCTCTGGGGGGGGGTGAGGGGTGGGGATGAGGTGA
 GAGGAGGGCAGCTCCCTGAGTGTGATGAGATTTTCCCTGACAGTGACCTTGGCCTCTCCCTCCCCCACTTCCCTTCTT
 TCCTTTCTTCCACCATTGCTTTCTTGTCTTGTAGAAATCTGAGTTTCCACTTCACTGGTGTGAGACGGAAACAGA
 20 AGCCGT
 GTATGT
 GATGCAAGGAGAGAGGAGAGGAGGGATACAGAGAGGAAATTAAGGGAGCTACAAGAGGCAATGTTGGGGTGTGTGTGT
 TGTGTGTGTGTGTGTATTTATTTGTATTGAAATACATTTCTTTTAAAAAATACTTATCCATTTATTTATTTATTTATGTCACGT
 GTGTGTGCTGCATGAGTTTGTGTGTGCTGAGT
 25 AACTGGAGTTGGAGGAGGTGTGAGTCCCTGACATGTTTGTGTGGAACTGAACCCCGGTCTATGCAAGAGCAGGAAGT
 GCAGTTATCTGCTGAGCCATCTCTCCAGTCTTGAATCCATTCTCTTAAATAACAGTGGCAGAGACATGATGGATTTA
 CGTATGGAATTAATGTGGCGGTCAATTAAGTTCGGGCACAGGCAAGCACCTGTAAGGCCATCACCAACCGCAACAGTGA
 ATGTGACCATCACCCCATGTTCTTCTGTGCTCCCTGTCCCTCCATCTCCATTCTCAAGCACCTCTTGCTCTGCTCTG
 30 TGGGTTCTGACTCTGCTATCACACACTACTGACTGCAATCTCTGCTCTCTTTTTTAAACATATTTTATTTGTGTTGT
 GTGTATGCACATGTGCCACATGTGTACAGATACTATGAGGGCCAGAAGAGGCCATGGCCCTCCCTGGAGCTGGAGTTACA
 GGCAGCGTGTGAGCTGCTGGTGTGGGTGCTGGGAACCAAACTGAATCTAAGCAAGCACTTTTAACTGTGAGGCAGC
 TCTCAGTACCTTCTTCAATTTCTCGCTGGGTTCATGTATGAGACACATGTAGCTAGAATATCTTGCTTATCTAATTA
 TGTACATTGTTTGTCTAAGAGAGAGTAATGCTCTATAGCCTGAGCTGGCCTCAACCTTGCCATCTCTGCTCAGCC
 35 TCCTCTCTGAGTGTAGGATGACAGCGAGTGGTAACCTACATGGTTTCTGTGTTTGTGTTCAAGACTGAAGGATAACAT
 TCATACAGAGAAGTCTGGGTCAAAAGTGTGCAATTCATGAAATGGCAACCCGTGATCAAGAAACAAACTCAGGGG
 CTGGAGAGATGGCACTGACTGCTTCCAGAGGTCCGGAGTTCAATTTCCAGCAACACATGGTGGCTCACAGCCATCTA
 TAAAGAGATCTGACGCCCTCTTCTGCTGTGTCTGAAGACAGCTACAGTGTACTACATAAATAAATAATCTTTAAAC
 ACACACACACACAATTACCACCCAGAAAGCCCACTCCATGTTCCCTCCACGTCTCTGCTACAGTACTCCAGGTT
 40 ACCACTGTTTCAAGCTTCTAACAACCTGGTTTACTTGGGCTCTTCTGCTCTGTGGAGCCACACATTTGTGTGCTCAT
 ACACGTTCTTTCTAGTAAGTTGCATATTACTCTGCGTTTTCATGTAATTTATTTATTTAGTTGTGTGTGCGTGTGGGC
 CCATGATGGCACAGTGTGTGGGATGTGAGATATTGTGAACAGGGGACAGTCTCTTTCTCAATCATGTGGGTTCCAG
 AGGTTGAACTCAGGTATCATGTGTGTGGCAGCAATGCCTTTACCCACTGAGACATCTCATATTCTTTTTTTTCCCTG
 45 AGGTGGGGGCTTGTTCATAGCCCAAAGTGGCTTTGCACTTGCAGTTCAAAGTGAACCTCTGCTCCACCTCTTAGAGTA
 TTGGAATTACGATGTGTACTACACACCTGACTGGATCATTAAATCTTTGATGGGGGCGGGGAAGCGACATGCTGCAGG
 TGAAGGGATGACTGGACATGAGCGTGAAGCCAGAGACAGCTTCACTGTTACAGTCTTCCCACTGAGCTAATTTT
 GGTGTTGCCAGAGAACACTTACAGAAAGTCTCAGTGCCATGTGAGTTCGGGTTGGAGTTCAACTCATCAGCTTGACAT
 TGGCTCTCTACCCACTGAGCCTTCTCACTACTCTCTACCTAGATCATTAAATCTTTTTTAAAGACTTATTAGGGGGC
 TGGAGAGATGGCTCAGCCGTTAAGAGCACCGAATGCCCTTCCAGAGGTCTGAGTTCAATTTCCAGCATGCCATTGTG
 50 CCAGTAGGGGGCGCAGGTGTTCAACGTGAGTAGTGTGTGCGAGTTTCCGCGGTGGAGAACCTCTTGACACCCCTGCTGT
 CCTGGTCATTCTGGGTGGGTGCATGGTGTATGCTTGTGTATGGAAGACTTTGACTGTTACAGTGAAGTTGGGCTTCCA
 CAGTTACACGCTCTCCCTGTTTCTTGAGGCGGGGTGCTGTGTCATTGCCGCGAGGGCTACAGCCGCTCCCAACGCTA
 GTTATCGCCTACCTCATGATGCGGCAGAGATGGACGTCAAGTCTGCTCTGAGTACTGTGAGGCAGAAATCGTGAGATCGG
 CCCCACGATGGCTTCTGCGCCAACTCTGCCAGCTCAATGACAGACTAGCCAAGGAGGGCAAGGTGAAACTCTAGGGTG
 55 CCCACAGCCTCTTTTGAGAGGTCTGACTGGGAGGGCCCTGGCAGCCATGTTTAGGAAACAGATATACCCACTCCCTGC
 ACCACAGACAGTGCACCATCTGTCCCACTCTGGTCTCGGGGGCCACTCCACCTTAGGGGACATGAAGAAGCTC
 CTAAGAAGTTCTGCTCTTAGCCATCTTCTGTAAATTTATGTCTCTCCCTGAGGTGAGGTTTCAAGTTTATGTCTCTG
 TCTGTGTCATGATACATCTCAGTGACCCAGGTGGGAGGGCTATCAGGTGATGGCCCGGACACGGGCACTCTTCAT
 GACCCCTCCCCACCTGGGTTCTTCTGTGTGGTCCAGAACACGAGCCTGGTAAAGGAATATGCAAAACACAGGCCCTG
 60 ACCTCCCCATGTCTGTTCTGGTCTTCTGAGCCGACAGCCCTGCTGAGGCAGACGAATGACATTAAGTTTGAAGCAG
 AGTGGAGATAGATTAGTACTAGATTTCCAAAAGAGGAAAAAAGGCTGCATTTTAAATTTATTTCTTGAATTTAA
 AGATACTACATAGGGGCCCTTGGGTAAGCAATCCATTTTCCAGAGGCTATCTTGATTCTTTGGAATGTTTAAAGTGT
 GCCTTGGCAGAGAGCTTACGATCTATATCTGTGCTTTCAGAGCCTTCCCTGAGGATGGCTCTGTTCTTTGCTTGTGTA
 65 AGAGCGATGCTTGGGAGGGTTTCCCTTTTTCAGAAATACAGGTTGTAAGTCCAGCCTATTACAAACCAACAAACAA
 CAAACAAACAAAGGACCTCCATTGGAAGATTGCAAGGATTTATCTGAATTTATAGTTGTGGTGAAGTTCAAGTCATCAC
 GCCAAGTGCTTGCATCTGTTGCTATTCTAAGAATAATTAGGAGGAGAACCTAGCCAATTGCAGCTCATGTCCGTGG
 GTGTGTGCACGGGTGCATATGTTGGAAGGGGTGCTGCTCCCTTGGGGACAGAGGAAATGAAAGGCCCTCTGCTCAC
 CCTGGCCATTTACGGGAGGCTCTGCTGGTTCACGGTGTCTGTGAGGATCTGAAACTGACTCGCTGGACAGAAACGAG

ATGAGTTTCAATCCCCAGCAACCATGTGGAAAAATAACCTTCTAACCTCAGAGTTGAGGGGAAAGGCAGGTGGATTCTGG
 GGGCTTACTGGCCAGCTAGCCAGCCTAACCTAAATGTCTCAGTCAGAGATCCTGTCTCAGGGAATAACTTGGGAGAATGA
 CTGAGAAAGACACCTCCTCAGGTCTCCCATGCAACCCACACAGACACACGGGGGGGGGTAATGTAATAAGCTAAGAAATA
 5 ATGAGGGGAAATGATTTTTTGTCTAAGAAATGAAATTCTGTGTTGGCCGCAAGAAGCCTGGCCAGGGAAGGAAGTGCCTTTG
 GCACACCAGCCTATAAGTCACCATGAGTTCCCTGGCTAAGAATCACATGTAATGGAGCCAGTCCCTCTTGCCTGGTGG
 TTGGCTCTCCCACTGGTTTTGAAGAGAAATTCAGAGAGATCTCCTTGGTCAGAATTGTAGGTGCTGAGCAATGTGGAGC
 TGGGGTCAATGGGATTCTTTAAAGGCATCCTTCCAGGGCTGGGTCTACTTCAATAGTAGSGTGCTGCACAGCAAGC
 GTGAGACCTTAGGTTAGAGTCCCAAGATCTGCCCAACCCCCCAAAAGGCATCCTTCTGCCTCTGGGTGGGTGGGGG
 10 GAGCAACACCTTTAACTAAGACCATTAGCTGGCAGGGGTAACAAATGACCTTGGCTAGAGGAATTTGGTCAAGCTGGAT
 TCCGCTTCTGTAGAAGCCCACTTGTTCCTTTGTTAAGCTGGCCACAGTTTGTGTTGAGAATGCCTGAGGGGCCAG
 GGAGCCAGACAATTAAGCCCAAGCTCATTTTGATATCTGAAAACACAGCCTGACTGCCCTGCCCTGGGAGGTACTGG
 GAGAGCTGGCTGTGTCCCTGCCCTCACCAACGCCCCCCCCCAACACACACTCCTCGGGTCACCTGGGAGGTGCCAGCAG
 CAATTTGGAAGTTTACTGAGCTTGAGAAGTCTTGGGAGGGGTGACGCTAAGCACACCCCTTCTCACCCCCCCCCACCCC
 ACCCCCGTGGAGGAGGGGTGAGGAAACATGGGACCAGCCCTGCTCCAGCCCGTCTTATTGGCTGGCATGAGGCAGAGG
 15 GGGCTTTAAAAGGCAACCGTATCTAGGCTGGACATGGAGCCTGTGCTACCGAGTGGCCCTCTCCACTGGCAGCATGC
 AGCCCTCACTAGCCCCGTGCCTCATCTGCTACTTGTGACGCTGCCTTCTGTGCTGTGGAGGGCCAGGGGTGGCAAGCC
 TTCAGGAATGATGCCACAGAGGTCTCCAGGGCTTGGAGAGTACCCGAGCCTCCTCTGAGAACAACAGACCATGAA
 CCGGGCGGAGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAAGGTACGGGATGAAGAAGCACATTAGTGGGG
 GGGGGTCTCTGGGAGGTGACTGGGGTGGTTTTAGCATCTTCTTACAGAGTTTGTGTGGGTGGCTAGCCTCTGTACATCA
 20 GGGCAGGGACACATTTGCCCTGGAAGAATACTAGCACAGCATAGAACTGGAGGGCAGCATTGGGGGGCTGGTAGAGAGC
 ACCCAAGGCAGGGTGGAGGCTGAGGTGAGCCGAGCTGGCATTAAACACGGGCATGGGCTGTATGATGGTCCAGAGAATC
 TCCTCCTAAGGATGAGGACACAGGTGAGTCTAGCTGTGACCAAGTGGGGAAGTATATGGTGGGCTGGATGCCAGATG
 CCATCCATGGCTGACTATATCCCACATGACCACCACATGAGGTAAGAAGGCCCCAGCTTGAAGATGGAGAAACCGAGA
 GGCTCCTGAGATAAAGTCACCTGGGAGTAAGAAGCTGAGACTGGAAGCTGGTTGATCCAGATGCCAAGGCAACCCTAG
 25 ATTGGGTTTGGGTGGGAACCTGAAGCCAGGAGGAATCCCTTTAGTTCCCTTGGCCAGGGTCTGCTCAATGAGCCAGA
 GGGTTAGCATTAAAGAACAGGGTTTGTAGGTGGCATGTGACATGAGGGGCAGCTGAGTGAAATGTCCCTGTATGAGCA
 CAGGTGGCACCCTTGGCTTGGCTTGCACCTGACCCAGCTTGGCTCATTCTGAGGACAGCAGAACTGTGGAGGC
 AGAGCCAGCACAGAGAGATGCTGGGGTGGGGTGGGGGTATCACGACGGAACCTAGCAGCAATGAATGGGGTGGGGTGG
 CAGCTGGAGGGACACTCCAGAGAAATGACCTTGTCTGGTCAACATTGTGTGGGAGGAGCTCATTTTCCAGCTTGCCAC
 30 CACATGCTGTCCCTCTGTCTCCTAGCCAGTAAGGGATGTGGAGGAAAGGGCCACCCAAAGGAGCATGCAATGCACTCA
 CGTTTTTGCAGAGGAAGTGTGTGACCTAAGGGCACTATTCTTGGAAAGCCCCAAACTAGTCTTCCCTTGGGCAACAGG
 CCTCCCCACATACCACCTCTGACGGGGTGGTAAATTAAGCCAGCCACAGAAAGGGTGGCAAGGCCCTACACCTCCCCCT
 GTTGTGCCCCCCCCCCCCCTGGAAGGTGCATCCTGGCTCTGCCCTCTGGCTTGGTACTGGGATTTTTTTTCTCTT
 TTAGTGCATATTGATCTGACACCATGGAACCTTTTGGAGGTAGACAGGACCCACACATGGATTAGTTAAAGCCTCCCAT
 35 CCATCTAAGCTCATGGTAGGATAGAGCATGTCCAAGAGAGGAGGGCAGGCATCAGACCTAGAAATATGGCTGGGCAT
 CCAACCCAATCTCCTTCCCCGAGAACAGACTCTAAGTCAGATCCAGCCACCTTGGATTAACAGCTCAAGGTACACAGA
 ACAAGAGAGTCTGGTATACAGCAGGTGCTAAACAAATGCTTGTGGTAGCAAAGCTATAGGTTTTGGGTGAGAACTCCGA
 CCAAGTCCGAGTGAAGAGCGAAAGGCCCTCTACTCGCCACCGCCCCCGCCCCCCTGGGGTCTATAACAGATCACTT
 TCACCTTGGGGAGCCAGAGAGCCCTGGCATCTTAGGTAGCCCCCCCCCGCCCCCCCCCGCAAGCAGCCACGCCCTGCC
 40 TTTGGGGCAAGTCTTTTCTCAGCCTGGACCTGTGATAATGAGGGGGTGGACGCGCCGCTTTGGTGCCTTTCAAGTTC
 AATGAATCTTATCCCTACCACCTGCCCTTCTACCCGCTCTCCACAGCAGCTGTCTGATTTATTACCTTCAATTAAC
 CTCCTCCTTCTTCCATCTCTGGGATACGCCCTGTGCCAGTGGCTGGTAAAGGAGCTTAGGAAGGACCAGAGCCAG
 GTGTGGCTAGAGGTACACAGGCAGGGTGGGGATGAGGAGCTAACTGGAAGAGTGTTTGGTTAGTAGGCACAAAGCCTT
 45 GGGTGGGATCCCTAGTACCGGAGAAGTGGAGATGGGCGCTGAGAAGTTCAAGACCATCCATCCTTAACATACAGCCAGT
 TTGAGGCCAGCCTGGGTACATAAAACCCCAATCTCAAAGCTGCCAATTCTGATTCTGTGCCACGTAGTGCCCGATGTA
 ATAGTGGATGAAGTCGTTGAATCCTGGGCAACCTATTTTACAGATGTGGGAAAGCAACTTAAAGTACCCTGCCACAC
 GATCACAAAGAAAGTAAGTGACAGAGCTCCAGTGTTCATCCCTGGGTTCAGGACAGGAGAGAGAAGCCAGGGTGGG
 ATCTCACTGTCTCCCGTGCCTCCTTCTATAATCCATACAGATTGCAAGCGCAGGGCAGGTTTGGAAAAAGAGAGAAG
 50 GGTGGAAGGAGCAGACAGTCTGGCCTAGGCTGCAGCCCTCACGCATCCCTCTCTCCGAGATGTGTCCGAGTACAGCT
 GCCGCGAGCTGCACTACCCGCTTCTGACAGACGGCCCATGCCGACGCGCAAGCCGTCACCGAGTTGGTGTGCTCC
 GGCCAGTGGCGCCCGCGCGCTGCTGCCCAACGCCATCGGGCGCGTGAAGTGGTGGCGCCGAACGAGCCGAGTTTCCG
 CTGCATCCCGGATCGTACCGCGCGCAGCGGTGCACTGCTGTGCCCGGGGGCGCGCCGCGCTCGCGCAAGGTGC
 GTCTGTGTGGCTCTGTCAAGTGAAGCGCCTCACCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCGCGAGACC
 55 GCGCGCGCGCAGAAGGGTTCGAAGCCGCGCGCCGCGCGCCGGGAGGCCAAAGCCAACAGGCGGAGCTGGAGAACGCCCTA
 CTAGAGCGAGCCCGCCTATGCAGCCCCCGCGCATCCGATTCTTTTCAAGTGAAGCCTGCAGCCCAAGCCAGGGGT
 GCCAAACTTTCCAGACCGTGTGGAGTTCCAGCCAGTAGAGACCGAGTCTTCTGCTCCGCTGCGGGGATGGGGAGG
 GGGTGGGGTTCGCGCGGCCAGGAGAGGAAGCTTGTAGTCCAGACTCTGCCTAGCCCCGGGTGGGATGGGGGTCTTTCTA
 CCTCGCGGACCTATACAGGACAAGGCAGTGTTCACCTTAAAGGGAGGGAGTGTGGAAACGAAGACCTGGGACTGG
 TTATGGAGCTACAGTAAGATCTACTCCTTCCACCAATGTAAGCCTGCGTGGGTAGATAGGTTTCTGACCTGACC
 60 TGGCCTAGTGTGATGTTGGGCTACGTGGTTCTCTTTTGGTACGGTCTCTTTGTAATAAGGAGCCGAACCTCTGCT
 GAGATTTCAAGGATTGGGGTACCCCGTGTAGACTGGTGGAGAGAGGAGAACAGGGGAGGGTTAGGGGAGAGATTGTGG
 TGGCAACCGCCTAGAAGAAGCTGTTTGTGGCTCCAGCCTCGCGCCTCAGAGGTTTGGCTTCCCCACTCCTTCTCT
 TCAAACTGCTCTTCAATCCATATCTGGGATAGGGAAGGCCAGGTCGAGAGATGGTGAAGGGCCAGAAATCACACTC
 65 CTGGCCCCCGAAGAGCAGTGTCCCGCCCCCACTGGCTGTATATTGTAAGGGATTTTCTACACAACAGTTTAAAGT
 CGTTGGAGGAAACTGGGCTTCCAGTCACTCCATCCTTGTCCCTTGGCAGGACACCACTCTGCTGCCACCCACGG
 ACACATTTCTGTCTAGAAACAGAGCGTGTGCTGTCTCTCTGAGACAGCATATCTTACATTAAGAAAGATAATACGGG
 GGGGGGGGGGAGGGCGCAAGTGTATACATATGCTGAGAAGCTGTGAGGCGCCACAGCACCCACCAATCTTTTGT
 AAATCATTTCCAGACACCTTACTTTCTGTGTAGATTTAATTGTTAAAGGGGAGGAGAGAGCGTTTGTAAACAGAA

TATTATAATCCAGGTTATAGTTCATTGCTGTAGAATTGGAGTCTTCATATCCAGGTAATCTCCACAGACATGCCACA
 AAACAACCTGTTCTACGAAATCTCTCATGGAATCTCCCTCCCGAGTAATCTAAACTGTGCAAACTACAGAATAAGTG
 ACAGTCACAGTCTCTAACGTTTTGGGCATGAGTCTGAAGTCTCATTGCTAAGTACTGGGAAGATGAAAACCTTACCTAGT
 5 GTCAGCATTTGGAGCAGAGCCCTTGGGATTTGAGATGGTCTTTGACAGAGCTCCTAATGGCTACATGGAGAGAGGGGCC
 TGGGAGAGACCCATACACCTTTTGCTGCTTATGTACCTGACCTGCTCCTTGGGAAGCTCTAGCAAGAAGGCTTCCCT
 GGATCACCACCCACCTTGCACCTCCAGAACTCAGAGCCAAATTAACCTTTCTTGTACTGCTCAAGACAGTCGGTC
 TGGGTTGTATCACTGTCAATGGGAACAGACTTGCCTGGATGGATAACTTGTACATTGCATAATGTCTAGAAATGAAAG
 TCCTATAGAGAAAAAGAAATTAGCTGGCACACAGATAGAGGCCCTGGAGGAGGCTGGCTTTGCTCTCCCGAGGAGGTG
 10 GCGAGTAAGGTGTAAATGTTTCATGGATGTAAATGGGCCATATATAGGGGTCTGGGGTAACAAGAAGGCTGTGAATATA
 AAGCACTGAAGGTATGTCTAGTCTGGAGAAGGTCACTACAGAGAGTTCTCCAACCTAGTGCCCATACACACACACACA
 CAC
 ATTGTGTGATTGTGTGTGTGACTCTGTATGTACATGCTCATCTTGCCCTATGAGTTGAAACCAATGGCCCTGAGAGG
 CATAACAACCACTGTGGCTGTGTGCTCAGCTTTTCTTAAAGCGTCTGTCTGGTTTCTGTCTAGCATCAGGCAGACT
 15 TGCAGCAGACTACATATGCTCAGCCCTGAAGTCTTCTAGGGTGCATGTCTCTCAGAAATTCAGAAAGTCACTGTGGC
 TCCAGGACCGCTGCCTCTCCCTCTGCCGCGAGGCTGCAGACTCTAGGCTGGGGTGGGAAGCAAGCTTACCTCTGGGAC
 AAGTATAACATGTTGGCTTTCTTCCCTCTGTGGCTCCAACTGGACATAAAATAGATGCAAGCTGTGTAATAAATATT
 TCCTCCCGTCCACTTAGTCTCAACAATAACTACTCTGAGAGCACTTATTAATAGGTGGCTTAGACATAAGCTTTGGCTC
 ATTCCCCACTAGCTCTTACTTCTTTAACTCTTCAAACCACTCTGTGTCTTCCACATGGTTAGTTACCTCTCTTCCAT
 CCTGGTTGCTTCTTCTTCGAGTCCGCTCAGTGTCTCTAGGTGATGCTTGAAGATATTCTTCTACAAAGCTGAGAG
 20 TGGTGGCACTCTGGGAGTTCAAGCCAGCCTGATCTACACAGCAAGCTCCAGGATATCCAGGGCAATGTTGGGAAAACCT
 TTCTCAAACAAAAGAGGGGTTCAAGTGTGAGGAGGAGACCCATGGGTTAAGAAGTCTAGACGAGCCATGGTGATGATA
 CCTTTTCATCAAGCACTTAGGAGGCAAGAAAGGTGAACTCTTTGACTTTGAGGCCAGCTAGGTTACATAGTGATACCC
 TGCTTAGT
 25 TATGTATAAGTATTTGCTGCACATATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTAT
 ACTCCCTAGAACTAGAGTATAGACAGTTGTGACATCCCCAACCCCCCACCATGTGGGTGCTTGAAGCTAACTCCTGT
 CCTTTGTAAGCAGCAGGTGTCTATGAACCTGAACCATCTCTCAGTCTCCAGATGTGCATTCTCAAAGAGAGTCTCTT
 CATATTTCCCTAAACTGAACATCCTTATCAGTGAGCATCTCAGTCCACCAAGCTACTGCAACCCCTCTTAGGGAACAT
 TCATATTCACTTCTACTTGGCTCATGAACTTAAGTAC
 30 CAAAAGCATGCATGTACACCACTCTTATAGACTATGCTTTGCTAAAGACTTTCTAGATACTTTAAACATCACTTCT
 GCCTTTTGGTGGGAGGTTCCAAGATTGGTACTGGCGTACTGGAACCTGAACAAGGTAGAGATCTAGAATACACAGCAGG
 TCAGAAGGGCCAGCTGTACAAGAGAGGTTCCACACCTTCCAGGAACACTGAGCAGGGGGCTGGGACCTTGCTCTCAG
 CCCAAGAACTAGTGCGTTTCTGTATGCATGCTCTCAGAGATTCCATAAGATCTGCCTTCTGCCATAAGATCTCCTGC
 ATCCAGACAAGCCTAGGGGAAGTTGAGAGGCTGCTGAGTCTCTCCACAGGCCCTTCTGCTGAGTATTTTTTTA
 35 TCTGGAGGAGAGGAATCAGGGTGGGAATGATCAAATACAATTATCAAGGAAAAGTAAAAACATATATATATATATAT
 AACTGATCTAGGGAGCTGGCTCAGCAGTTAAGAGTTCTGGCTGCCCTTGTCTCAGATCTGTCTTGGATTCCCAGCACCA
 CATGATGGCTTTCAACTGTATCTCTGCTTCCAGGGGATCCACAGCCTCTTCTGACCTCCATAGACAAGACCTAGTCTCT
 TGCAAGAGCACCAATGCTCTTATCTGTTGATCCATCTCTAGCTCATGTCAGATGATGATGATGATGATGATGATGAT
 40 GCTTTTACGAAGATGTCACTGCCAGTCACTTGGCATGAGTGATATTTGATTTCTTCTATGTTCTCACCTTGCAA
 TTTATAAGAAAGATATCTGCATTGTCTCCTGAGAGAACAAGGGTGGAGGGCTACTGAGATGGCTTAGGGGTAAAGGT
 GCTTGCCACAAAATCTGACAACTTAAGTTTGGTCTTGGAAATCCACATGGTGGAGAGAGAGAAGAGATTCCTGTAAGTTGT
 CCTCAAACCTTCCACACATGTGCTGTGGCTTATGTGTAACCCCAATAAGTAAAGATAGTTTAAACACTACATAAGGTAG
 GGTTCCTCATGACCCCAAGGAATGATGCCCTGATAGAGCTTATGCTGAAACCCCATCTCCATTGTGCCATCTGGAAG
 45 AGACAATTGCATCCCGAAACAGAATCTTCATGAATGGATTATGAGCTATTAAGAAAGTGGCTTGGTTATTGCATGCG
 TGGCGCGTAATGACCTCCACCATGATGTTATCCAGCATGAAGGTCCTCACCAGAAGTCATACAAATCTTCTTAGGCTTC
 CAGAGTGTGAGCAAAAAAGCACCTCTAAATAAATTAAGTCTCAGGTAGTTAACCACCGAAAATGAACCAAGGC
 AGTTCTAATACAAAACCACTTCCCTTCCCTGTTCAAACCCAGTGCCTTATATCTAAAGATAAACTTCAAGCAAGCT
 50 TTTAGGTTGCCAGTATTTATGTAACAACAAGGCCCTTGACACACATCTGTAACCTCTAGTACTGGGCTCAGGGGAGAG
 GACAGGTGGAGCCCTGGAGTTTGAATCCAGGTTCTGTGAGAACTCTGTCTGAAAAGACAATATGGTGTGAGTACCCGGG
 AGGATATCTGATATTGACTTCTGGCCAACACAGCCATCTCTGCACATCTGTAGTTGCAAGCCTTTTGCACTAAGTTTG
 GCCAGAGTCAGAGTTTGCAAGTGTGTTGGACTGAATGCACGTGTTGCTGGTGATCTACAAGTCAACCTCTCTCAAG
 55 CTAGCAGCACTGGCTTCGGCCAGCTGCTCATTCAAGCCTCTTGGCAGAGTATCAGCGGGATGGGGAGCAGGGCCCTC
 CCTAGAACACCAAGCCTGTGGTTGTTTATTACAGGACATTATTAGGGCCAAGATGACAGATAACTCTATCACTTGGCCAA
 CAGTCGGGTGTTGCGGTGTTAGGTTATTTCTGTGTCTGCAGAAAACAGTGCACCTGGACAAAAGAAATAATGATATCA
 TTTTTCATTACAGCAACTAGATTCCGTGGTACAAAAGGCTCCCTGGGGAACGAGGCGGGACAGCGCGGCTCTGAGTCG
 60 GTCTGTGTACTACAGGGAGGAGGGTGGCAAGCCCTGGTCTCTACGGGTGGGGGAAGGGGGAAGCTGTGCGGCCAG
 TGACTTTTTCCCTTTCTCTTTTCTTAGAAACCACTCAATTTAAGATAATGAGTCTCTCTCATTACAGTGTGCTCACT
 ATTCATAGGGAATATCCACCCCGCCCTGTCAATCTGGCTAAGTAAGACAAGTCAAATTTAAAGGGAACGTTTTTCTA
 AAAATGTGGCTGGACCGTGTGCGGCACGAAACAGGGATGGCGGTCTAAGTTACATGCTCTCTGCGAGCCCGGTGCTC
 65 ATGTATCCATACCTGGGATAGGGAGGCTCTTACAGGAGTCACTAGCCCTCCCTCAGGAAAAGATTCCACTTCCGGT
 TTAGTTAGCTTCCACCTGGTCCCTTATCCGCTGTCTCTGCCACTAGTCTCATCCATCCGGTTCCGCGCTCATCCAC
 TTGCCCTTTTAGTTCTTGAAGAGCAGACCGTAGTCTTGGCAGGTGGGCCATTGGTCACTCCGCTACCACTGTACCATG
 GCCACCAAGGTGTCAATTAATATGAGCTCACTGAGTCTGCGGGATGGCTGGTTGGTGAATATGCTTGTGCAAAATCG
 TGAGAACTGGAGTTCAATTCAGCAGCATGGATGTTTCCAGCACCTGGAAGGCAGGGAGCAGAGATCTTAAGCTCCT
 GGCCAGACAGCCAGCCTAATTAGTAATCAGTGAGAGACCTGTCTCAAGAAACAAGATGGAACATCAAGGTCACCTC
 TTGTCTCCACACACACAAATACACATGCACATACATCCACACAGGCAACACATGCACACACCTGAACCCCTCCA
 CAAATACATACATAAAAAATAAATACATACACATACATACATACACCAACATTCCTCTCTTAGTCTCTGGCTAC

Sequence ID No. 18: Human Beer Genomic Sequence (This gene has two exons, at positions 161-427 abd 3186-5219).

35 tagaggagaa gtctttgggg agggtttgct ctgagcacac ccctttccct ccctccgggg 60
ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
40 agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
ggtggcgtgc cctcctctgg ctggtacat gcagctccca ctggccctgt gtctcgtctg 240
cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcagg cgttcaagaa 300
45 tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc acccctttga 420
50 gaccaaaggt atgggggtga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga 480
aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
ccagcactgg tcgaggaaca gtcttgacct gaggtggggg aagaatggct cgctgggtgca 600
55 gccttcaa at tcaggtgcag aggcattgagg caacagacgc tggtagagc ccagggcagg 660
gaggacgctg ggggtggtgag ggtatggcat cagggcattca gaacaggctc aggggctcag 720
60 aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgtc cagctgctgg 780

35	tagaggagaa gtcttttgggg aggggtttgct ctgagcacac ccctttccct ccctccgggg 60
	ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
40	agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
	ggtggcgtgc cctcctctgg ctggtacat gcagctccca ctggccctgt gtctcgtctg 240
	cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcagg cgttcaagaa 300
45	tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
	gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc accccttga 420
50	gaccaaaggt atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggttttaga 480
	aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
	ccagcactgg tcgaggaaca gtcttgccctg gaggtggggg aagaatggct cgctggtgca 600
55	gccttcaa at tcaggtgcag aggcattgagg caacagacgc tggtagagac ccagggcagg 660
	gaggacgctg ggggtggtgag ggtatggcat cagggcatca gaacaggctc aggggctcag 720
60	aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgtc cagctgctgg 780

taccactggg aagggaacaa ggtaagggag cctcccatcc acagaacagc acctgtgggg 840
 caccggacac tctatgctgg tgggtggctgt cccaccaca cagaccaca tcatggaatc 900
 5 cccaggaggt gaacccccag ctcgaagggg aagaaacagg ttccaggcac tcagtaactt 960
 ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctgggtg 1020
 10 tgtggggggg tgtgggggac agatctccac aaagcagtgg ggaggaaggc cagagaggca 1080
 cccctgcagt gtgcattgcc catggcctgc ccaggagct ggcacttgaa ggaatgggag 1140
 ttttcggcac agtttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag 1200
 15 agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccacc cagtcccaac 1260
 cttgcctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc 1320
 20 acagagaagc ccaggtgaca gtgtgcatct ggctctataa ttggcaggaa tccctgaggcc 1380
 atggggggcgt ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc 1440
 aggtggcaga gaagtccact gccaggtc ctggacccca gccctccccg cctcacaacc 1500
 25 tgttgggact atggggtgct aaaaagggca actgcatggg aggccagcca ggaccctccg 1560
 tcttcaaaat ggaggacaag ggcgctccc cccacagctc cccttctagg caaggtcagc 1620
 30 tgggctccag cgactgctg aagggtgta aggaaccaa acacaaaatg tccaccttgc 1680
 tggactccca cgagaggcca cagcccctga ggaagccaca tgctcaaac aaagtcatga 1740
 tctgcagagg aagtgcctgg cctaggggag ctattctcga aaagccgcaa aatgccccct 1800
 35 tccctgggca aatgcccccc tgaccacaca cacattccag ccctgcagag gtgaggatgc 1860
 aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctccctgc 1920
 40 tgtgcttgct ctccagagtg ggggtggggg gtggccttct ctgtcccctc tctggtttgg 1980
 tcttaagact atttttcatt ctttcttgtc acattggaac tatccccatg aaacctttgg 2040
 ggggtggactg gtactcacac gacgaccagc tatttaaaaa gctcccacc atctaagtc 2100
 45 accataggag acatggtcaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc 2160
 tctgctgcc cagggagtat caccatgagg cgccttca gataacacag aacaagaaat 2220
 50 gtgccagca gagagccagg tcaatgtttg tggcagctga acctgtaggt tttgggtcag 2280
 agctcagggc ccctatggta ggaaagtaac gacagtaaaa agcagccctc agctccatcc 2340
 cccagcccag cctccatgg atgctcgaac gcagagcctc cactcttgcc ggagccaaaa 2400
 55

ggtgctggga ccccagggaa gtggagtccg gagatgcagc ccagcctttt gggcaagttc 2460
 ttttctctgg ctgggcctca gtattctcat tgataatgag ggggttggac aactgcctt 2520
 5 tgattccttt caagtotaat gaattcctgt cctgatcacc tccccttcag tccctgcct 2580
 ccacagcagc tgccctgatt tattacttc aattaacctc tactcctttc tccatccct 2640
 gtccaccct cccaagtggc tggaaaagga atttgggaga agccagagcc aggcagaagg 2700
 10 tgtgctgagt acttaccctg cccaggccag ggaccctgcg gcacaagtgt ggcttaaate 2760
 ataagaagac cccagaagag aaatgataat aataatacat aacagccgac gctttcagct 2820
 15 atatgtgcca aatggtatth tctgcattgc gtgtgtaatg gattaactcg caatgcttgg 2880
 ggcggcccat tttgcagaca ggaagaagag agaggttaag gaacttggcc aagatgacac 2940
 ctgcagtgag cgatggagcc ctggtgtttg aaccacagca gtcatttggc tccgagggga 3000
 20 caggggtgcg aggagagctt tccaccagct ctagagcacc tgggacctc ctgcaataga 3060
 tgttcagggg caaaagcctc tggagacagg cttggcaaaa gcagggctgg ggtggagaga 3120
 25 gacgggcccg tccagggcag ggggtggccag gcggggggcc accctcacgc ggcctctct 3180
 ccacagacgt gtccagtagc agctgcccg agctgcactt caccgctac gtgaccgatg 3240
 ggccgtgccg cagcgccaag ccggtcaccg agctggtgtg ctccggccag tgcggcccgg 3300
 30 cgcgcctgct gcccaacgcc atcgcccgcg gcaagtgggtg gcgacctagt gggcccgact 3360
 tccgctgcat ccccgaccgc taccgcgcgc agcgcgtgca gctgctgtgt cccggtggtg 3420
 35 aggcgcccgc cgcgcgcaag gtgcgcctgg tggcctcgtg caagtgcaag cgcctcacc 3480
 gcttcacaaa ccagtoggag ctcaaggact tcgggaccga ggccgctcgg ccgcagaagg 3540
 gccggaagcc gcggccccgc gcccgagcgc ccaaagccaa ccaggccgag ctggagaacg 3600
 40 cctactagag cccgcccgc cccctccca ccggcgggcg ccccgccct gaaccgcgc 3660
 cccacatttc tgcctctgc gcgtggtttg attgtttata tttcattgta aatgcctgca 3720
 45 acccagggca gggggtgag accttcagg cctgaggaa tccggggcg cggaaggcc 3780
 cccctcagcc cgccagctga ggggtccac ggggcagggg agggattga ggtcacaga 3840
 cactgagcca cgcagccccg cctctggggc gcctacctt tgctggtccc acttcagagg 3900
 50 aggcagaaat ggaagcattt tcaccgcct ggggttttaa gggagcgtg tgggagtggg 3960
 aaagtccagg gactggttaa gaaagtggga taagattccc ccttgacact cgctgccat 4020
 55 cagaaagcct gaggcgtgcc cagagcaca gactgggggc aactgtagat gtggtttota 4080

gtccctggctc tgccactaac ttgctgtgta accttgaact acacaattct ccttcgggac 4140
 ctcaatttcc actttgtaaa atgaggggtg aggtgggaat aggatctcga ggagactatt 4200
 5 ggcatatgat tccaaggact ccagtgcctt ttgaatgggc agaggtgaga gagagagaga 4260
 gaaagagaga gaatgaatgc agttgcattg attcagtgcc aagggtcactt ccagaattca 4320
 10 gagttgtgat gctctcttct gacagccaaa gatgaaaaac aaacagaaaa aaaaaagtaa 4380
 agagtctatt tatggctgac atatttacgg ctgacaaact cctggaagaa gctatgctgc 4440
 ttcccagcct ggcttccccg gatgtttggc tacctccacc cctccatctc aaagaaataa 4500
 15 catcatccat tggggtagaa aaggagaggg tccgaggggtg gtgggagggga tagaaatcac 4560
 atccgccccca acttcccaaa gagcagcatc cctccccga cccatagcca tgttttaaag 4620
 20 tcaccttcog aagagaagtg aaaggttcaa ggacactggc cttgcaggcc cgaggagca 4680
 gccatcacia actcacagac cagcacatcc cttttgagac accgccttct gccaccact 4740
 cacggacaca tttctgcta gaaaacagct tcttactgct cttacatgtg atggcatatc 4800
 25 ttacactaaa agaattattat tgggggaaaa actacaagtg ctgtacatat gctgagaaac 4860
 tgcagagcat aatagctgcc acccaaaaat ctttttgaaa atcatttcca gacaacctct 4920
 30 tactttctgt gtagttttta attgttaaaa aaaaaaagtt ttaaacagaa gcacatgaca 4980
 tatgaaagcc tgcaggactg gtcgtttttt tggcaattct tcacgtggg acttgtccac 5040
 aagaatgaaa gtagtggtt ttaaagagtt aagttacata tttattttct cacttaagtt 5100
 35 atttatgcaa aagtttttct ttagagaaat gacaatgtta atattgcttt atgaattaac 5160
 agtctgttct tccagagtcc agagacattg ttaataaaga caatgaatca tgaccgaaag 5220
 40 gatgtggtct cattttgtca accacacatg acgtcatttc tgtcaaagtt gacaccttc 5280
 tottggtcac tagagctcca accttggaac caccttgac tgcctctctgg tggcccttgt 5340
 ggcaattatg tcttcctttg aaaagtcatg tttatccctt cctttccaaa ccagaccgc 5400
 45 atttcttcac ccagggcatg gtaataacct cagccttgta tccttttagc agcctccct 5460
 ccattgctggc ttccaaaatg ctgttctcat tgtatcactc cctgctcaa aagccttcca 5520
 50 tagctcccc ttgcccagga tcaagtgcag ttccctatc tgacatggga ggccttctct 5580
 gcttgactcc cacctccac tccaccaagc ttcctactga ctccaaatgg tcatgcagat 5640
 cctgcttcc ttagtttgcc atccacactt agcaccocca ataactaatc ctctttcttt 5700
 55

aggattcaca ttacttgtca tctcttcccc taaccttcca gagatgttcc aatctcccat 5760
 gatccctctc tctcttgagg ttccagcccc tttgtctac accactactt tggttcctaa 5820
 5 tttctgttttc catttgacag tcattcatgg aggaccagcc tggccaagtc ctgcttagta 5880
 ctggcataga caacacaaag ccaagtacaa ttcaggacca gctcacagga aacttcatct 5940
 tcttogaagt gtggatttga tgcctcctgg gtagaaatgt aggatcttca aaagtgggccc 6000
 10 agcctcctgc acttctctca aagtctcgcc tccccagggt gtcttaatag tgctggatgc 6060
 tagctgagtt agcatcttca gatgaagagt aacctaaag ttactcttca gttgccctaa 6120
 15 ggtgggatgg tcaactggaa agctttaaat taagtccagc ctaccttggg ggaaccacc 6180
 cccacaaaga aagetgaggt ccctcctgat gacttgctag ttaactacc aataaccac 6240
 ttgaattaat catcatcatc aagtctttga taggtgtgag tgggtatcag tggccgggtcc 6300
 20 ctctcctgggg ctccagcccc cgaggaggcc tcagtgagcc cctgcagaaa atccatgcat 6360
 catgagtgtc tcagggccca gaatatgaga gcaggtagga aacagagaca tcttccatcc 6420
 25 ctgagaggca gtgcggtcca gtgggtgggg acacgggctc tgggtcaggt ttgtgttgtt 6480
 tgtttgtttg ttttgagaca gagtctcgct ctattgccca ggctggagtg cagtgtcaca 6540
 atctcggtt actgcaactt ctgccttccc ggattcaagt gattctcctg cctcagctc 6600
 30 cagagtagct gggattacag gtgcgtgccca ccacgcctgg ctaatttttg tatttttgat 6660
 agagacgggg tttcaccatg ttggccaggc tagtctcgaa ctcttgacct caagtgatct 6720
 35 gcctgcctcg gcctcccaa gtgctgggat tacaggcgtg agccaccaca cccagcccca 6780
 ggttggtgtt tgaatctgag gagactgaag caccaagggg ttaaattgtt tgcccacagc 6840
 catacttggg ctcagttcct tgcctaccc ctcaactgag ctgcttagaa cctggtgggc 6900
 40 acatgggcaa taaccaggtc aactgtttt gtaccaagtg ttatgggaat ccaagatagg 6960
 agtaatttgc tctgtggagg ggatgaggga tagtggttag ggaaagcttc acaaagtggg 7020
 45 tgttgcttag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag 7080
 caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg 7140
 taccgagtcc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc 7200
 50 aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
 cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggtcggg ttagaggtta 7320
 55 tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag 7380

gaacaaacaa cagacctagc tgggaggggc agcattttgt tgtagggggc ggggcacatg 7440
 ttctgggggt acagccagac tcagggcttg tattaatagt ctgagagtaa gacagacaga 7500
 5 gggatagaag gaaataggtc cctttctctc tctctctctc tctctctctc actctctctc 7560
 tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
 10 gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca 7680
 ggaccccaaa attccctggt ttccttgaat caggcaggac ttacgcagct gggaggggtg 7740
 agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaaagctg 7800
 15 gtgccatgtc ccacaccgc ccacctcca cctgctcctt gacacagccc tgtgctccac 7860
 aaccggctc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat 7920
 20 cccacccca ttcttggaac ctgccctctg tcttctcctt tgtccaaggg caggcaaggg 7980
 ctcagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gagatgcagg 8040
 aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc cagggtgggc 8100
 25 tcgtttacac ctgtaggcca agcgtaatta ttaacagctc ccacttctac tctaaaaaat 8160
 gaccaatct gggcagtaaa ttatatggtg cccatgctat taagagctgc aacttgctgg 8220
 30 gcgtggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
 gaggtcacga gttagagact ggctggcca gcatggcaaa acccatctt tactaaaaat 8340
 aaaaaatta gcaaggcatg gtggcatgca cctgtaatcc cagggtactg ggaggctgag 8400
 35 acaggagaat ggcttgaacc caggaggcag aggttgcaat gagccaagat tgtgccactg 8460
 ccctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaggat actgtcaatc 8520
 40 actgcaggaa gaaccaggt aatgaatgag gagaagagag gggctgagtc accatagtgg 8580
 cagcaccgac tcctgcagga aaggcgagac actgggtcat ggggtactgaa gggtgccctg 8640
 aatgacgttc tgcttttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt 8700
 45 gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
 atgccaatt tcctacaat tgtctggggg gcctaagctt ctgcccacca agagggccag 8820
 50 agctggcagc gagcagctgc aggtaggaga gataggtagc cataagggag gtgggaaaga 8880
 gagatggaag gagaggggtg cagagcacac acctccctg cctgacaact tcctgagggc 8940
 tggatcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaag 9000
 55

aaggagaggg tggggatgga gaggaagaga gggatgatcat tcattcattc cattgctact 9060
 gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt 9120
 5 ggagcctcat ggagctcaca gggagtgtctg gcaaggagat ggataatgga cggataacaa 9180
 ataaacattt agtacaatgt ccgggaatgg aaagttctcg aaagaaaaat aaagctggtg 9240
 agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggaggt ggcatttgag 9300
 10 c 9301

From the foregoing, it will be appreciated that, although specific
 15 embodiments of the invention have been described herein for purposes of illustration,
 various modifications may be made without deviating from the spirit and scope of the
 invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. An isolated nucleic acid molecule selected from the group consisting of:
 - 5 (a) an isolated nucleic acid molecule comprising sequence ID Nos., 1, 5, 9, 11, 13, or 15, or complementary sequence thereof;
 - (b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and
 - (c) an isolated nucleic acid that encodes a TGF-beta binding-protein
10 according to (a) or (b).
2. The isolated nucleic acid molecule according to claim 1 wherein said nucleic acid molecule encodes a protein comprising the protein of Sequence ID NO. 2.
3. The isolated nucleic acid molecule according to claim 1 wherein
15 said nucleic acid molecule encodes a protein comprising the protein of Sequence ID NO. 6.
4. The isolated nucleic acid molecule according to claim 1 wherein said nucleic acid molecule encodes a protein comprising the protein of Sequence ID NO. 10.
- 20 5. The isolated nucleic acid molecule according to claim 1 wherein said nucleic acid molecule encodes a protein comprising the protein of Sequence ID NO. 12.
6. The isolated nucleic acid molecule according to claim 1 wherein said nucleic acid molecule encodes a protein comprising the protein of Sequence ID
25 NO. 14.

7. The isolated nucleic acid molecule according to claim 1 wherein said nucleic acid molecule encodes a protein comprising the protein of Sequence ID NO. 16.

8. An expression vector, comprising a promoter operably linked to a
5 nucleic acid molecule according to any one of claims 1 to 7.

9. The expression vector according to claim 8 wherein said promoter is selected from the group consisting of CMV I-E promoter, SV40 early promoter and MuLV LTR.

10. The expression vector according to claim 8 wherein said
10 promoter is a tissue-specific promoter.

11. A method of producing a TGF-beta binding protein, comprising, culturing a cell which contains a vector according to claim 8 under conditions and for a time sufficient to produce said protein.

12. The method according to claim 11, further comprising the step of
15 purifying said protein.

13. A viral vector capable of directing the expression of a nucleic acid molecule according to any one of claims 1 to 7.

14. The viral vector according to claim 13 wherein said vector is selected from the group consisting of herpes simplex viral vectors, adenoviral vectors,
20 adenovirus-associated viral vectors and retroviral vectors.

15. A host cell carrying a vector according to any one of claims 8 to
14.

16. The host cell according to claim 15 wherein said cell is selected

from the group consisting of a human cell, dog cell, monkey cell, rat cell and mouse cell.

17. An isolated protein, comprising a TGF-beta binding-protein encoded by the nucleic acid molecule according to any one of claims 1 to 7.

5 18. An antibody which specifically binds to the protein according to claim 17.

19. The antibody according to claim 18 wherein said antibody is a monoclonal antibody.

20. The antibody according to claim 19 wherein said monoclonal
10 antibody is a murine or human antibody.

21. The antibody according to claim 18 wherein said antibody is selected from the group consisting of $F(ab')_2$, $F(ab)_2$, Fab' , Fab , and Fv .

22. A hybridoma which produces an antibody according to claim 19.

23. A fusion protein, comprising a first polypeptide segment
15 comprising a TGF-beta binding-protein encoded by the nucleic acid molecule according to any one of claims 1 to 7, or a portion thereof of at least 10 amino acids in length, and a second polypeptide segment comprising a non-TGF-beta binding-protein.

24. The fusion protein according to claim 23 wherein said first polypeptide segment is at least 20 amino acids in length.

20 25. The fusion protein according to claim 23 wherein said first polypeptide segment is at least 50 amino acids in length.

26. The fusion protein according to claim 23 wherein said second

polypeptide comprises multiple anionic amino acid residues.

27. An isolated oligonucleotide which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, under conditions of high stringency.

5 28. The isolated oligonucleotide according to claim 27 wherein said oligonucleotide is at least 20 nucleotides in length.

29. The isolated oligonucleotide according to claim 27 wherein said oligonucleotide is at least 30 nucleotides in length.

30. The isolated oligonucleotide according to claim 27 wherein said
10 oligonucleotide is at least 50 nucleotides in length.

31. The isolated oligonucleotide according to claim 27 wherein said oligonucleotide is between 50 to 100 nucleotides in length.

32. A pair of primers which specifically amplifies all or a portion of a nucleic acid molecule according to any one of claims 1 to 7.

15 33. A ribozyme which cleaves RNA encoding a protein according to claim 17.

34. The ribozyme according to claim 33 wherein said protein comprises the protein of Sequence ID NO. 2.

35. The ribozyme according to claim 33 wherein said protein
20 comprises the protein of Sequence ID NO. 6.

36. The ribozyme according to claim 33 wherein said RNA encodes a protein comprising the protein of Sequence ID NO. 10.

37. The ribozyme according to claim 33 wherein said RNA encodes a protein comprising the protein of Sequence ID NO. 12.

38. The ribozyme according to claim 33 wherein said RNA encodes a protein comprising the protein of Sequence ID NO. 14.

5 39. The ribozyme according to claim 33 wherein said RNA encodes a protein comprising the protein of Sequence ID NO. 16.

40. The ribozyme according to claim 33 wherein said ribozyme is composed of ribonucleic acids.

41. The ribozyme according to claim 40 wherein one or more of said
10 ribonucleic acids are 2'-O-methyl ribonucleic acids.

42. The ribozyme according to claim 33 wherein said ribozyme is composed of a mixture of deoxyribonucleic acids and ribonucleic acids.

43. The ribozyme according to claim 33 wherein said ribozyme is composed of nucleic acids having phosphothioate linkages.

15 44. A nucleic acid molecule comprising a nucleic acid sequence which encodes a ribozyme according to claim 33.

45. The nucleic acid molecule of claim 44, wherein the nucleic acid is DNA or cDNA.

46. The nucleic acid molecule of claim 44, under the control of a
20 promoter to transcribe the nucleic acid.

47. A host cell comprising the ribozyme of claim 33.

48. A vector, comprising the nucleic acid molecule of claim 44.

49. The vector of claim 54, wherein the vector is a plasmid, a virus, retrotransposon or a cosmid.

50. The vector of claim 49 wherein said virus is selected from the
5 group consisting of retroviruses, adenoviruses, and adeno-associated viruses.

51. A host cell containing the vector according to any one of claims
48 to 50.

52. The host cell according to claim 51 wherein said host cell is stably transformed with said vector.

10 53. The host cell according to claim 51 wherein the host cell is a human cell.

54. A method for producing a ribozyme, comprising providing DNA encoding the ribozyme according to claim 33 under the transcriptional control of a promoter, and transcribing the DNA to produce the ribozyme.

15 55. The method of claim 54 wherein the ribozyme is produced *in vitro*.

56. The method of claim 54, further comprising purifying the ribozyme.

57. A method for increasing bone mineralization, comprising
20 introducing into a warm-blooded animal an effective amount of the ribozyme according to any one of claims 33 to 43.

58. A method of increasing bone mineralization, comprising

introducing into a patient an effective amount of the nucleic acid molecule of claim 44, under conditions favoring transcription of the nucleic acid molecule to produce a ribozyme.

5 59. A pharmaceutical composition, comprising the ribozyme according to any one of claims 33 to 43, and a pharmaceutically acceptable carrier or diluent.

60. A pair of primers capable of specifically amplifying all or a portion of a nucleic acid molecule according to any one claims 1 to 7.

10 61. A method for detecting a nucleic acid molecule which encodes a TGF-beta binding protein, comprising incubating an oligonucleotide according to any one of claims 27 to 31 under conditions of high stringency, and detecting hybridization of said oligonucleotide.

62. The method according to claim 61 wherein said oligonucleotide is labeled.

15 63. The method according to claim 61 wherein said oligonucleotide is bound to a solid support.

64. A method for detecting a TGF-beta binding protein, comprising incubating an antibody according to any one of claims 18 to 21 under conditions and for a time sufficient to permit said antibody to bind to a TGF-beta binding protein, and
20 detecting said binding.

65. The method according to claim 64 wherein said antibody is bound to a solid support.

66. The method according to claim 64 wherein said antibody is labeled.

67. The method according to claim 66 wherein said antibody is labeled with a marker selected from the group consisting of enzymes, fluorescent proteins, and radioisotopes.

68. A transgenic animal whose germ cells and somatic cells contain a
5 nucleic acid molecule encoding a TGF-beta binding-protein according to claim 1 which is operably linked to a promoter effective for the expression of said gene, said gene being introduced into said animal, or an ancestor of said animal, at an embryonic stage, with the proviso that said animal is not a human.

69. The transgenic animal according to claim 68 wherein TGF-beta
10 binding-protein is expressed from a vector according to any one of claims 8 to 10.

70. A transgenic knockout animal, comprising an animal whose germ cells and somatic cells comprise a disruption of at least one allele of an endogenous nucleic acid molecule which hybridizes to the nucleic acid molecule according to claim 1, wherein said disruption prevents transcription of messenger RNA from said allele as
15 compared to an animal without said disruption, with the proviso that said animal is not a human.

71. The transgenic animal according to claim 70 wherein said disruption is a nucleic acid deletion, substitution, or, insertion.

72. The transgenic animal according to claim 68 or 70 wherein the
20 animal is selected from the group consisting of a mouse, a rat and a dog.

73. A method for determining whether a candidate molecule is capable of increasing bone mineral content, comprising:

(a) mixing one or more candidate molecules with TGF-beta-binding-protein encoded by the nucleic acid molecule according to any one of claims 1 to 7 and
25 a selected member of the TGF-beta family of proteins;

(b) determining whether the candidate molecule alters the signaling of the TGF-beta family member, or alters the binding of the TGF-beta binding-protein to the TGF-beta family member.

74. The method according to claim 73 wherein said member of the
5 TGF-beta family of proteins is BMP6.

75. A method for determining whether a candidate molecule is capable of increasing bone mineral content, comprising: determining whether a candidate molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof.

10 76. The method according to claim 75 wherein said analogue of bone is hydroxyapatite.

77. A kit for detection of TGF-beta binding-protein gene expression, comprising a container that comprises a nucleic acid molecule, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule
15 comprising the nucleotide sequence of SEQ ID NO: 1, 5, 7, 9, 11, 13, or 15; (b) a nucleic acid molecule comprising the complement of the nucleotide sequence of (a); (c) a nucleic acid molecule that is a fragment of (a) or (b) of at least 20 nucleotides in length.

78. A kit for detection of TGF-beta binding-protein, comprising a
20 container that comprises an antibody according to any one of claims 18 to 21.

79. An antisense oligonucleotide, comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, and wherein said oligonucleotide inhibits the expression of TGF-beta binding protein according to claim 17.

25 80. The oligonucleotide according to claim 79 wherein said

oligonucleotide is 15 nucleotides in length.

81. The oligonucleotide according to claim 79 wherein said oligonucleotide is 20 nucleotides in length.

82. The oligonucleotide according to claim 79 wherein said
5 oligonucleotide is 50 nucleotides in length.

83. The oligonucleotide according to claim 79, wherein said oligonucleotide is comprised of one or more nucleic acid analogs.

84. The oligonucleotide according to claim 79, wherein said oligonucleotide is comprised of one or more ribonucleic acids.

10 85. The oligonucleotide according to claim 79, wherein said oligonucleotide is comprised of one or more deoxyribonucleic acids.

86. The oligonucleotide according to claim 79 wherein said oligonucleotide sequence comprises one or more modified covalent linkages.

87. The oligonucleotide according to claim 86 wherein said modified
15 covalent linkage is selected from the group consisting of a phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene(methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage.

COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION

ABSTRACT OF THE DISCLOSURE

A novel class or family of TGF- β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

WPN/240083/508P1-AP/V4

Common Cysteine Backbone

1				50	
human_gremlin.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_cerberus.pro	MHLLLFQLLV	LLPLGKTTRH	QDGRQNQSSL	SPVLLPRNQR	ELPTGNHEEA
human_dan.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_beer.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	51				100
human_gremlin.pro	~~~~~	~~~~~M	SRTAYTVGAL	LLLLGTLLPA	AEGKKKGSQG
human_cerberus.pro	EEKPDLFVAV	PHLVAT.SPA	GEGQRQREKM	LSRFGRFWKK	PEREMHPSRD
human_dan.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_beer.pro	~~~~~	~~~~~	~~~~~	~~~~~MQLPLA	LCLVCLLVHT
	101				150
human_gremlin.pro	AI.PPPDKAQ	HNDSEQTQSP	QQPGSRNRGR	GQGRGTAMPG	EEVLESSQEA
human_cerberus.pro	SDSEFPFPGT	QSLIQPID.G	MKMEKSPLRE	EAKKFWHHFM	FRKTPASQGV
human_dan.pro	~~~~~	~~~~~	~~~~~	MLRVLVGAVL	PAMLLAAPP
human_beer.pro	AFRVVEGQGW	QAFKNDATET	IPELGEYPEP	PPELENNKTM	NRAENGGRPP
	151	↓	↓	↓	200
human_gremlin.pro	LHVTERKYLK	RDWCKTQPLK	QTIHEEGCNS	RTIINRF.CY	GQCNSFYIPR
human_cerberus.pro	ILPIKSHEVH	WETCRTVPFS	QTITHEGCEK	VVVQNNL.CF	GKCGSVHFP.
human_dan.pro	INKLALFPDK	SAWCEAKNIT	QIVGHSGCEA	KSIQNRA.CL	GQCFSYSVPN
human_beer.pro	HHPFETKDVS	EYSRELBHFT	RYVTDGPCRS	AKPVTELVCS	GQCGPARLLP
	201	↓	↓		250
human_gremlin.pro	HIRKEEGSFQ	SCSF...CKP	KKFTTMMVTL	NCPQLQPPTK	K.KRVTRVKQ
human_cerberus.pro	..GAAQHSHT	SCSH...CLP	AKFTTMHLPL	NCTELSSVIK	V...VMLVEE
human_dan.pro	TFPQSTESLV	HCDS...CMP	AQSMWEIVTL	ECPGHHEVPR	VDKLVEKILH
human_beer.pro	NAIGRGKWWR	PSGPDFRCIP	DRYRAQRVQL	LCPGGEAPRA	RKVRLVAS..
	↓↓↓				300
human_gremlin.pro	CRÇ.ISIDLD	~~~~~	~~~~~	~~~~~	~~~~~
human_cerberus.pro	CQCKVKTEHE	DGHILHAGSQ	DSFIPGVSA-	~~~~~	~~~~~
human_dan.pro	CSCQACGKEP	SHEGLSVYVQ	GEDGPGSQPG	THPHPHPHPH	PGGQTPEPED
human_beer.pro	CKCKRLTRFH	NQSELKDFTG	EAARPQKGRK	PRPRARSAKA	NQAELENAY-
	301	314			
human_gremlin.pro	~~~~~	~~~~~			
human_cerberus.pro	~~~~~	~~~~~			
human_dan.pro	PPGAPHTEEE	GAED			
human_beer.pro	~~~~~	~~~~~			

Figure 1

Human Beer Gene Expression by RT-PCR




Fig. 2

RNA In Situ Hybridization of Mouse Embryo Sections




Fig. 3

Antibody Selectivity




Fig. 4

Evaluation of Beer binding to BMP family members Anti-FLAG Immunoprecipitation

Beer	+	+	-
BMP-6	+	+	-

BMP-6 control



Beer	+	+
BMP-5	+	-

BMP-5 control



*Anti-BMP-6 western blot

BMP-4	C	-	+
Beer	-	-	+
Cerberus	-	+	+



*Anti-BMP-5 western blot

*Anti-BMP-4 western blot

Fig. 5

BMP-5/Beer Dissociation Constant Characterization


.75 1.5 7.5 15 30 60 120 nM BMP-5



*Anti-FLAG immunoprecipitation *Anti-BMP-5 western blot

Ionic Disruption of BMP-5/ Beer Binding

NaCl(mM)	500	150	150	BMP-5
Beer	+	+	-	
BMP-5	+	+	+	



* Anti FLAG immunoprecipitation
* Anti BMP-5 western

Fig. 6

DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that:

Our residences, post office addresses, and citizenships are as stated below under our names.


We believe we are the original, first, and joint inventors of the invention entitled "COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION," which is described and claimed in the specification and claims of Patent Application No. 09/449,218, which we filed in the United States Patent and Trademark Office on November 24, 1999 and for which a patent is sought.

We have reviewed and understand the contents of the above-entitled specification, including the claims, as amended by any amendment specifically referred to herein (if any).


We acknowledge our duty to disclose information of which we are aware which is material to the patentability and examination of this application in accordance with 37 C.F.R. § 1.56(a).

We hereby appoint RICHARD W. SEED, Reg. No. 16,557; ROBERT J. BAYNHAM, Reg. No. 22,846; GEORGE C. RONDEAU, JR., Reg. No. 28,893; DAVID H. DEITS, Reg. No. 28,066; WILLIAM O. FERRON, JR., Reg. No. 30,633; DAVID J. MAKI, Reg. No. 31,392; RICHARD G. SHARKEY, Reg. No. 32,629; DAVID V. CARLSON, Reg. No. 31,153; KARL R. HERMANN, Reg. No. 33,507; DAVID D. MCMASTERS, Reg. No. 33,963; MICHAEL J. DONOHUE, Reg. No. 35,859; LORRAINE LINFORD, Reg. No. 35,939; ELLEN M. BIERMAN, Reg. No. 38,079; ANN T. KADLECEK, Reg. No. 39,244; DAVID W. PARKER, Reg. No. 37,414; E. RUSSELL TARLETON, Reg. No. 31,800; KEVIN S. COSTANZA, Reg. No. 37,801; THOMAS E. LOOP, Reg. No. 42,810; STEPHEN J. ROSENMAN, Reg. No. 43,058; BRIAN L. JOHNSON, Reg. No. 40,033; SUSAN D. BETCHER, Reg. No. 43,498; JANE E. R. POTTER, Reg. No. 33,332; KENNETH H. TARBET, Reg. No. 43,181; WILLIAM T. CHRISTIANSEN, Reg. No. 44,614; ROBERT IANNUCCI, Reg. No. 33,514; GARY M. MYLES, Reg. No. P-46,209; and ERIC J. GASH, Reg. No. P-46,274; comprising the firm of Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, Washington 98104-7092; as our attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Please direct all correspondence to **Jane E. R. Potter** at Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, Washington 98104-7092, telephone calls to (206) 622-4900 and telecopies to (206) 682-6031.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.


Mary E. Brunkow

Date 3 Feb. 2000
Residence : City of Seattle, County of King
State of Washington
Citizenship : United States of America
P.O. Address : 9829 Triton Drive NW
Seattle, Washington 98117



David J. Galas

Date 3/2/00
Residence : ~~City of Mercer Island, County of King~~ City of Claremont
State of Washington County of Los Angeles
State of California
Citizenship : United States of America
P.O. Address : ~~3301 94th Avenue SE~~ 854 Guadalupe Dr.
Claremont, CA 91711
Mercer Island, Washington 98040




Brian Kovacevich

Date 2/3/00
Residence : City of Renton, County of King
State of Washington
Citizenship : United States of America
P.O. Address : 4308 NE 6th Place
Renton, Washington 98059




John T. Mulligan

Date 2/7/2000
Residence : City of Seattle, County of King
State of Washington
Citizenship : United States of America
P.O. Address : 5823 17th Avenue NE
Seattle, Washington 98105



Bryan W. Paepers

Date 2/3/00
Residence : City of Seattle, County of King
State of Washington
Citizenship : United States of America
P.O. Address : 1617 Summit Avenue, #43
Seattle, Washington 98122



Jeffrey Van Ness


Date

2/7/2000

Residence : City of Seattle, County of King
State of Washington

Citizenship : United States of America

P.O. Address : 10020 49th Avenue NE
Seattle, Washington 98125



David G. Winkler

Date

2/3/2000

Residence : City of Seattle, County of King
State of Washington

Citizenship : United States of America

P.O. Address : 7037 20th Avenue NE
Seattle, Washington 98115

U:\sharons\Darwin
(240083.508)

SEQUENCE LISTING

5 <110> Brunkow, Mary E.
 Galas, David J.
 Kovacevich, Brian
 Mulligan, John T.
 Paeper, Bryan W.
 10 Van Ness, Jeffrey
 Winkler, David G.

15 <120> COMPOSITIONS AND METHODS FOR INCREASING
 BONE MINERALIZATION

20 <130> 240083.508

25 <140> US
 <141> 1999-11-24

30 <160> 41

35 <170> FastSEQ for Windows Version 3.0

40 <210> 1
 <211> 2301
 <212> DNA
 <213> Homo sapien

45 <400> 1

agagcctgtg	ctactggaag	gtggcgtgcc	ctcctctggc	tggtaccatg	cagctcccac	60
tggccctgtg	tctcgtctgc	ctgctggtac	acacagcctt	ccgtgtagtg	gagggccagg	120
ggtggcaggc	gttcaagaat	gatgccacgg	aatcatccc	cgagctcgga	gagtaccccg	180
agcctccacc	ggagctggag	aacaacaaga	ccatgaaccg	ggcggagAAC	ggagggcggc	240
ctccccacca	cccctttgag	accaaagacg	tgtccgagta	cagctgccgc	gagctgcact	300
tcacccgcta	cgtgaccgat	gggcccgtgc	gcagcgccaa	gccggtcacc	gagctggtgt	360
gctccggcca	gtgcggcccg	gcgcgcctgc	tgcccaacgc	catcggccgc	ggcaagtggc	420
ggcgacctag	tgggcccgcg	ttccgctgca	tccccgaccg	ctaccgcgcg	cagcgcgtgc	480
agctgctgtg	tcccggtggt	gaggcgccgc	gcgcgcgcaa	ggtgcgcctg	gtggcctcgt	540
gcaagtgcaa	gcgcctcacc	cgcttcacaa	accagtcgga	gctcaaggac	ttcgggaccg	600
aggccgctcg	gccgcagaag	ggccggaagc	cgccggcccg	cgcccgagag	gccaagcca	660
accaggccga	gctggagaac	gcctactaga	gcccgcgcgc	gcccctcccc	accggcgggc	720
gccccggccc	tgaaccgcgc	ccccacattt	ctgtcctctg	cgcgtaggtt	gattgtttat	780
atttcattgt	aatgcctgc	aaccagggc	agggggtga	gacctccag	gccctgagga	840
atccccggcg	ccggcaaggc	ccccctcagc	ccgccagctg	aggggtccca	cggggcaggg	900
gaggggaattg	agagtcacag	acactgagcc	acgcagcccc	gcctctgggg	ccgcctacct	960
ttgctggtcc	cacttcagag	gaggcagaaa	tggaagcatt	ttcacgccc	tggggtttta	1020
agggagcggt	gtgggagtgg	gaaagtccag	ggactgggta	agaaagtgg	ataagattcc	1080
cccttgcaac	tcgctgcccc	tcagaaagcc	tgaggcggtg	ccagagcaca	agactggggg	1140
caactgtaga	tgtggtttct	agtcctggct	ctgccactaa	cttgctgtgt	aaccttgAAC	1200
tacacaattc	tccttcggga	cctcaatttc	cactttgtaa	aatgaggggt	gaggtgggaa	1260
taggatctcg	aggagactat	tggcatatga	ttccaaggac	tccagtgcct	tttgaatggg	1320
cagaggtgag	agagagagag	agaaagagag	agaatgaatg	cagttgcatt	gattcagtgc	1380
caaggtcact	tccagaattc	agagttgtga	tgtctctctc	tgacagccaa	agatgaaaaa	1440
caaacagaaa	aaaaaaagta	aagagtctat	ttatggctga	catatttacg	gctgacaaaac	1500

tcctggaaga agctatgctg cttcccagcc tggcttcccc ggatgtttgg ctacctccac 1560
 ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggg 1620
 ggtgggaggg atagaaatca catccgcccc aacttcccaa agagcagcat ccctcccccg 1680
 acccatagcc atgtttttaa gtcaccttcc gaagagaagt gaaagggtca aggacactgg 1740
 5 ccttgcaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
 caccgccttc tgcccaccac tcacggacac atttctgctt agaaaacagc ttcttactgc 1860
 tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
 gctgtacata tgctgagaaa ctgcagagca taatagctgc cacccaaaaa tctttttgaa 1980
 aatcatttcc agaacaacctc ttactttctg tgtagttttt aattgttaaa aaaaaaaagt 2040
 10 tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
 ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
 atttatttct tcaacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatgtt 2220
 aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
 acaatgaatc atgaccgaaa g 2301

15

<210> 2

<211> 213

<212> PRT

<213> Homo sapien

20

<400> 2

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
 1 5 10 15
 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 25 20 25 30
 Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 30 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 35 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 40 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 45 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 Leu Glu Asn Ala Tyr
 210

50

<210> 3

<211> 2301

<212> DNA

<213> Homo sapien

55

<400> 3

	agagcctgtg	ctactggaag	gtggcgtgcc	ctcctctggc	tggtaccatg	cagctccac	60
	tggccctgtg	tctcgtctgc	ctgctggtac	acacagcctt	ccgtgtagtg	gagggctagg	120
	ggtggcagge	gttcaagaat	gatgccacgg	aatcatccc	cgagctcgga	gagtaccccg	180
5	agcctccacc	ggagctggag	aacaacaaga	ccatgaaccg	ggcggagaac	ggagggcggc	240
	ctccccacca	cccctttgag	accaaagacg	tgtccgagta	cagctgccgc	gagctgcact	300
	tcacccgcta	cgtgaccgat	gggccgtgcc	gcagcgccaa	gccggtcacc	gagctggtgt	360
	gctccggcca	gtgcggcccg	gcgcgctgc	tgcccaacgc	catcgccgc	ggcaagtggg	420
	ggcgacctag	tgggcccgac	tccgctgca	tccccgaccg	ctaccgcgcg	cagcgctgce	480
10	agctgctgtg	tcccgggtgt	gaggcgccgc	gcgcgcgcaa	ggtgcgcctg	gtggcctcgt	540
	gcaagtgcaa	gogcctcacc	cgcttcaca	accagtcgga	gctcaaggag	ttcgggaccg	600
	aggccgctcg	gccgcagaag	ggcgggaagc	cgccggcccc	cgcccgagc	gccaaagcca	660
	accaggccga	gctggagaac	gcctactaga	gcccccccg	gccccctccc	accggcgggc	720
	gccccggccc	tgaacccgcg	ccccacatct	ctgtcctctg	cgctggtttt	gattgtttat	780
15	atttcattgt	aaatgcctgc	aaccagggc	agggggctga	gaccttcag	gcctgagga	840
	atcccgggcg	ccggcaaggc	ccccctcagc	ccgccagctg	aggggtccca	cggggcaggg	900
	gaggggaattg	agagtcacag	acactgagcc	acgcagcccc	gcctctgggg	ccgcctacct	960
	ttgtctggtcc	cacttcagag	gaggcagaaa	tgggaagcatt	ttcacgccc	tggggtttta	1020
	agggagcggt	gtgggagtgg	gaaagtccag	ggactgggta	agaaagtgg	ataagattcc	1080
20	cccttgacc	tgcgtgcccc	tcagaaagcc	tgaggcgtgc	ccagagcaca	agactggggg	1140
	caactgtaga	tgtggtttct	agtccctggc	ctgccactaa	cttgctgtgt	aaccttgaac	1200
	tacacaattc	tccttcggga	cctcaatttc	cactttgtaa	aatgaggggtg	gaggtgggaa	1260
	taggatctcg	aggagactat	tggcatatga	ttccaaggac	tccagtgcct	tttgaatggg	1320
	cagaggtgag	agagagagag	agaaagagag	agaatgaatg	cagttgcatt	gattcagtgc	1380
25	caaggtcact	tccagaattc	agagtgtgta	tgtctctctc	tgacagccaa	agatgaaaaa	1440
	caaacagaaa	aaaaaaagta	aagagtctat	ttatggctga	catatttacg	gctgacaaac	1500
	tcctggaaga	agctatgctg	cttcccagcc	tggcttcccc	ggatgtttgg	ctacctccac	1560
	ccctccatct	caaagaaata	acatcatcca	ttggggtaga	aaaggagagg	gtccgagggg	1620
	ggtgggaggg	atagaaatca	catccgcccc	aacttcccaa	agagcagcat	ccctcccccg	1680
30	acccatagcc	atgtttttaa	gtcaccttcc	gaagagaagt	gaaaggttca	aggacactgg	1740
	ccttgtaggc	ccgagggagc	agccatcaca	aactcacaga	ccagcacatc	ccttttgaga	1800
	caccgccttc	tgccaccac	tcacggacac	atttctgcct	agaaaacagc	ttcttactgc	1860
	tcttacatgt	gatggcatat	cttacctaa	aagaatatta	ttgggggaaa	aactacaagt	1920
	gctgtacata	tgtgagaaa	ctgcagagca	taatagctgc	cacccaaaaa	tctttttgaa	1980
35	aatcatttcc	agacaacctc	ttactttctg	tgtagttttt	aattgttaaa	aaaaaaaaagt	2040
	tttaaacaga	agcacatgac	atatgaaagc	ctgcaggact	ggtcgttttt	ttggcaattc	2100
	ttccacgtgg	gacttgtcca	caagaatgaa	agtagtggtt	tttaaagagt	taagttacat	2160
	atatttttcc	tcaactaagt	tatttatgca	aaagtttttc	ttgtagagaa	tgacaatggt	2220
	aatattgctt	tatgaattaa	cagtctgttc	ttccagagtc	cagagacatt	gttaataaag	2280
40	acaatgaatc	atgaccgaaa	g				2301

<210> 4

<211> 23

<212> PRT

45 <213> Homo sapien

<400> 4

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr

1

5

10

15

50 Ala Phe Arg Val Val Glu Gly

20

<210> 5

<211> 2301

55 <212> DNA

<213> Homo sapien

<400> 5

5	agagcctgtg	ctactggaag	gtggcggtgcc	ctcctctggc	tggtaccatg	cagctcccac	60
	tggccctgtg	tctcatctgc	ctgctggtac	acacagcctt	ccgtgtagtg	gagggccagg	120
	ggtggcaggc	gttcaagaat	gatgccacgg	aatcatccg	cgagctcgga	gagtaccccg	180
	agcctccacc	ggagctggag	aacaacaaga	ccatgaaccg	ggcggagaac	ggagggcggc	240
	ctccccacca	cccctttgag	accaaagacg	tgtccgagta	cagctgcgcg	gagctgcact	300
	tcacccgcta	cgtgacgat	gggcccgtgcc	gcagcgccaa	gccggtcacc	gagctggtgt	360
10	gctccggcca	gtgcggcccc	gcgcgcctgc	tgcccaacgc	catcgccgcg	ggcaagtggg	420
	ggcgacctag	tgggcccgcg	ttccgctgca	tccccgaccg	ctaccgcgcg	cagcgcgtgc	480
	agctgctgtg	tcccgggtgt	gaggcgccgc	gcgcgcgcaa	ggtgcgcctg	gtggccctcg	540
	gcaagtgcga	gcgcctcacc	cgcttcacaa	accagtccga	gctcaaggac	ttcgggaccg	600
	aggcgcgtcg	gccgcagaag	ggcgggaagc	cgccggcccc	cgcccgaggc	gccaaagcca	660
15	accaggccga	gctggagaac	gcctactaga	gcccgcgcgc	gcccctcccc	accggcgggc	720
	gccccggccc	tgaacccgcg	ccccacattt	ctgtcctctg	cgcgtgggtt	gattgtttat	780
	atttcattgt	aatgcctgc	aaccagggc	agggggctga	gaccttcacg	gccctgagga	840
	atccccggcg	ccggcaaggc	ccccctcagc	ccgccagctg	aggggtccca	cggggcaggg	900
	gagggaaattg	agagtcacag	acactgagcc	acgcagcccc	gcctctgggg	ccgcctacct	960
20	ttgctggtcc	cacttcagag	gaggcagaaa	tggaagcatt	ttcaccgccc	tgggggttta	1020
	agggagcggg	gtgggagtg	gaaagtccag	ggactgggta	agaaagttgg	ataagattcc	1080
	cccttgccac	tcgctgcccc	tcagaaagcc	tgaggcgtgc	ccagagcaca	agactggggg	1140
	caactgtaga	tgtggtttct	agtcctggct	ctgccactaa	cttgcrgtgt	aaccttgaac	1200
	tacacaattc	tccttcggga	cctcaatttc	cactttgtaa	aatgaggggtg	gaggtgggaa	1260
25	taggatctcg	aggagactat	tggcatatga	ttccaaggac	tccagtgcct	tttgaatggg	1320
	cagaggtgag	agagagagag	agaaagagag	agaatgaatg	cagttgcatt	gattcagtgc	1380
	caaggctcact	tccagaattc	agagttgtga	tgctctcttc	tgacagccaa	agatgaaaaa	1440
	caaacagaaa	aaaaaaagta	aagagtctat	ttatggctga	catattttacg	gctgacaaac	1500
	tcctggaaga	agctatgctg	cttcccagcc	tggtctcccc	ggatgtttgg	ctacctccac	1560
30	ccctccatct	caaagaaata	acatcatcca	ttggggtaga	aaaggagagg	gtccgagggt	1620
	ggtgggaggg	atagaaatca	catccgcccc	aacttcccaa	agagcagcat	ccctcccccg	1680
	acccatagcc	atgttttaaa	gtcaccttcc	gaagagaagt	gaaagggttc	aggacactgg	1740
	ccttgccaggc	ccgaggggagc	agccatcaca	aactcacaga	ccagcacatc	ccttttgaga	1800
	caccgccttc	tgcccaccac	tcacggacac	atttctgcct	agaaaacagc	ttcttactgc	1860
35	tottacatgt	gatggcatat	cttactactaa	aagaatatta	ttgggggaaa	aactacaagt	1920
	gctgtacata	tgctgagaaa	ctgcagagca	taatagctgc	cacccaaaaa	tctttttgaa	1980
	aatcatttcc	agacaacctc	ttactttctg	tgtagttttt	aattgttaaa	aaaaaaaagt	2040
	tttaaacaga	agcacatgac	atatgaaagc	ctgcaggact	ggctgttttt	ttggcaattc	2100
	ttccacgtgg	gacttgtcca	caagaatgaa	agtagtggtt	tttaagaggt	taagttacat	2160
40	atttattttc	tcacttaagt	tatttatgca	aaagtttttc	ttgtagagaa	tgacaatgtt	2220
	aatattgctt	tatgaattaa	cagtctgttc	ttccagagtc	cagagacatt	gttaataaag	2280
	acaatgaatc	atgaccgaaa	g				2301

<210> 6

45 <211> 213

<212> PRT

<213> Homo sapien

<400> 6

50	Met	Gln	Leu	Pro	Leu	Ala	Leu	Cys	Leu	Ile	Cys	Leu	Leu	Val	His	Thr
	1				5					10				15		
	Ala	Phe	Arg	Val	Val	Glu	Gly	Gln	Gly	Trp	Gln	Ala	Phe	Lys	Asn	Asp
				20					25					30		
	Ala	Thr	Glu	Ile	Ile	Arg	Glu	Leu	Gly	Glu	Tyr	Pro	Glu	Pro	Pro	Pro
55				35					40					45		

5

```

ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgaggggt 1620
ggtagggagg atagaaatca catccgcccc aacttcccaa agagcagcat ccctcccccg 1680
acccatagcc atgtttttaa gtcaccttcc gaagagaagt gaaagggttca aggacactgg 1740
ccttgacagg ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
5 caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
gctgtacata tgctgagaaa ctgcagagca taatagctgc caccacaaaa tcttttgaa 1980
aatcatttcc agacaacctc ttactttctg tgtagttttt aattgtttaa aaaaaaagt 2040
tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtagttttt ttggcaattc 2100
10 ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
atatttttcc tcaactaagt tatttatgca aaagtttttc ttgtagagaa tgacaatggt 2220
aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
acaatgaatc atgaccgaaa g 2301

```

```

15 <210> 8
    <211> 213
    <212> PRT
    <213> Homo sapien

```

```

20 <400> 8
Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
  1             5             10             15
Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
      20             25             30
25 Ala Thr Glu Ile Ile Arg Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
      35             40             45
Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
      50             55             60
Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
30 65             70             75             80
Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
      85             90             95
Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
      100            105            110
35 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
      115            120            125
Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
      130            135            140
Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
40 145            150            155            160
Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
      165            170            175
Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
      180            185            190
45 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
      195            200            205
Leu Glu Asn Ala Tyr
      210

```

```

50 <210> 9
    <211> 642
    <212> DNA
    <213> Cercopithecus pygerythrus

```

```

55 <400> 9

```

atgcagctcc cactggccct gtgtcttgte tgcctgctgg tacacgcage cttccgtgta 60
 gtggagggcc aggggtggca ggccttcaag aatgatgccca cggaaatcat ccccgagctc 120
 ggagagtacc ccgagcctcc accggagctg gagaacaaca agaccatgaa ccggcgaggag 180
 aatggagggc ggcctcccca ccaccccttt gagaccaaag acgtgtccga gtacagctgc 240
 5 cgagagctgc acttcacccg ctacgtgacc gatgggcccgt gccgcagcgc caagccagtc 300
 accgagttgg tgtgtccgg ccagtgcggc cgggcaagcc tgetgcccga cggcatcggc 360
 cgcggcaagt ggtggcgccc gagtgggccc gacttccgct gcatccccga ccgctaccgc 420
 gcgcagcgtg tgcagctgct gtgtcccggt ggtgcgcgcgc cgcgcgcgcg caaggtgcgc 480
 ctggtggcct cgtgcaagtg caagcgctc acccgcttcc acaaccagtc ggagctcaag 540
 10 gacttcggtc ccgagggcgc tcggcgcgag aaggggccgga agccgcgggc ccgcgcccgg 600
 ggggccaaag ccaatcaggc cgagctggag aacgcctact ag 642

<210> 10
 <211> 213
 15 <212> PRT
 <213> Cercopithecus pygerythrus

<400> 10
 Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Ala
 20 1 5 10 15
 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 25 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 30 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 35 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 40 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 45 Leu Glu Asn Ala Tyr
 210

<210> 11
 <211> 638
 50 <212> DNA
 <213> Mus musculus

<400> 11
 atgcagccct cactagcccc gtgcctcatt tgcctacttg tgcacgctgc cttctgtgct 60
 55 gtggagggcc aggggtggca agccttcagg aatgatgccca cagaggtcat ccagggtt 120

ggagagtacc ccgagcctcc tcctgagaac aaccagacca tgaaccgggc ggagaatgga 180
 ggcagacctc cccaccatcc ctatgacgcc aaaggtgtgt ccgagtacag ctgccgcgag 240
 ctgcactaca cccgcttctt gacagacggc ccatgccgca gcgccaagcc ggtcaccgag 300
 ttggtgtgct ccggccagtg cggccccgcg cggctgctgc ccaacgccat cgggcgcgtg 360
 5 aagtgggtggc gcccgaacgg accggatttc cgctgcatcc cggatcgcta ccgcgcgcag 420
 cgggtgcagc tgctgtgccc cgggggcgcg gcgcgcgcgt cgcgcaaggt gcgtctggtg 480
 gcctcgtgca agtgcaagcg cctcaccgcg ttccacaacc agtcggagct caaggacttc 540
 gggccggaga ccgcgcggcc gcagaagggt cgcaagccgc ggccccggcg ccggggagcc 600
 aaagccaacc aggcggagct ggagaacgcc tactagag 638

10

<210> 12
 <211> 211
 <212> PRT
 <213> Mus musculus

15

<400> 12
 Met Gln Pro Ser Leu Ala Pro Cys Leu Ile Cys Leu Leu Val His Ala
 1 5 10 15
 Ala Phe Cys Ala Val Glu Gly Gln Gly Trp Gln Ala Phe Arg Asn Asp
 20 20 25 30
 Ala Thr Glu Val Ile Pro Gly Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg Pro Pro
 50 55 60
 25 His His Pro Tyr Asp Ala Lys Asp Val Ser Glu Tyr Ser Cys Arg Glu
 65 70 75 80
 Leu His Tyr Thr Arg Phe Leu Thr Asp Gly Pro Cys Arg Ser Ala Lys
 85 90 95
 Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala Arg Leu
 100 105 110
 30 Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn Gly Pro
 115 120 125
 Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val Gln Leu
 130 135 140
 35 Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg Leu Val
 145 150 155 160
 Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln Ser Glu
 165 170 175
 Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly Arg Lys
 180 185 190
 40 Pro Arg Pro Gly Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu Leu Glu
 195 200 205
 Asn Ala Tyr
 210

45

<210> 13
 <211> 674
 <212> DNA
 <213> Rattus norvegicus

50

<400> 13
 gaggaccgag tgcccttctt ccttctggca ccatgcagct ctcaactagcc ccttgcccttg. 60
 cctgcctgct tgtacatgca gccttcgttg ctgtggagag ccaggggtgg caagccttca 120
 agaatgatgc cacagaaatc atccccggac tcagagagta cccagagcct cctcaggaac 180
 55 tagagaacaa ccagaccatg aaccgggccg agaacggagg cagaccccc caccatcctt 240

	atgacaccaa agacgtgtcc gagtacagct gccgcgagct gcactacacc cgcttcgtga	300
	ccgacggccc gtgccgcagt gccaagccgg tcaccgagtt ggtgtgctcg ggccagtgcg	360
	gccccgcgcg gctgctgccc aacgccatcg ggcgcgtgaa gtggtggcgc ccgaacggac	420
	ccgacttccg ctgcatcccg gatcgctacc gcgcgcagcg ggtgcagctg ctgtgccccg	480
5	gcgggcgggc gccgcgctcg cgcaagggtgc gtctggtggc ctctgtcaag tgcaagcgcc	540
	tcacccgctt ccacaaccag tcggagctca aggacttcgg acctgagacc gcgcggccgc	600
	agaagggctg caagccgcgg ccccgcgccc ggggagccaa agccaaccag gcggagctgg	660
	agaacgcta ctag	674
10	<210> 14	
	<211> 213	
	<212> PRT	
	<213> Rattus norvegicus	
15	<400> 14	
	Met Gln Leu Ser Leu Ala Pro Cys Leu Ala Cys Leu Leu Val His Ala	
	1 5 10 15	
	Ala Phe Val Ala Val Glu Ser Gln Gly Trp Gln Ala Phe Lys Asn Asp	
	20 25 30	
20	Ala Thr Glu Ile Ile Pro Gly Leu Arg Glu Tyr Pro Glu Pro Pro Gln	
	35 40 45	
	Glu Leu Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg	
	50 55 60	
	Pro Pro His His Pro Tyr Asp Thr Lys Asp Val Ser Glu Tyr Ser Cys	
25	65 70 75 80	
	Arg Glu Leu His Tyr Thr Arg Phe Val Thr Asp Gly Pro Cys Arg Ser	
	85 90 95	
	Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala	
	100 105 110	
30	Arg Leu Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn	
	115 120 125	
	Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val	
	130 135 140	
	Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg	
35	145 150 155 160	
	Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln	
	165 170 175	
	Ser Glu Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly	
	180 185 190	
40	Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu	
	195 200 205	
	Leu Glu Asn Ala Tyr	
	210	
45	<210> 15	
	<211> 532	
	<212> DNA	
	<213> Bos torus	
50	<400> 15	
	agaatgatgc cacagaaatc atccccgagc tgggcgagta ccccgagcct ctgccagagc	60
	tgaacaacaa gaccatgaac cgggcggaga acggagggag acctccccac caccctttg	120
	agaccaaaga cgctccgag tacagctgcc gggagctgca cttcaccgcg tacgtgaccg	180
	atgggcgctg ccgcagcgcc aagccggtca ccgagctggt gtgctcgggc cagtgcggcc	240
55	cggcgcgcct gctgccaac gccatcgcc gcggcaagtg gtggcgccca agcgggcccg	300

acttccgctg catccccgac cgctaccgcg cgcagcgggt gcagctgttg tgtcctggcg 360
 gcgcggcgcc gcgcgcgcgc aagggtgcgc tgggtggcctc gtgcaagtgc aagcgctca 420
 ctgccttcca caaccagtcc gagctcaagg acttcggggc cgaggccgcg cggccgcaaa 480
 cgggcccggaa gctgoggccc cgcgcccggg gcaccaaagc cagccgggccc ga 532

5

<210> 16
 <211> 176
 <212> PRT
 <213> Bos torus

10

<400> 16
 Asn Asp Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro
 1 5 10 15
 Leu Pro Glu Leu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly
 20 25 30
 Arg Pro Pro His His Pro Phe Glu Thr Lys Asp Ala Ser Glu Tyr Ser
 35 40 45
 Cys Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg
 50 55 60
 Ser Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro
 65 70 75 80
 Ala Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro
 85 90 95
 Ser Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg
 100 105 110
 Val Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val
 115 120 125
 Arg Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn
 130 135 140
 Gln Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Thr
 145 150 155 160
 Gly Arg Lys Leu Arg Pro Arg Ala Arg Gly Thr Lys Ala Ser Arg Ala
 165 170 175

25

<210> 17
 <211> 35828
 <212> DNA
 <213> Mus musculus

35

<220>
 <221> misc_feature
 <222> (1)...(35828)
 <223> n = A,T,C or G

40

<400> 17
 cgcgttttgg tgagcagcaa tattgogctt cgatgagcct tggcgttgag attgatacct 60
 ctgctgcaca aaaggcaatc gaccgagctg gaccagcgca ttcgtgacac cgtctccttc 120
 gaacttattc gcaatggagt gtcattcatc aaggacngcc tgatcgcaaa tgggtgctatc 180
 cagcgagcgg caatcgaaaa ccctcagccg gtgaccaata tctacaacat cagccttggg 240
 atcctgctg atgagccagc gcagaacaag gtaaccgtca gtgccgataa gttcaaagt 300
 aaacctgggt ttgataccaa cattgaaacg ttgatcgaaa acgcgctgaa aaacgctgct 360
 gaatgtgcgg cgtgggatgt cacaagcaa atggcagcag acaagaaagc gatggatgaa 420
 ctggcttctt atgtccgcac ggccatcatg atggaatgtt tccccgggtg tgttatctgg 480
 cagcagtgcc gtcgatagta tgcaattgat aattattatc atttgcggt cctttccggc 540
 gatccgcctt gttacggggc ggcgacctcg cgggttttcg ctatttatga aaattttccg 600

45

55

	gtttaaggcg	tttccgttct	tcttcgtcat	aacttaatgt	ttttatttaa	aataccctct	660
	gaaaagaaag	gaaacgacag	gtgctgaaag	cgagcttttt	ggcctctgtc	gtttccttct	720
	tctgtttttg	tccgtggaat	gaacaatgga	agtcaacaaa	aagcagagct	tatcgatgat	780
	aagcgggtcaa	acatgagaat	tcgcgccgc	ataatacgac	tcactatagg	gatcgacgcc	840
5	tactccccgc	gcatgaagcg	gaggagctgg	actccgcatg	cccagagacg	cccccaacc	900
	cccaaagtgc	ctgacctcag	cctctaccag	ctctggcttg	ggcttgggcg	gggtcaaggc	960
	taccacgttc	tcttaacagg	tggctgggct	gtctcttggc	cgcgcgcat	gtgacagctg	1020
	cctagttctg	cagtgaagtc	accgtggaat	gtctgccttc	gttgccatgg	caacgggatg	1080
	acgtttacaat	ctgggtgtgg	agcttttctt	gtccgtgtca	ggaaatccaa	ataccctaaa	1140
10	ataccctaga	agaggaagta	gctgagccaa	ggctttcctg	gcttctccag	ataaagtttg	1200
	acttagatgg	aaaaaaacaa	aatgataaag	acccgagcca	tctgaaaatt	cctcctaatt	1260
	gcaccactag	gaaatgtgta	tattattgag	ctcgtatgtg	ttcttatttt	aaaaagaaaa	1320
	ctttagtcat	gttattaata	agaatttctc	agcagtggga	gagaaccaat	attaacacca	1380
	agataaaagt	tggcatgatc	cacattgcag	gaagatccac	gttgggtttt	catgaatgtg	1440
15	aagaccccat	ttattaaagt	cctaagctct	gtttttgcac	actaggaagc	gatggccggg	1500
	atggctgagg	ggctgtaagg	atctttcaat	gtcttacatg	tgtgtttcct	gtcctgcacc	1560
	taggacctgc	tgcctagcct	gcagcagagc	cagaggggtt	tcacatgatt	agtctcagac	1620
	acttgggggc	aggttgcatg	tactgcatcg	cttattttcca	tacggagcac	ctactatgtg	1680
	tcaaacacca	tatgggtgtc	actcttcaga	acggtgggtg	tcacatgggt	gcatttgctg	1740
20	acggttggtg	tgggtggtaga	gagctgagat	atatggagcg	actcttcagc	attctgtcaa	1800
	cgtggctgtg	cattcttgct	cctgagcaag	tggctaaaca	gactcacagg	gtcagcctcc	1860
	agctcagtcg	ctgcatagtc	ttagggaacc	tctcccagtc	ctccctacct	caactatcca	1920
	agaagccagg	gggcttggcg	gtctcaggag	cctgcttgct	gggggacagg	ttgttgagtt	1980
	ttatctgcag	taggttgctt	aggcatagtg	tcaggactga	tggctgcctt	ggagaacaca	2040
25	tcctttgccc	tctatgcaaa	tctgaccttg	acatgggggc	gctgctcagc	tgggaggtatc	2100
	aactgcatac	ctaaagccaa	gcctaaagct	tcttcgtcca	cctgaaactc	ctgggaaagc	2160
	gggcttcccg	cacatcctct	caggccagtg	agggagtctg	tgtgagctyc	actttccaat	2220
	ctcaggggcg	gagaggcaga	gggaggtggg	ggcagagcct	tgcagctctt	tctccccttc	2280
	tggacagcgc	tctggtcag	cagcccatat	gagcacaggc	acatccccac	cccaccccca	2340
30	cctttcctgt	cctgcagaat	ttaggctctg	ttcacggggg	gggggggggg	ggggcagtc	2400
	tatectctct	taggtagaca	ggactctgca	ggagacactg	ctttgtaaga	tactgcagtt	2460
	ttaaatttga	tgttgtgagg	ggaaagcgaa	gggcctcttt	gaccattcag	tcaaggtacc	2520
	ttctaactcc	catcgatttg	gggggctact	ctagtgtctg	acattgcaga	gagcctcaga	2580
	actgtagtta	ccagtgtggt	aggattgatc	cttcaggggg	cctgacatgt	gacagttcca	2640
35	ttcttcaccc	agtcaccgaa	cattttattca	gtacctaccc	cgtaacaggc	accgtagcag	2700
	gtactgaggg	acgggaccact	caaagaactg	acagaccgaa	gccttggaat	ataaacacca	2760
	aagcatcagg	ctctgccaac	agaacactct	ttaacactca	ggccctttaa	cactcaggac	2820
	ccccaccccc	accccaagca	gttggcactg	ctatccacat	tttacagaga	ggaaaaacta	2880
	ggcacaggac	gatataaagt	gcttgcttaa	gcttgtctgc	atggtaaagt	gcagggctgg	2940
40	attgagaccc	agacattcca	actctagggg	ctatttttct	tttttctcgt	tgttcgaatc	3000
	tgggtcttac	tgggtaaact	caggttagcc	tcacactcat	atccttctcc	catggcttac	3060
	gagtgtctag	attccagggtg	tgtgtacca	tgtctgactc	cctgtagctt	gtctatacca	3120
	tcctcacaac	ataggaattg	tgatagcagc	acacacaccg	gaaggagctg	gggaaatccc	3180
	acagagggct	ccgcaggatg	acaggcgaat	gcctacacag	aagggtggga	agggaaagcag	3240
45	agggaaacagc	atgggctgtg	gaccacaagt	ctatttgggg	aagctgccgg	taaccgtata	3300
	tggctggggg	gaggggagag	gtcatgagat	gaggcaggaa	gagccacagc	aggcagcggg	3360
	tacgggctcc	ttattgccaa	gaggctcgga	tcttctctct	cttctctctt	ccggggctgc	3420
	ctgttcattt	tccaccactg	cctcccatcc	aggtctgtgg	ctcaggacat	caccagctg	3480
	cagaaactgg	gcatacacca	cgtctgaat	gctgccgagg	gcaggtcctt	catgcacgtc	3540
50	aacaccagtg	ctagcttcta	cgaggattct	ggcatcacct	acttgggcat	caaggccaat	3600
	gatacgcagg	agttcaacct	cagtgtttac	tttgaaaggg	ccacagattt	cattgaccag	3660
	gcgctggccc	ataaaaaatg	taaggaaact	acattccggc	acccatggag	cgtaagccct	3720
	ctgggacctg	cttctctcaa	agaggccccc	acttgaaaaa	ggttccagaa	agatcccaaa	3780
	atatgccacc	aactagggat	taagtgtcct	acatgtgagc	cgatgggggc	cactgcatat	3840
55	agtctgtgcc	atagacatga	caatggataa	taatatttca	gacagagagc	aggagtttag	3900

	tagctgtgct	cctttccott	taattgagtg	tgcccatttt	tttattcatg	tatgtgtata	3960
	catgtgtgtg	cacacatgcc	ataggttgat	actgaacacc	gtcttcaatc	gttccccacc	4020
	ccaccttatt	ttttgaggca	gggtctcttc	cctgatcctg	gggtcattg	gtttatctag	4080
	gctgctggcc	agtgaactct	ggagttctgc	ttttctctac	ctccctagcc	ctgggactgc	4140
5	aggggcatgt	gctgggccag	gcttttatgt	cgcgttgggg	atctgaactt	aggtccctag	4200
	gcctgagcac	cgtaaagact	ctgccacatc	cccagcctgt	ttgagcaagt	gaaccattcc	4260
	ccagaattcc	cccagtgggg	ctttcctacc	cttttattgg	ctaggcattc	atgagtggtc	4320
	acctcgccag	aggaatgagt	ggccacgact	ggctcagggg	cagcagccta	gagatactgg	4380
	gttaagtctt	cctgccgctc	gctccctgca	gccgcagaca	gaaagttaga	ctgaatgaga	4440
10	gctggctagt	ggtcagacag	gacagaaggc	tgagaggggc	acagggcaga	tgtcagcaga	4500
	gcagacaggt	tctccctctg	tgggggaggg	gtggcccaat	gcaggtgtaa	ttggccttct	4560
	ttgtgctcca	tagaggcttc	ctgggtacac	agcagcttcc	ctgtcctggg	gattcccaaa	4620
	gagaactccc	taccactgga	cttacagaag	ttctattgac	tggtgtaacg	gttcaacagc	4680
	tttggctctt	gggtgacggg	gcatactgct	gtatcagctc	aagagctcat	tcacgaatga	4740
15	acacacacac	acacacacac	acacacacac	acacaagcta	attttgatat	gccttaacta	4800
	gctcagtgac	tgggcatttc	tgaacatccc	tgaagttagc	acacatttcc	ctctgggtgtt	4860
	cctggcttaa	caccttctaa	atctatatatt	tatctttgct	gccctgttac	cttctgagaa	4920
	gcccctaggg	ccacttccct	tcgcacctac	attgctggat	ggtttctctc	ctgcagctct	4980
	taaatctgat	ccctctgcct	ctgagccatg	ggaacagccc	aataactgag	ttagacataa	5040
20	aaacgtctct	agccaaaact	tcagctaaat	ttagacaata	aatcttactg	gttgtggaat	5100
	ccttaagatt	cttcatgacc	tccttcacat	ggcacgagta	tgaagcttta	ttacaattgt	5160
	ttattgatca	aactaactca	taaaaagcca	gttgtctttc	acctgctcaa	ggaaggaaca	5220
	aaattcatcc	ttaactgate	tgtgcacctt	gcacaatcca	tacgaatata	ttaagagtac	5280
	taagattttg	gttgtgagag	tcacatgtta	cagaatgtac	agctttgaca	aggtgcaccc	5340
25	ttgggatgcc	gaagtgaact	gctgttccag	ccccctacct	tctgaggctg	ttttggaagc	5400
	aatgctctgg	aagcaacttt	aggaggtagg	atgctggaac	agcgygtcac	ttcagcatcc	5460
	cgatgacgaa	tcccgtaaaa	gctgtacatt	ctgtaacaga	ctgggaaagc	tgacagcttt	5520
	aaggccaggg	ccctatgggc	cctcttaate	cctgtcacac	ccaacccgag	cccttctcct	5580
	ccagccgttc	tgtgcttctc	actctggata	gatggagaac	acggccttgc	tagttaaagg	5640
30	agtgaggctt	caccttcttc	acatggcagt	ggttgggtcat	cctcattcag	ggaactctgg	5700
	ggcattctgc	cttacttctc	tctttttgga	ctacagggaa	tatatgctga	cttgttttga	5760
	ccttgtgtat	ggggagactg	gatctttggg	ctggaatgtt	tctgtctagt	tttcccccac	5820
	cctttggcaa	acctatctta	tatcttacca	ctaggcatag	tgccctcctg	tctggagcct	5880
	gccttcaggc	tgggtctcgg	ggaccatgtc	cctggtttct	ccccagcata	tggtgttcac	5940
35	agtgttcact	gcgggtgggt	gctgaacaaa	gcggggattg	catcccagag	ctccggtgcc	6000
	ttgtgggtac	actgctaaga	taaaatggat	actggcctct	ctctgaccac	ttgcagagct	6060
	ctgggtgcctt	gtgggtacac	tgctaagata	aatgggatac	tggcctctct	ctatccactt	6120
	gcaggactct	agggaaacagg	aatccattac	tgagaaaaacc	aggggctagg	agcagggagg	6180
	tagctgggca	gctgaagtgc	ttggcgacta	accaatgaat	accagagttt	ggatctctag	6240
40	aatactctta	aatctgggt	gggcagagtg	gctgcctgt	aatcccagaa	ctcgggaggg	6300
	ggagacaggg	aatcatcaga	gcaaaactggc	taaccagaat	agcaaaacac	tgagctctgg	6360
	gctctgtgag	agatcctgcc	ttaacatata	agagagagaa	taaaacattg	aagaagacag	6420
	tagatgccaa	ttttaagccc	ccacatgcac	atggacaagt	gtgogtttga	acacacatat	6480
	gcactcatgt	gaaccaggca	tgcacactcg	ggcttatcac	acacataatt	tgaaagagag	6540
45	agtgagagag	gagagtgcac	attagagttc	acaggaaaagt	gtgagtgagc	acacccatgc	6600
	acacagacat	gtgtgccagg	gagtaggaaa	ggagcctggg	tttgtgtata	agagggagcc	6660
	atcatgtgtt	tctaaggagg	gcgtgtgaag	gagcgcttgt	gtgggctggg	actggagcat	6720
	ggttgttaact	gagcatgctc	cctgtgggaa	acaggagggg	ggccaccctg	cagaggggtcc	6780
	cactgtccag	cgggatcagt	aaaagcccct	ctgtagaact	ttaggttaata	gccagagaga	6840
50	gaaaggtagg	aaagtggggg	gactcccatc	tctgatgtag	gaggatctgg	gcaagtagag	6900
	gtgcgtttga	ggtagaaaga	gggggtgcaga	ggagatgctc	ttaattctgg	gtcagcagtt	6960
	tctttccaaa	taatgcctgt	gaggaggtgt	aggtggtggc	cattcactca	ctcagcagag	7020
	ggatgatgat	gcccgggtgga	tgctggaaat	ggccgagcat	caaccctggc	tctggaagaa	7080
	ctccatcttt	cagaaggaga	gtggatctgt	gtatggccag	cggggtcaca	ggtgcttggg	7140
55	gcccctgggg	gactcctagc	actgggtgat	gtttatcgag	tgctcttgtg	tgccaggcac	7200

	tggcctgggg	ctttgtttct	gtctctgttt	tgtttctgtt	tttgagacag	actcttgcta	7260
	tgatccgtg	tcaatcttgg	aatctcactg	catagcccag	gctgcggaga	gaggggaggg	7320
	caataggcct	tgtaagcaag	ccacacttca	gagaactagac	tccaccctgc	gaatgatgac	7380
	aggtcagagc	tgagttccgg	aagatttttt	ttccagctgc	caggtggagt	gtggagtggc	7440
5	agctagcggc	aagggtagag	ggcgagctcc	ctgtgcagga	gaaatgcaag	caagagatgg	7500
	caagccagtg	agttaagcat	tctgtgtggg	gagcaggtgg	atgaagagag	aggctgggct	7560
	ttcgctctg	gggggggggt	gaggggtggg	gatgaggtga	gaggagggca	gctccctgca	7620
	gtgtgatgag	atttttcctg	acagtgcct	ttggcctctc	cctccccac	ttcccttctt	7680
	tcctttcttc	ccaccattgc	tttcttgtc	cttgagaaat	tctgagtttc	cacttcaactg	7740
10	gtgatgcaga	cggaaacaga	agcctgtgtg	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	7800
	gtgtgtgtgt	ttgtgtgtat	gtgtgtgtgt	gtgtttgtgt	gtatgtgtgt	cagtgggaat	7860
	ggctcatagt	ctgcaggaag	gtgggcagga	aggaataagc	tgtaggctga	ggcagtgtgg	7920
	gatgcaggga	gagaggagag	gagggatacc	agagaaggaa	attaaggag	ctacaagagg	7980
	gcattgttgg	ggtgtgtgtg	tgtgtgtgtt	gtttatat	gtattggaaa	tacattcttt	8040
15	taaaaaatac	ttatccattt	atttattttt	atgtgcacgt	gtgtgtgcct	gcagtgttcc	8100
	atgtgtgcc	cgtgtgtgcg	ggaacccttg	gagggcaca	gggggcatct	gatccccctg	8160
	aactggagtt	ggaggaggtt	gtgagtcctc	tgacatgttt	gctgggaact	gaaccccggt	8220
	cctatgcaag	agcaggaagt	gcagttatct	gctgagccat	ctctccagtc	ctgaaatcca	8280
	ttctcttaaa	atacacgtgg	cagagacatg	atgggattta	cgtatggatt	taatgtggcg	8340
20	gtcattaagt	tccggcacag	gcaagcacct	gtaaagccat	caccacaacc	gcaacagtga	8400
	atgtgaccat	cacccccatg	ttcttcatgt	cccctgtccc	ctccatcctc	cattctcaag	8460
	cacctcttgc	tctgcctctg	tcgctggaga	acagtgtgca	tctgcacact	cttatgtcag	8520
	tgaagtcaca	cagcctgcac	cccttcctgg	tctgagtatt	tgggttctga	ctctgctatc	8580
	acacactact	gtactgcatt	ctctcgtctc	ctttttttta	acatatTTTT	atttgtttgt	8640
25	gtgtatgcac	atgtgccaca	tgtgtacaga	tactatggag	gccagaagag	gccatggccg	8700
	tccttgagc	tggagttaca	ggcagcgtgt	gagctgctg	gtgtgggtgc	tgggaaccac	8760
	acttgaatct	aaagcaagca	cttttaactg	ctgaggcagc	tctcagtacc	cttcttcat	8820
	tctccgctg	ggttccattg	tatggacaca	tgtagctaga	atatcttgc	tatctaatta	8880
	tgtacattgt	tttgtgctaa	gagagagtaa	tgctctatag	cctgagctgg	cctcaacctt	8940
30	gccatccctc	tgcctcagcc	tcctccctct	gagtgtctag	atgacaggcg	agtggttaact	9000
	tacatgggtt	catgttttgt	tcaagactga	aggataacat	tcatacagag	aaggtctggg	9060
	tcacaaagt	tgcagttcac	tgaatggcac	aaccctgtat	caagaaacaa	aactcagggg	9120
	ctggagagat	ggcactgact	gctcttccag	aggtccggag	ttcaattccc	agcaaccaca	9180
	tgggtggctca	cagccatcta	taacgagatc	tgacgccctc	ttctggtgtg	tctgaagaca	9240
35	gctacagtgt	actcacataa	aataaataaa	tcttttaaac	acacacacac	acacaattac	9300
	cacccagaa	agcccatcc	atgttccctc	ccacgtctct	gcctacagta	ctcccagggt	9360
	accactgttc	aggcttctaa	caacctgggt	tacttgggct	tcttttctgc	tctgtggagc	9420
	cacacatttg	tgtgcctcat	acacgttctt	tctagtaagt	tgcataattac	tctgcgtttt	9480
	tacatgtatt	tatttattgt	agtgtgtgtg	gcgtgtgggc	ccatgcatgg	cacagtgtgt	9540
40	ggggatgtca	gagtattgtg	aacaggggac	agttcttttc	ttcaatcatg	tgggttccag	9600
	aggttgaact	caggtcatca	tgtgtggcag	caaagtccct	tacccactga	gacatctcca	9660
	tattcttttt	ttttccctg	aggtgggggc	ttgttccata	gcccacactg	gctttgcaact	9720
	tgcagttcaa	agtgcctccc	tgtctccacc	tcttagagta	ttggaattac	gatgtgtact	9780
	accacacctg	actggatcat	taattctttg	atggggggcg	ggaagcgcac	atgctgcagg	9840
45	tgaagggatg	actggactgg	acatgagcgt	ggaagccaga	gaacagcttc	agtctaattgc	9900
	tctcccaact	gagctatttc	ggtttgccag	agaacaactt	acagaaagtt	ctcagtgcc	9960
	tgtggattcg	gggttggagt	tcaactcatc	agcttgacat	tggtcctctc	accactgag	10020
	ccttctcact	actctctacc	tagatcatta	attctttttt	aaaaagactt	attagggggc	10080
	tggagagatg	gctcagccgt	taagagcacc	gaatgccctt	ccagaggtcc	tgaattcaat	10140
50	tcccagcatg	ccattgctgg	gcagtggggg	gcgcaggtgt	tcaacgtgag	tagctgttgc	10200
	cagttttccg	cgggtggagaa	cctcttgaca	ccctgctgtc	cctgggtcatt	ctgggtgggt	10260
	gcatggtgat	atgcttgttg	tatggaagac	tttgactgtt	acagtgaagt	tgggcttcca	10320
	cagttaccac	gtctccctg	tttcttgacg	gccgggtgct	tgtccattgc	cgcgagggct	10380
	acagccgctc	cccaacgcta	gttatcgctt	acctcatgat	gcggcagaag	atggacgtca	10440
55	agtctgctct	gagtactgtg	aggcagaatc	gtgagatcgg	ccccaacgat	ggcttcctgg	10500

	cccaactctg	ccagctcaat	gacagactag	ccaaggaggg	caaggtgaaa	ctctaggggtg	10560
	cccacagcct	cttttgacaga	ggtctgactg	ggagggccct	ggcagccatg	tttaggaaac	10620
	acagtatacc	cactccctgc	accaccagac	acgtgccac	atctgtccca	ctctggctct	10680
	cgggggccac	tccaccctta	gggagcacat	gaagaagctc	cctaagaagt	tctgtctctt	10740
5	agccatcctt	tctgttaatt	tatgtctctc	cctgaggtga	ggttcagggt	tatgtccctg	10800
	tctgtggcat	agatacatct	cagtgaacca	gggtgggagg	gctatcaggg	tgcattggccc	10860
	gggacacggg	cactcttcat	gacccctccc	ccacctgggt	tcttctctgt	tgggtccagaa	10920
	ccacgagcct	ggtaaaggaa	ctatgcaaac	acaggccctg	acctcccat	gtctgttctt	10980
	ggtcctcaca	gcccagacag	cctgtctgag	gcagacgaat	gacattaagt	tctgaagcag	11040
10	agtggagata	gattagtga	tagatttcca	aaaagaagga	aaaaaaaggc	tgcattttta	11100
	aattatttcc	ttagaattaa	agatactaca	tagggggccct	tgggtaagca	aatccatttt	11160
	tcccagaggg	tatcttgatt	ctttggaatg	tttaaagtgt	gccttgccag	agagcttacg	11220
	atctatatct	gotgtctcag	agccttccct	gaggatggct	ctgttctctt	gcttggttaga	11280
	agagcgatgc	cttgggcagg	gtttccccc	tttcagaata	cagggtgtaa	agtccagcct	11340
15	attacaaaca	aacaaacaaa	caaacaaaca	aaggacctcc	atttgagaaa	ttgcaaggat	11400
	tttatcctga	attatagtgt	tggtaggttc	aagtcacac	gccaagtgt	tgccatcctg	11460
	gttgctattc	taagaataat	taggaggagg	aacctagcca	attgcagctc	atgtccgtgg	11520
	gtgtgtgcac	gggtgcata	gttggaagg	gtgcctgtcc	ccttggggac	agaaggaaaa	11580
	tgaaggcccc	ctctgtctac	cctggccatt	tacgggaggc	tctgtctggt	ccacgggtgt	11640
20	tgtgcaggat	cctgaaactg	actegctgga	cagaaacgag	acttggcggc	accatgagaa	11700
	tggagagaga	gagagcaaa	aaagaaacag	cctttaaaag	aactttctaa	gggtgggttt	11760
	tgaacctcgc	tggaccttgt	atgtgtgcac	atttgccaga	gattgaacat	aatcctcttg	11820
	ggacttcacg	ttctcattat	ttgtatgtct	ccggggtcac	gcagagccgt	cagccaccac	11880
	cccagcacc	ggcacatagg	cgtctcataa	aagccccatt	tatgagaacc	agagctgttt	11940
25	gagtaccccg	tgtatagaga	gagttgttgt	cgtggggcac	ccggatccca	gcagcctggt	12000
	tgcctgcctg	taggatgtct	tacaggagtt	tgcagagaaa	ccttcccttg	agggaaagaa	12060
	atatcagggg	tttttgttga	atatttcaaa	ttcagcttta	agtgtgaagc	tcagcagttg	12120
	tcattggttaa	ggtaaggaa	atgccttttc	cagagctgct	gcaagaggca	ggagaagcag	12180
	acctgtctta	ggatgtcact	cccagggtaa	agacctctga	tcacagcagg	agcagagctg	12240
30	tgcagcctgg	atgggtcattg	tcccctattc	tgtgtgacca	cagcaacct	ggtcacatag	12300
	ggctggctcat	cctttttttt	tttttttttt	tttttttttg	gcccagaatg	aagtgacctg	12360
	agccaagttg	tgtacctcag	tcttttagttt	ccaagcggct	ctcttgcctc	atacaatgtg	12420
	cattttcaaaa	taacactgta	gagttgacag	aactggttca	tgtgttatga	gagaggaaaa	12480
35	gagaggaaag	aacaaaacaa	aacaaaacac	cacaaaccaa	aaacatctgg	gctagccagg	12540
	catgattgca	atgtctacag	gcccagttca	tgagaggcag	agacaggaag	accgccgaaa	12600
	ggtaaggat	agcatggct	acgtatcgag	actccagcca	gggctacgg	cccaagatcc	12660
	taggttttgg	attttgggct	ttggtttttg	agacagggtt	tctctgtgta	gccctggctg	12720
	tcttggaaact	cgtctgttag	accaggctgg	cctcaaacct	agagatctgc	ctgactctgc	12780
	ctttgagggc	tgggacgaat	gccaccactg	cccaactaag	attccattaa	aaaaaaaaaa	12840
40	agttcaagat	aattaagagt	tgccagctcg	ttaaagctaa	gtagaagcag	tctcaggcct	12900
	gctgcttgag	gctgttcttg	gcttggacct	gaaatctgcc	cccaacagtg	tccaagtgc	12960
	catgactttg	agccatctcc	agagaaggaa	gtgaaaattg	tggctcccca	gtcgattggg	13020
	acacagtctc	tctttgtcta	ggtaacacat	ggtagacacat	agcattgaac	tctccactct	13080
	gaggggtgggt	ttccctcccc	ctgcctcttc	tgggttgggt	accccatagg	acagccacag	13140
45	gacagtcact	agcacctact	ggaaacctct	ttgtgggaac	atgaagaaag	agcctttggg	13200
	agattcctgg	ctttccatta	gggtgaaag	tacaacgggt	cttgggtggc	tttgccctcg	13260
	gtttataaaa	ctagctacta	ttcttcagg	aaaataccga	tgtgtgggaa	aagccaacct	13320
	cgtggctgcc	cgtgagtagg	gggtgggggt	gggaatcctg	gatagtgttc	tatccatgga	13380
	aagtgggtgga	ataggaatta	aggtgttcc	cccccccc	aacctcttcc	tcagaccag	13440
50	ccactttcta	tgacttataa	acatccagg	aaaaattaca	aacataaaaa	tgggtttctct	13500
	tctcaatctt	ctaaagtctg	cctgcctttt	ccaggggtag	gtctgtttct	ttgtgttct	13560
	attgtcttga	gagcacagac	taacacttac	caaatgagg	aactcttggc	ccataactaag	13620
	gctcttctgg	gctccagcac	tcttaagtta	ttttaagaat	tctcacttgg	ccttttagcac	13680
	acccgccacc	cccaagtggg	tgtggataat	gccatggcca	gcagggggca	ctgttgaggc	13740
55	gggtgccttt	ccaccttaag	ttgcttatag	tatttaagat	gctaaatgtt	ttaatcaaga	13800

	gaagcactga	tcttataata	cgaggataag	agattttctc	acaggaaatt	gtctttttca	13860
	taattctttt	acaggctttg	tcctgatcgt	agcatagaga	gaatagctgg	atatttaact	13920
	tgtattccat	tttctctcgc	cagcgttagg	ttaactccgt	aaaaagtgat	tcagtggacc	13980
	gaagaggctc	agagggcagg	ggatgggtgg	gtgaggcaga	gcactgtcac	ctgccaggca	14040
5	tgggagggtc	tgccatccgg	gaggaaaagg	aaagtttagc	ctctagtcta	ccaccagtgt	14100
	taacgcactc	taaagtgtga	acaaaaataa	atgtcttaca	ttacaaagac	gtctgttttg	14160
	tgtttccttt	tgtgtgtttg	ggctttttat	gtgtgcttta	taactgctgt	gggtgtgctg	14220
	ttgttagttt	tgaggtagga	tctcaggctg	gccttgaact	tctgatcgcc	tgccctcgcc	14280
	cctgccccctg	ccctgtcccc	tgccctccaag	tgctaggact	aaaagcacat	gccaccacac	14340
10	cagtacagca	tttttctaac	atttaaaaaat	aatcacctag	gggctggaga	gagggttcca	14400
	gctaagagtg	cacactgctc	ttgggttagga	cctgagttta	gttcccagaa	cctatactgg	14460
	gtggctccag	gtccagagga	tccaggacct	ctggcctcca	tgggcatctg	ctcttagcac	14520
	ataccacat	acagatacac	acataaaaaat	aaaatgaagc	ctttaaaaaac	ctcctaaaaac	14580
	ctagcccttg	gaggtacgac	tctggaaagc	tggcatactg	tgtaagtcca	tctcatgggtg	14640
15	ttctgggctaa	cgtaagactt	acagagacag	aaaagaactc	aggggtgtgct	gggggttggg	14700
	atggaggaag	agggatgagt	agggggagca	cggggaactt	gggcagtga	aattctttgc	14760
	aggacactag	aggaggataa	ataccagtca	tggcaccac	tactggacaa	ctccaggga	14820
	ttatgctggg	tgaaaagaga	aggcccaggg	tattggtctg	attggctgca	tttgctgaac	14880
	atTTTTTTTaa	attgaaaaga	aaaagatgta	aatcaagggt	agatgagtgg	ttgctgtgag	14940
20	ctgagagctg	gggtgagtga	gacatgtgga	caactccatc	aaaaagcgac	agaaagaacg	15000
	ggctgtgggtg	acagctacct	ctaactctcca	cctccgggag	gtgatcaagg	ttagccctca	15060
	gctagcctgt	ggtgcatgag	accctgtttc	aaaaacttta	ataaagaaat	aatgaaaaaa	15120
	gacatcaggg	cagatccttg	gggccaagg	cggacaggcg	agtctcgtgg	taaggtcgtg	15180
	tagaagcggg	tgcatgagca	cgtgccgcag	gcatcatgag	agagccctag	gtaagtaagg	15240
25	atggatgtga	gtgtgtcggc	gtcggcgcac	tgcacgtcct	ggctgtgggtg	ctggactggc	15300
	atcttttggtg	agctgtggag	gggaaatggg	tagggagatc	ataaaatccc	tccgaattat	15360
	ttcaagaact	gtctattaca	attatctcaa	aatattaaaa	aaaaagaaga	attaaaaaac	15420
	aaaaaaccta	tccaggtgtg	gtggtgtgca	cctatagcca	cgggcacttg	gaaagctgga	15480
	gcaagaggat	ggcgagtttg	aaggatatctg	gggctgtaca	gcaagaccgt	cgtcccaaaa	15540
30	ccaaacccaaa	cagcaaaccc	attatgtcac	acaagagtgt	ttatagttag	cggcctcgct	15600
	gagagcatgg	ggtgggggtg	gggggtgggg	acagaaatat	ctaaactgca	gtcaataggg	15660
	atccactgag	accctggggc	ttgactgcag	cttaaccttg	ggaaatgata	agggttttgt	15720
	gttgagtaaa	agcatcgatt	actgacttaa	cctcaaatga	agaaaaagaa	aaaaagaaaa	15780
	caacaaaagc	caaaccaagg	ggctgggtgag	atggctcagt	gggtaagagc	accgactgc	15840
35	tcttccgaag	gtccagagtt	caaatcccag	caaccacatg	gtggctcaca	accatctata	15900
	acagatatg	atgccctctt	ctgggtgtgtc	tgaagacagc	tacagtgtac	ttacatataa	15960
	taaataaatc	ttaaaaaaa	aaaaaaa	aaaagccaaa	ccgagcaaac	caggcccca	16020
	aacagaaggc	aggcacgacg	gcaggcacca	cgagccatcc	tgtgaaaagg	cagggtctacc	16080
	catggggccga	ggagggtcca	gagagatagg	ctggtaagct	cagtttctct	gtataccctt	16140
40	tttcttggtg	acactacttc	aattacagat	aaaataacaa	ataaacaata	tctagagcct	16200
	ggccaactctc	tgtctgcttg	atTTTTTctg	ttacgtccag	cagggtggcg	aagtgttcca	16260
	aggacagatc	gcatcattaa	ggtggccagc	ataatctccc	atcagcaggt	ggtgctgtga	16320
	gaaccattat	ggtgtctaca	gaatcccggg	cccaggagct	gcccctctcc	aagtctggag	16380
	caataggaaa	gctttctggc	ccagacaggg	ttaacagtcc	acattccaga	gcaggggaaa	16440
45	aggagactgg	aggtcacaga	caaaagggcc	agcttctaac	aacttcacag	ctctggtagg	16500
	agagatagat	cacccccaac	aatggccaca	gctgggtttg	tctgccccga	aggaactga	16560
	cttaggaagc	aggtatcaga	gtcccttccc	tgaggggact	tctgtctgcc	ttgtaaagct	16620
	gtcagagcag	ctgcattgat	gtgtgggtga	cagaagatga	aaaggaggac	ccaggcagat	16680
	cgccacagat	ggaccggcca	cttacaagtc	gaggcagggtg	gcagagcctt	gcagaagctc	16740
50	tgcagggtgga	cgacactgat	tcattaccga	gttagcatac	cacagcgggc	taggcggacc	16800
	acagcctcct	tcccagtcct	cctccagggc	tggggagtcc	tccaaccttc	tgtctcagtg	16860
	cagcttccgc	cagccctccc	tccttttgca	cctcagggtg	gaacctccc	tcctctcctt	16920
	ctccctgtgg	catggccctc	ctgctactgc	aggctgagca	ttggatttct	ttgtgcttag	16980
	atagacctga	gatggctttc	tgatttatat	atatatatcc	atcccttggg	tcttacatct	17040
55	aggacccaga	gctgtttgtg	ataccataag	aggctgggga	gatgatattg	taagagtgtc	17100

	tgctgtacaa	gcatgaagac	atgagttcga	atccccagca	accatgtgga	aaaataacct	17160
	tctaacctca	gagttgaggg	gaaaggcagg	tggattctgg	gggcttactg	gccagctagc	17220
	cagcctaacc	taaatgtctc	agtcagagat	cctgtctcag	ggaataactt	gggagaatga	17280
	ctgagaaaga	cacctcctca	ggtctcccat	gcacccacac	agacacacgg	ggggggggta	17340
5	atgtaataag	ctaagaaata	atgagggaaa	tgattttttg	ctaagaaatg	aaattctgtg	17400
	ttggccgcaa	gaagcctggc	caggggaagga	actgcctttg	gcacaccagc	ctataagtca	17460
	ccatgagttc	cctggcctaag	aatcacatgt	aatggagccc	aggtcctctc	tgcctggtgg	17520
	ttgcctctcc	cactggtttt	gaagagaaat	tcaagagaga	tctccttggt	cagaattgta	17580
	ggtgctgagc	aatgtggagc	tgggggtcaat	gggattcctt	taaaggcatc	cttcccaggg	17640
10	ctgggtcata	cttcaatagt	aggggtgcttg	cacagcaagc	gtgagacctt	agggttagagt	17700
	ccccagaatc	tgcccccaac	cccccaaaaa	ggcatccttc	tgcctctggg	tgggtggggg	17760
	gagcaaacac	ctttaactaa	gaccattagc	tggcaggggt	aacaaatgac	cttggctaga	17820
	ggaatttggt	caagctggat	tccgccttct	gtagaagccc	cacttgtttc	ctttgttaag	17880
	ctggcccaca	gtttgttttg	agaatgcctg	agggggccag	ggagccagac	aattaaaagc	17940
15	caagctcatt	ttgatatctg	aaaaccacag	cctgactgcc	ctgcccgtgg	gaggtactgg	18000
	gagagctggc	tgtgtccctg	cctcaccaac	gccccccccc	ccaacacaca	ctcctcgggt	18060
	cacctgggag	gtgccagcag	caatttggaa	gtttactgag	cttgagaagt	cttgggaggg	18120
	ctgacgctaa	gcacacccct	tctccacccc	ccccaccccc	acccccgtga	ggaggagggt	18180
	gaggaaacat	gggaccagcc	ctgctccagc	ccgtccttat	tggctggcat	gaggcagagg	18240
20	gggctttaaa	aaggcaaccg	tatctaggct	ggacactgga	gcctgtgcta	ccgagtggcc	18300
	tcctccacct	ggcagcatgc	agccctcact	agccccgtgc	ctcatctgcc	tacttgtgca	18360
	cgtctgccttc	tgtgctgtgg	agggccaggg	gtggcaagcc	ttcaggaatg	atgccacaga	18420
	ggtcacccca	gggcttgagg	agtaccccca	gcctcctcct	gagaacaacc	agaccatgaa	18480
	ccgggcccag	aatggaggca	gacctcccca	ccatccctat	gacgccaag	gtacgggatg	18540
25	aagaagcaca	ttagtggggg	gggggggtcct	gggaggtgac	tgggggtggt	ttagcatcct	18600
	cttcagaggt	ttgtgtgggt	ggctagcctc	tgtacatca	gggcagggac	acatttgcct	18660
	ggaagaatac	tagcacagca	ttagaacctg	gagggcagca	ttggggggct	ggtagagagc	18720
	acccaaggca	gggtggaggc	tgaggtcagc	cgaagctggc	attaacacgg	gcatgggctt	18780
	gtatgatggt	ccagagaatc	tcctcctaag	gatgaggaca	caggtcagat	ctagctgctg	18840
30	accagtgggg	aagtgatatg	gtgaggctgg	atgccagatg	ccatccatgg	ctgtactata	18900
	tcccacatga	ccaccacatg	aggtaaagaa	ggccccagct	tgaagatgga	gaaaccgaga	18960
	ggctcctgag	ataaagtcac	ctgggagtaa	gaagagctga	gactggaagc	tggtttgatc	19020
	cagatgcaag	gcaaccctag	attgggtttg	ggtgggaacc	tgaagccagg	aggaatccct	19080
	ttagttcccc	cttgcccagg	gtctgctcaa	tgagcccaga	gggttagcat	taaaagaaca	19140
35	gggtttgtag	gtggcatgtg	acatgagggg	cagctgagtg	aaatgtcccc	tgtatgagca	19200
	caggtggcac	cacttgccct	gagcttgcac	cctgacccca	gctttgcctc	attcctgagg	19260
	acagcagaaa	ctgtggaggc	agagccagca	cagagagatg	cctgggggtg	gggtgggggt	19320
	atcacgcacg	gaactagcag	caatgaattg	ggtgggggtg	cagctggagg	gacactccag	19380
	agaaatgacc	ttgctgggtc	ccatttgtgt	gggaggagag	ctcattttcc	agcttgccac	19440
40	cacatgctgt	ccctcctgtc	tcctagccag	taagggatgt	ggaggaaagg	gccaccccaa	19500
	aggagcatgc	aatgcagtc	cgtttttgca	gaggaagtgc	ttgacctaa	ggcactattc	19560
	ttggaaagcc	ccaaaactag	tccttcctct	ggcaaacagg	cctcccccc	ataccacctc	19620
	tgcaggggtg	agtaaatata	gccagccaca	gaaggggtgc	aaggccatca	cctccccctc	19680
	gttgtgcccc	cccccccccc	gtgaagggtc	atcctggcct	ctgccccctc	ggctttggta	19740
45	ctgggatttt	ttttttcctt	ttatgtcata	ttgatcctga	caccatggaa	cttttgagg	19800
	tagacaggac	ccacacatgg	attagttaaa	agcctcccat	ccatctaagc	tcattgtagg	19860
	agatagagca	tgtccaagag	aggagggcag	gcacagacc	tagaagatat	ggctgggcat	19920
	ccaacccaat	ctccttcccc	ggagaacaga	ctctaagtca	gatccagcca	cccttgagta	19980
	accagctcaa	ggtacacaga	acaagagagt	ctggtataca	gcaggtgcta	aacaaatgct	20040
50	tgtggtagca	aaagctatag	gttttggtgc	agaactccga	ccaagtccg	gagtgaagag	20100
	cgaaaggccc	tctactcgcc	accgccccgc	ccccacctgg	ggctctataa	cagatcactt	20160
	tcacccttgc	gggagccaga	gagccctggc	atcctaggtg	gcccccccc	cccccccccc	20220
	gcaagcagcc	cagccctgcc	tttggggcaa	gttcttttct	cagcctggac	ctgtgataat	20280
	gaggggggtg	gacgcgccgc	ctttggctgc	tttcaagtct	aatgaattct	tatccctacc	20340
55	acctgccttt	ctaccccgtc	cctccacagc	agctgtcctg	atttattacc	ttcaattaac	20400

	ctccactcct	ttctccatct	cctgggatac	cgeccctgtc	ccagtggctg	gtaaaggagc	20460
	ttaggaagga	ccagagccag	gtgtggctag	aggctaccag	gcagggctgg	ggatgaggag	20520
	ctaaactgga	agagtgtttg	gttagtaggc	acaaagcctt	gggtgggatac	cctagtaccg	20580
	gagaagtgga	gatgggcgct	gagaagttca	agaccatcca	tccttaacta	cacagccagt	20640
5	ttgaggccag	cctgggctac	ataaaaaccc	aatctcaaaa	gctgccaatt	ctgattctgt	20700
	gccacgtagt	gcccgatgta	atagtggatg	aagtcgttga	atcctggggc	aacctatttt	20760
	acagatgtgg	ggaaaagcaa	ctttaagtac	cctgcccaca	gatcacaag	aaagtaagtg	20820
	acagagctcc	agtgtttcat	ccctgggttc	caaggacagg	gagagagaag	ccagggtggg	20880
	atctcactgc	tccccgggtgc	ctccttccta	taatccatac	agattcgaaa	gcgcagggca	20940
10	ggttttgaaa	aagagagaag	ggtggaagga	gcagaccagt	ctggcctagg	ctgcagcccc	21000
	tcacgcaccc	ctctctccgc	agatgtgtcc	gagtacagct	gccgcgagct	gcactacacc	21060
	cgcttccctga	cagacggccc	atgcccgcag	gccaaagccg	tcaccgagtt	ggtgtgtctc	21120
	ggccagtcgc	gccccgcgcg	gctgctgccc	aacgccatcg	ggcgcgtgaa	gtggtgctgc	21180
	ccgaacggac	cggattttccg	ctgcatcccg	gatcgctacc	gcgcgcagcg	ggtgcagctg	21240
15	ctgtgccccg	ggggcgcggc	gccgcgctcg	cgcaaggctg	gtctggtggc	ctcgtgcaag	21300
	tgcaagcgcc	tcacccgctt	ccacaaccag	tcggagctca	aggacttcgg	gccggagacc	21360
	gagcgccgcg	agaagggctg	caagccgcg	cccggcgccc	ggggagccaa	agccaaccag	21420
	gcgagagctg	agaacgccta	ctagagcgag	cccgcgccta	tcagagcccc	gcgcgatccg	21480
	attcgttttc	agtgtaaagc	ctgcagccca	ggccaggggt	gccaaacttt	ccagaccgtg	21540
20	tggagttccc	agcccagtag	agaccgcagg	tccttctgcc	cgctgcgggg	gatggggagg	21600
	gggtgggggt	cccgcggggc	aggagaggaa	gcttgagtc	cagactctgc	ctagcccccg	21660
	gtgggatggg	ggtctttcta	ccctcgcccg	acctatacag	gacaaggcag	tgtttccacc	21720
	ttaaagggaa	gggagtgtgg	aacgaaagac	ctgggactgg	tcattggacgt	acagtaagat	21780
	ctactccttc	cacccaaatg	taaagcctgc	gtgggctaga	tagggtttct	gacctgacc	21840
25	tggccactga	gtgtgatgtt	gggctacgtg	gttctctttt	ggtacggtct	tctttgtaaa	21900
	atagggaccg	gaactctgct	gagattccaa	ggattggggg	accccggtgt	gactggtgag	21960
	agagaggaga	acaggggagg	ggttagggga	gagattgtgg	tgggcaaccg	cctagaagaa	22020
	gctgtttgtt	ggctcccagc	ctcgccgcct	cagaggtttg	gcttccccca	ctccttcctc	22080
	tcaaactctgc	cttcaaactc	atatctggga	tagggaaggc	cagggtccga	gagatggtgg	22140
30	aaggggccaga	aatcacactc	ctggcccccc	gaagagcagt	gtcccgcgcc	caactgcctt	22200
	gtcatattgt	aaagggattt	tctacacaac	agtttaagg	cggtggagga	aactgggctt	22260
	gccagtcacc	tcccatecct	gtcccttgcc	aggacaccac	ctcctgcctg	ccacccacgg	22320
	acacattttct	gtctagaaac	agagcgtcgt	cgtgctgtcc	tctgagacag	catatcttac	22380
	attaaaaaga	ataatacggg	gggggggggc	ggagggcgca	agtgttatac	atatgctgag	22440
35	aagctgtcag	gcgccacagc	accaccacac	atctttttgt	aaatcatttc	cagacacctc	22500
	ttactttctg	tgtagatttt	aattgttaaa	aggggaggag	agagagcggt	tgtaacagaa	22560
	gcacatggag	gggggggtag	gggggttggg	gctgggtgag	ttggcgaaact	ttccatgtga	22620
	gactcatcca	caaagactga	aagccgcgct	ttttttttta	agagttcagt	gacatattta	22680
	ttttctcatt	taagttattt	atgccacatt	ttttttcttg	tagagaaagg	cagtgttaat	22740
40	atcgctttgt	gaagcacaag	tgtgtgtggt	tttttgtttt	ttgttttttc	cccagaccaga	22800
	ggcattgtta	ataaagacaa	tgaatctcga	gcaggaggct	gtggtcttgt	tttgtcaacc	22860
	acacacaatg	tctcgccact	gtcatctcac	tcccttcctt	tggtcacaag	acccaaacct	22920
	tgacaacacc	tccgactgct	ctctggtagc	ccttggtggc	atacgtgttt	cctttgaaaa	22980
	gtcacattca	tcctttcctt	tgcaaacctg	gctctcattc	cccagctggg	tcacgtcat	23040
45	accctcacc	cagcctccct	ttagctgacc	actctccaca	ctgtcttcca	aaagtgcacg	23100
	tttcaccgag	ccagttccct	ggtccaggtc	atcccattgc	tcctccttgc	tccagaccct	23160
	tctcccacaa	agatgttcat	ctccactcc	atcaagcccc	agtggccctg	cggctatccc	23220
	tgtctcttca	gttagctgaa	tctacttgct	gacaccacat	gaattccttc	ccctgtctta	23280
	aggttcattg	aactcttgcc	tgcccctgaa	ccttcacagga	ctgtcccagc	gtctgatgtg	23340
50	tcctctctct	tgtaaagccc	cacccacta	tttgattccc	aattctagat	cttccttctg	23400
	tcattccttc	acgggatagt	gtctcatctg	gccaaagcct	gcttgatatt	gggataaatg	23460
	cåaagccaag	tacaattgag	gaccagttca	tcattggggc	aagctttttc	aaaatgtgaa	23520
	ttttacacct	atagaagtgt	aaaagccttc	caaagcagag	gcaatgcctg	gctcttcctt	23580
	caacatcagg	gctcctgctt	tatgggtctg	gtggggtagt	acattcataa	acccaacact	23640
55	aggggtgtga	aagcaagatg	attgggagtt	cgaggccaat	cttggtctatg	aggccctgtc	23700

	tcaacctctc	ctccctccct	ccagggtttt	gttttgtttt	gtttttttga	tttgaaactg	23760
	caacacttta	aatccagtc	agtgcattct	tgcgtgaggg	gaactctatc	cctaataata	23820
	gcttccatct	tgatttgtgt	atgtgcacac	tgggggttga	acctgggect	ttgtacctgc	23880
	cgggcaagct	ctctactgct	ctaaaccag	ccctcactgg	ctttctgttt	caactcccaa	23940
5	tgaattcccc	taaatgaatt	atcaatatca	tgtctttgaa	aaataccatt	gagtgctgct	24000
	gggtgtccctg	tggttccaga	ttccaggaag	gacttttccag	ggaatccagg	catcctgaag	24060
	aatgtcttag	agcaggaggc	catggagacc	ttggccagcc	ccacaaggca	gtgtggtgca	24120
	gaggggtgagg	atggaggcag	gcttgcaatt	gaagctgaga	cagggctactc	aggattaaaa	24180
	agcttccccc	aaaacaattc	caagatcagt	tcctgggtact	tgcacctgtt	cagctatgca	24240
10	gagcccagtg	ggcataggtg	aagacaccgg	ttgtactgtc	atgtactaac	tgtgcttcag	24300
	agccggcaga	gacaaataat	gttatgggtga	ccccagggga	cagtgattcc	agaaggaaca	24360
	cagaagagag	tgctgctaga	ggctgcctga	aggagaaggg	gtcccagact	ctctaagcaa	24420
	agactccact	cacataaaga	cacaggctga	gcagagctgg	ccgtggatgc	agggagccca	24480
	tccaccatcc	tttagcatgc	ccttgatattc	ccatcacatg	ccagggatga	ggggcatcag	24540
15	agagtccaag	tgatgcccc	acccaaacac	acctaggact	tgctttctgg	gacagacaga	24600
	tgcaggagag	actaggttgg	gctgtgatcc	cattaccaca	aagagggaaa	aaacaaaaaa	24660
	caaacaaaaca	aacaaaaaaa	aacaaaacaa	aacaaaaaaa	aacccaaggt	ccaaattgta	24720
	ggtcagggtta	gagtttattt	atggaaagtt	atattctacc	tccatggggg	ctacaaggct	24780
	ggcgcccatc	agaaagaaca	aacaacaggc	tgatctggga	ggggtgggtac	tctatggcag	24840
20	ggagcacgtg	tgcttggggg	acagccagac	acggggcctg	tattaatcac	agggcctgta	24900
	ttaataggct	gagagtcaag	cagacagaga	gacagaagga	aacacacaca	cacacacaca	24960
	cacacacaca	cacacacaca	catgcacaca	ccactcactt	ctcactcgaa	gagcccttac	25020
	ttacattcta	agaacaaacc	attcctcctc	ataaaggaga	caaagttgca	gaaacccaaa	25080
	agagccacag	gggtccctact	ctctttgaaa	tgacttggac	ttgttgacag	gaagacagag	25140
25	gggtctgcag	aggtctcctg	ggtgaccag	agccacagac	actgaaatct	gggtgctgaga	25200
	cctgtataaa	ccctcttcca	caggttccct	gaaaggagcc	cacattcccc	aacctgtct	25260
	cctgaccact	gaggatgaga	gcacttgggc	cttccccatt	cttggagtgc	acctgtgctt	25320
	ccccatctga	gggcacatga	ggtctcaggt	cttgggaaag	ttccacaagt	attgaaagtg	25380
	ttcttgtttt	gttttgtgatt	taatttaggt	gtatgagtcg	ttttgcttga	atatatgcct	25440
30	gtgtagcatt	tacaagcctg	gtgcctgagg	agatcagaag	atggcatcag	atacctgga	25500
	actggacttg	cagacagtta	tgagccactg	tgtgggtgct	aggaacagaa	cctggatcct	25560
	cgggaagagc	agacagccag	cgctcttagc	cactaagcca	tcactgaggt	tctttctgtg	25620
	gctaaagaga	caggagacaa	aggagagttt	cttttagtca	ataggacat	gaatgttctt	25680
	cgtaacgtga	gactagggca	gggtgatccc	ccagtgcac	cgatggccct	gtgtagtatt	25740
35	tagcagctct	agtcttatte	cttaataagt	cccagtttgg	ggcaggagat	atgtattccc	25800
	tgctttgaag	tggctgaggt	ccagttatct	acttccaagt	acttgtttct	ctttctggag	25860
	ttgggggaagc	tccctgectg	cctgtaaaatg	tgtccattct	tcaaccttag	acaagatcac	25920
	tttccctgag	cagtcaggcc	agtcctaaagc	ccttcaattt	agctttcata	aggaacaccc	25980
	cttttgttgg	gtggagggtga	cacttgccct	gaatccagc	attaagaagg	cagagacagt	26040
40	cggatctctg	tgagttcaca	gccagcctgg	tctacggagt	gagttccaag	acagccaggc	26100
	ctacacagag	aaacctgtc	tcgaaaaaaa	caaaaacaaa	agaaataaag	aaaaagaaaa	26160
	caaaaacgaa	caaacagaaa	aacaagccag	agtgtttgtc	cccgtatttt	attaatcata	26220
	tttttgtccc	tttgccattt	tagactaaaa	gactcgggaa	agcaggtctc	tctctgtttc	26280
	tcacccggac	acaccagaaa	ccagatgtat	ggaagatggc	taatgtgctg	cagttgcaca	26340
45	tctggggctg	ggtggattgg	ttagatggca	tgggctgggt	gtgggttacga	tgactgcagg	26400
	agcaaggagt	atgtggtgca	tagcaaacga	ggaagtttgc	acagaacaac	actgtgtgta	26460
	ctgatgtgca	ggtatgggca	catgcaagca	gaagccaagg	gacagcctta	gggtagtgtt	26520
	tccacagacc	cctccccctt	tttaacatgg	gcactctctca	ttggcctgga	gcttgccaac	26580
	tgggctgggc	tggctagctt	gtaggtccca	gggatctgca	tatctctgcc	tccctagtgc	26640
50	tgggattaca	gtcatatatg	agcacacctg	gcttttttat	gtgggttctg	ggctttgaac	26700
	ccagatctga	gtgcttgcaa	ggcaatcggg	tgaatgactg	cttcatctcc	ccagaccctg	26760
	ggattctact	ttctattaaa	gtatttctat	taaatcaatg	agcccctgcc	cctgcactca	26820
	gcagttctta	ggcctgctga	gagtcagggt	gggagtgaga	gcaagcctcg	agaccccatc	26880
	agcgaagcag	aggacaaaga	aatgaaaact	tgggattcga	ggctcgggat	atggagatac	26940
55	agaaaggggc	aggggaaggaa	atgaaccaga	tgaatagagg	cagggaagggg	agggccctgc	27000

	atacatggaa	cctggtgtac	atgttatctg	catgggggttt	gcattgcaat	ggctcttcag	27060
	caggttcacc	acactgggaa	acagaagcca	aaaagaagag	taggtggtgt	tggagtcaga	27120
	tactgtcagt	catgcctgaa	gaaatggaag	caattaacga	tgcgccgcaa	ttaggatatt	27180
	agctccctga	agaaaggcaa	gaagctgggc	tgtgggcact	gaagggagct	ttgaatgatg	27240
5	tcacattctc	tgtatgccta	gcagggcagt	attgggagact	gagacttgac	ttgtgtgtcc	27300
	atatgattcc	tccttttcc	acagtcactc	ggggctcctg	agcttcctgc	ttgtccaaga	27360
	acctggagct	ggcagtgagg	agctgcagtg	atagatgtct	gcaagaaaga	tctgaaaaga	27420
	gggaggaaga	tgaaggaccc	agaggaccac	cgacctctgc	tgcctgacaa	agctgcagga	27480
	ccagtctctc	ctacagatgg	gagacagagg	cgagagatga	atgggtcaggg	gaggagttag	27540
10	agaaaggaga	gggtgaggca	gagaccaaag	gagggaaaca	cttgtgtctc	acagctactg	27600
	actgagtacc	agctgctgtg	cagacagcca	atgccaaagg	tgcgctgac	atggcacctc	27660
	gtgggactcc	tagcccagtg	ctggcagagg	ggagtgtctga	atgggtgcatg	gtttggatat	27720
	gatctgaatg	tgggtccagcc	ctagtttcc	tccagttgct	gggataaagc	accctgacca	27780
	aaagctactt	tttgtttgtt	tgttttgggt	tggttttgtt	tggtttttgc	aggcagggtt	27840
15	tctctgtatc	accctagctg	tccctggaact	cactctgtag	accaggctgg	cctcgaaactc	27900
	agaaatcccc	ctgcctctgc	ctcctaagtg	ctggaattaa	aggcctgcgc	caccactgcc	27960
	ggcccaaagc	tactttaaga	gagagagagg	aatgtataag	tattataatt	ccaggttata	28020
	gttcattgct	gtagaattgg	agtcttcata	ttccaggtaa	tctcccacag	acatgccaca	28080
	aaacaacctg	ttctacgaaa	tctctcatgg	actcccttcc	ccagtaattc	taaactgtgt	28140
20	caaatctaca	agaaatagtg	acagtcacag	tctctaactg	tttgggcatg	agtctgaagt	28200
	ctcattgcta	agtactggga	agatgaaaac	ttacctaagt	gtcagcattt	ggagcagagc	28260
	ctttgggatt	tgagatgggc	ttttgcagag	ctcctaattg	ctacatggag	agagggggcc	28320
	tgggagagac	ccatacacct	tttgctgcct	tatgtcacct	gacctgctcc	ttgggaagct	28380
	ctagcaagaa	ggccttccct	ggatcaccca	ccaccttgca	cctccagaac	tcagagccaa	28440
25	attaaacttt	cttgttactg	tcgtcaaagc	acagtcggtc	tgggttgtat	cactgtcaat	28500
	gggaaacaga	cttgccctgga	tggataactt	gtacattgca	taattgtctag	aaatgaaaag	28560
	tcctatagag	aaaaagaaaa	ttagctggca	cacagataga	ggccctggag	gaggctggct	28620
	ttgtcctccc	cgaggagggtg	gagagtaagg	tgtaaatgtt	catggatgta	aatgggcccc	28680
	tatatgaggg	tctggggtaa	caagaaggcc	tgtgaatata	aagcactgaa	ggtatgtcta	28740
30	gtctggagaa	ggtcactaca	gagagttctc	caactcagtg	cccatacaca	cacacacaca	28800
	cacacacaca	cacacacaca	cacacacaca	ccacaaagaa	aaaaaggaag	aaaaatctga	28860
	gagcaagtac	agtacttaaa	attgtgtgat	tgtgtgtgtg	actctgatgt	cacatgetca	28920
	tcttgcccta	tgagttgaaa	accaaattggc	ccctgagagg	cataacaacc	acactgttgg	28980
	ctgtgtgctc	acgtttttct	taaagcgtct	gtctgggttg	ctgctagcat	caggcagact	29040
35	tgcagcagac	tacatatgct	cagccctgaa	gtccttctag	ggtgcatgtc	tcttcagaat	29100
	ttcagaaagt	catctgtggc	tccaggaccg	cctgcactct	ccctctgcgc	cgaggctgca	29160
	gactctaggg	tgggggtggaa	gcaacgctta	cctctgggac	aagtataaca	tgttggcttt	29220
	tctttccctc	tgtggctcca	acctggacat	aaaatagatg	caagctgtgt	aataaatatt	29280
	tcctcccgct	cacttagttc	tcaacaataa	ctactctgag	agcacttatt	aatagggtggc	29340
40	ttagacataa	gctttggctc	attccccac	tagctcttac	ttctttaact	ctttcaaacc	29400
	attctgtgtc	ttccacatgg	ttagttacct	ctccttccat	cctggttcgc	ttcttccctc	29460
	gagtcgccct	cagtgtctct	aggtgatgct	tgtaaagatat	tctttctaca	aagctgagag	29520
	tgggtggcact	ctgggagttc	aaagccagcc	tgatctacac	agcaagctcc	aggatatcca	29580
	gggcaatgtt	gggaaaacct	ttctcaaaca	aaaagagggg	ttcagttgtc	aggaggagac	29640
45	ccatgggtta	agaagtctag	acgagccatg	gtgatgcata	cctttcatcc	aagcacttag	29700
	gaggcaaaga	aagggtgaaac	tctttgactt	tgaggccagc	taggtttacat	agtgatcccc	29760
	tgcttagtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgttaatt	taaaagtcta	29820
	aaaatgcatt	cttttaaaaa	tatgtataag	tatttgccctg	cacatatgta	tgtatgtatg	29880
	tataccatgt	gtgtgtctgg	tgtgaaagga	ctaggcatag	actccctaga	actagagtca	29940
50	tagacagttg	tgacactccc	caacccccca	ccatgtgggt	gcttgaagct	aaactcctgt	30000
	cctttgtaaa	gcagcagggtg	tctatgaacc	ctgaaccatc	tctccagctc	ccagatgtgc	30060
	attctcaaag	aggagtccct	catatttccc	taaactgaac	atccttatca	gtgagcatcc	30120
	tcaggtcacc	aaagctactg	caaaccctct	tagggaacat	tcactattca	cttctacttg	30180
	gctcatgaaa	cttaagtaca	cacacacaaa	cacacacaca	cacacagagt	catgcactca	30240
55	caaaagcatg	catgtacacc	attcttatta	gactatgctt	tgctaaaaaga	ctttcctaga	30300

	tacttttaaaa	catcacttct	gccttttggg	gggcagggtc	caagattggg	actggcgtag	30360
	tggaaactga	acaaggtaga	gatctagaaa	tcacagcagg	tcagaagggc	cagcctgtac	30420
	aagagagagt	tccacacctt	ccaggaacac	tgagcagggg	gctggggacct	tgccctctcag	30480
5	cccaagaaac	tagtgcggtt	cctgtatgca	tgccctctcag	agattccata	agatctgcct	30540
	tctgccataa	gatctcctgc	atccagacaa	gcctaggggg	agttgagagg	ctgcctgagt	30600
	ctctcccaca	ggccccctct	tgccctggcag	tattttttta	tctggaggag	aggaatcagg	30660
	gtgggaatga	tcaaatacaa	ttatcaagga	aaaagtaaaa	aacatatata	tatatatatt	30720
	aactgatcta	gggagctggc	tcagcagtta	agagtcttgg	ctgcccttgc	ttcagatctt	30780
	gctttgatcc	ccagcaccca	catgatggct	ttcaactgta	tctctgcttc	caggggatcc	30840
10	aacagcctct	tctgacctcc	atagacaaga	cctagtcctc	tgcaagagca	ccaaatgctc	30900
	ttatctgttg	atccatctct	ctagcctcat	gccagatcat	ttaaaactac	tggaactgtg	30960
	cccattttac	gaagatgtca	ctgcccagtc	atttgccatg	agtggatatt	tcgattcttt	31020
	ctatgtttct	acccttgcaa	tttataagaa	agatatctgc	atttgtctcc	tgagagaaca	31080
	aaggggtggg	ggctactgag	atggctctag	gggtaaagggt	gettggccaca	aaatctgaca	31140
15	acttaagttt	ggtcttggaa	tcacatgggt	ggagagagag	aagagattcc	cgtaagttgt	31200
	cctcaaactt	ccacacacatg	tgtctgtggc	tatgtgtaac	cccaataagt	aaagatagtt	31260
	ttaaacacta	cataaggtag	ggtttcttca	tgaccccaag	gaatgatgcc	cctgatagag	31320
	cttatgctga	aaccccatct	ccattgtgcc	atctggaaag	agacaattgc	atcccggaaa	31380
	cagaatcttc	atgaatggat	taatgagcta	ttaaagaaag	ggcttggtta	ttgcacatgc	31440
20	tggcggcgta	atgacctcca	ccatgatgtt	atccagcatg	aaggctcctca	ccagaagtca	31500
	tacaaatctt	cttaggcttc	cagagtcgtg	agcaaaaaaa	gcacacctct	aaataaatta	31560
	actagcctca	ggtagttaac	caccgaaaat	gaaccaaggc	agttctaata	caaaaccact	31620
	tccttccct	gttcaaacca	cagtgcccta	ttatctaaaa	gataaacttc	aagccaagct	31680
	tttaggttgc	cagtatttat	gtaacaacaa	ggcccgttga	cacacatctg	taactcctag	31740
25	tactgggcct	caggggcaga	gacaggtgga	gccctggagt	ttgaattcca	ggttctgtga	31800
	gaaactctgt	ctgaaaagac	aatatggtga	gtgaccgggg	aggatatctg	atattgactt	31860
	ctggccaaca	cacagccatc	tctgcacatc	tgtagttgca	agccttttgc	actaagtttg	31920
	gccagagtca	gagtttgcaa	gtgtttgtgg	actgaatgca	cgtgttgctg	gtgatctaca	31980
	aagtcaccct	ccttctcaag	ctagcagcac	tggtctcggc	cagctgctca	ttcaagcctc	32040
30	tttgacagag	catcacgggg	atgggggagc	agggcccttc	cctagaacac	caagcctgtg	32100
	gttggttatt	caggacatta	ttgagggcca	agatgacaga	taactctatc	acttggccaa	32160
	cagtcgggtg	ttgcggtgtt	aggttatttc	tgtgtctgca	gaaaacagtg	caacctggac	32220
	aaaagaaata	aatgatataca	tttttcattc	aggcaactag	attccgtggg	acaaaaggct	32280
	ccttggggaa	cgaggccggg	acagcgcggc	tcctgagtcg	ctatttccgt	ctgtcaactt	32340
35	ctctaattct	ttgatctcct	ccctctgtct	gtttccttcc	tcttgctggg	gccagtgga	32400
	gtctgtgtac	tcacagggag	gaggggtggc	aagccctggg	cctctacggg	ctgggggaag	32460
	gggggaagct	gtcggcccag	tgacttttcc	ccctttctct	ttttcttaga	aaccagtctc	32520
	aatttaagat	aatgagtctc	ctcattcacg	tgtgtcact	attcataggg	acttatccac	32580
	ccccgccctg	tcaatctggc	taagtaagac	aagtcaaat	taaaagggaa	cgtttttcta	32640
40	aaaatgtggc	tggaccgtgt	gcgggcacga	aaccagggat	ggcggctcaa	gttacatgct	32700
	ctctgccagc	cccgggtgct	tttcctttcg	gaaaggagac	ccggaggtaa	aacgaagttg	32760
	ccaacttttg	atgatggtgt	gcgcgggtg	actctttaa	atgtcatcca	tacctgggat	32820
	aggggaaggct	cttcaggag	tcattctagcc	ctcccttcag	gaaaagattc	cacttccggg	32880
	ttagttagct	tcacctggg	cccttatccg	ctgtctctgc	ccactagtc	tcattccatcc	32940
45	ggtttccgcc	ctcatccacc	ttgccctttt	agttcctaga	aagcagcacc	gtagtcttgg	33000
	caggtggggc	attggtcact	ccgtaccac	tgttaccatg	gccaccaagg	tgtcatttaa	33060
	atatgagctc	actgagtcct	gcgggatggc	ttggttggtg	atatgcttgc	tgcaaaatcg	33120
	tgagaactgg	agttcaattc	ccagcacatg	gatgtatttc	cagcacctgg	aaggcagggg	33180
	gcagagatct	taaagctcct	ggccagacag	ccagccctaa	ttagtaatca	gtgagagacc	33240
50	ctgtctcaag	aaacaagatg	gaacatcaaa	ggtcaacctc	ttgtctccac	acacacaaat	33300
	acacacatgc	acatacatcc	acacacaggg	aaacacatgc	acacacctga	acacctcca	33360
	caaatacata	cataaaaaaa	taaatacata	cacacatata	tacatacacc	aactatccct	33420
	ctccttagtc	tcctggctac	gctcttgtca	ccccactaa	ggcttcaact	tcttctatct	33480
	cttcatcttg	actcctctgt	actttgcatg	ccttttccag	caaaggcttt	cttttaaatc	33540
55	tccgtcattc	ataaactccc	tctaaatttc	ttccctgccc	cttttctttc	tctctaggga	33600

	gataaagaca	cacactacaa	agtcaccgtg	ggaccagttt	attcaccac	ccaccctgc	33660
	ttctgttcat	ccggccagct	aagtagtcca	acctctctgg	tgtgtaccc	tggaccctgg	33720
	cttcaccaca	gtcctccat	gtacccagc	cctgcaaacc	ttcagcctag	cctctggttc	33780
	tccaaccagc	acaggcccag	tctggcttct	atgtcctaga	aatctccttc	attctctcca	33840
5	tttccctcct	gaatctacca	ccttctttct	cccttctcct	gacctctaat	gtcttggtca	33900
	aacgattaca	aggaagccaa	tgaaattagc	agtttgggg	acctcagagt	cagcagggga	33960
	gctgggatga	attcacattt	ccaggccttt	gctttgctcc	ccggattctg	acaggcagtt	34020
	ccgaagctga	gtccaggaag	ctgaatttaa	aatcacactc	cagctgggtt	ctgaggcagc	34080
	cctaccacat	cagctggccc	tgactgagct	gtgtctgggt	ggcagtggtg	ctggtggtgc	34140
10	tggtggtgct	ggtggtggtg	gtggtggtgg	tggtggtggt	ggtggtggtg	tgtgtgtgtg	34200
	ttttctgctt	ttacaaaact	tttctaattc	ttatacaaa	gacaaatctg	cctcatatag	34260
	gcagaaagat	gacttatgcc	tatataagat	ataaagatga	ctttatgcca	cttattagca	34320
	atagttactg	tcaaaagtaa	ttctatttat	acacccttat	acatggtatt	gcttttgttg	34380
	gagactctaa	aatccagatt	atgtatttaa	aaaaaaattc	cccagt.cctt	aaaaggtgaa	34440
15	gaatggaccc	agatagaagg	tcacggcaca	agtatggagt	cggagtgtgg	agtcctgcca	34500
	atggtctgga	cagaagcatc	cagagagggt	ccaagacaaa	tgcctcgctt	cctaagggaac	34560
	aetggcagcc	ctgatgaggt	accagagatt	gctaagtggg	ggaatacagg	atcagaccca	34620
	tggaggggct	taaagcgtga	ctgtagcagc	cctccgctga	ggggctccag	gtgggcccgc	34680
	aaggtgctgc	agtgggagcc	acatgagagg	tgatgtcttg	gagtcacctc	gggtaccatt	34740
20	gtttaggagg	gtggggattt	gtggtgtgga	gacaggcagc	ctcaaggatg	cttttcaaca	34800
	atggttgatg	agttggaact	aaaacagggg	ccatcacact	ggctcccata	gctctgggct	34860
	tgccagcttc	cacatctgcc	ccccaccccc	tgtctggcac	cagctcaagc	tctgtgattc	34920
	tacacatcca	aaagaggaag	agtagcctac	tgggcacgcc	acctcttctg	gacctcagg	34980
	tgagagtgtg	gcaagcccta	ggctcctgtc	caggatgcag	ggctgccaga	taggatgctc	35040
25	agctatctcc	tgagctggaa	ctatttttag	aataaggatt	atgcccgccc	ggggttggcc	35100
	agcaccacag	cagcctgtgc	ttgcgtaaaa	gcaagtgtct	ttgatttatc	taaaaacaga	35160
	gccgtggacc	caccacaggg	acaagtatgt	atgcacatct	ttcatgtatc	tgaaaagcga	35220
	cacaaccatt	tttcacatca	tggcatcttc	ctaaccceca	ttcttttttg	ttttgttttt	35280
	ttgagacagg	gtttctctgt	gtagtcctgg	ctgtcctgga	actcactttg	tagaccaggc	35340
30	tggcctcgaa	ctcagaaatc	ctgggattaa	aggtgtgtgc	caccacgccc	ggccctaacc	35400
	cccattctta	atggtgatcc	agtggttgaa	atttcgggcc	acacacatgt	ccattaggga	35460
	ttagctgctg	tcttctgagc	tacctggtac	aatctttatc	ccctggggcc	tgggtcctg	35520
	atccctgact	cgggcccgat	caagtccagt	tcctggggcc	gatcaagtc	agttcctggg	35580
	ccggaacaag	tccagtcctt	agctcgatta	gctcatcctg	gctccctggc	ctgttcttac	35640
35	ttacactctt	ccccctgtct	tggacttggt	gctttcttta	ctcaagttgt	ctgccacagt	35700
	ccctaagcca	cctctgtgta	acaactaaga	taatacttcc	ctcaagcacg	gaaagtcctg	35760
	agtcaccaca	ccctctggag	gtgtgtggac	acatgttcat	gcgtgtgggt	gcgcttacgt	35820
	acgtgtgc						35828
40	<210> 18						
	<211> 9301						
	<212> DNA						
	<213> Homo sapien						
45	<400> 18						
	tagaggagaa	gtcttttggg	agggtttgct	ctgagcacac	ccctttccct	ccctccgggg	60
	ctgagggaaa	catgggacca	gcctgcccc	agcctgtcct	cattggctgg	catgaagcag	120
	agaggggctt	taaaaaggcg	accgtgtctc	ggctggagac	cagagcctgt	gctactggaa	180
	ggtggcgctg	cctcctctgg	ctggtaccat	gcagctccca	ctggccctgt	gtctcgtctg	240
50	cctgctggta	cacacagcct	tccgtgtagt	ggagggccag	gggtggcagg	cgttcaagaa	300
	tgatgccacg	gaaatcatcc	ccgagctcgg	agagtacccc	gagcctccac	cggagctgga	360
	gaacaacaag	accatgaacc	gggaggagaa	cggagggcgg	cctccccacc	accccttga	420
	gaccaaagg	atgggggtgga	ggagagaatt	cttagtaaaa	gatcctgggg	aggttttaga	480
	aacttctctt	tgggaggctt	ggaagactgg	ggtagaccca	gtgaagattg	ctggcctctg	540
55	ccagcactgg	tcgaggaaca	gtcttgctg	gaggtggggg	aagaatggct	cgctggtgca	600

	gccttcaa	at	tcaggtgcag	aggcatgagg	caacagacgc	tggtagagagc	ccagggcagg	660
	gaggacgctg	gggtgggtgag	ggtatggcat	cagggcatca	gaacaggctc	aggggctcag		720
	aaaagaaaag	gtttcaaaga	atctcctcct	gggaatatag	gagccacgtc	cagctgctgg		780
	taccactggg	aagggaacaa	ggtaagggag	cctcccatcc	acagaacagc	acctgtgggg		840
5	caccggacac	tctatgctgg	tgggtggctgt	ccccaccaca	cagaccaca	tcatggaatc		900
	cccaggaggt	gaacccccag	ctcgaagggg	aagaaacagg	ttccaggcac	tcagtaactt		960
	ggtagtgaga	agagctgagg	tgtgaacctg	gtttgatcca	actgcaagat	agccctgggtg		1020
	tgtggggggg	tgtggggggac	agatctccac	aaagcagtg	ggaggaaggc	cagagaggga		1080
	cccctgcagt	gtgcattgcc	catggcctgc	ccaggggagct	ggcacttgaa	ggaatgggag		1140
10	ttttcggcac	agtttttagcc	cctgacatgg	gtgcagctga	gtccaggccc	tggaggggag		1200
	agcagcatcc	tctgtgcagg	agtagggaca	tctgtcctca	gcagccaccc	cagtcccaac		1260
	cttgccctcat	tccagggggag	ggagaaggaa	gaggaacctt	gggttcctgg	tcaggcctgc		1320
	acagagaagc	ccaggtgaca	gtgtgcatct	ggctctataa	ttggcaggaa	tcctgaggcc		1380
	atggggggcgt	ctgaaatgac	acttcagact	aagagcttcc	ctgtcctctg	gccattatcc		1440
15	aggtggcaga	gaagtccact	gcccaggctc	ctggaccca	gcccctccc	cctcacaacc		1500
	tgttgggact	atgggggtgct	aaaaagggca	actgcatggg	aggccagcca	ggacctccg		1560
	tcttcaaaat	ggaggacaag	ggcgccctcc	cccacagctc	cccttctagg	caaggtcagc		1620
	tgggctccag	cgactgcctg	aagggtctga	aggaacccaa	acacaaaatg	tccaccttgc		1680
	tggactccca	cgagaggcca	cagccctga	ggaagccaca	tgtcaaaat	aaagtcatga		1740
20	tctgcagagg	aagtgcctgg	cctagggg	ctattctcga	aaagccgcaa	aatgccccct		1800
	tccctgggca	aatgcccccc	tgaccaacaca	cacattccag	ccctgcagag	gtgaggatgc		1860
	aaaccagccc	acagaccaga	aagcagcccc	agacgatggc	agtggccaca	tctccccctgc		1920
	tgtgcttgct	cttcagagtg	gggggtggggg	gtggccttct	ctgtccccctc	tctgggtttgg		1980
	tcttaagact	atcttttcatt	ctttcttctg	acattggaac	tatccccatg	aaaccttttg		2040
25	gggtggactg	gtactcacac	gacgaccagc	tatttaaaaa	gtccccaccc	atctaagtcc		2100
	accataggag	acatgggtcaa	ggtgtgtgca	ggggatcagg	ccaggcctcg	gagcccaatc		2160
	tctgcctgcc	cagggagtat	caccatgagg	cgcccatcca	gataaacacag	aacaagaaat		2220
	gtgcccagca	gagagccagg	tcaatgtttg	tggcagctga	acctgtagyt	tttgggtcag		2280
	agctcagggc	ccctatggta	ggaaagtaac	gacagtaaaa	agcagccctc	agctccatcc		2340
30	cccagcccag	cctcccatgg	atgctcgaac	gcagagcctc	cactcttgcc	ggagccaaaa		2400
	ggtgctggga	ccccagggaa	gtggagtccg	gagatgcagc	ccagcctttt	gggcaagttc		2460
	ttttctctgg	ctgggcctca	gtattctcat	tgataatgag	ggggttgag	acactgcctt		2520
	tgattccttt	caagtctaat	gaattcctgt	cctgatcacc	tccccctcag	tccctgcctt		2580
	ccacagcagc	tgccttgatt	tattaccttc	aattaacctc	tactcctttc	tccatccccct		2640
35	gtccacccct	cccaagtggc	tggaaaagga	atttgggaga	agccagagcc	aggcagaagg		2700
	tgtgctgagt	acttacccctg	cccaggccag	ggacctgctg	gcacaagtgt	ggcttaaate		2760
	ataagaagac	cccagaagag	aaatgataat	aataatacat	aacagccgac	gctttcagct		2820
	atatgtgcca	aatgggtat	tctgcattgc	gtgtgtaatg	gattaactcg	caatgcttgg		2880
	ggcgcccat	tttgacagaca	ggaagaagag	agaggttaag	gaacttgccc	aagatgacac		2940
40	ctgcagttag	cgatggagcc	ctgggtgttg	aacccagca	gtcatttggc	tccgagggga		3000
	caggggtgcg	aggagagctt	tccaccagct	ctagagcatc	tgggaccttc	ctgcaataga		3060
	tgttcagggg	caaaagcctc	tggagacagg	cttggaacaa	gcagggctgg	ggtggagaga		3120
	gacggggccg	tccagggcag	gggtggccag	gcggggcgcc	acctcacgc	gcgcctctct		3180
	ccacagacgt	gtccgagtac	agctgcgcg	agctgcactt	caccgcctac	gtgaccgatg		3240
45	ggcctgtccg	cagcgccaag	ccggtcacgc	agctgggtgtg	ctccggccag	tgcggcccg		3300
	cgcgcctgct	gcccacgcgc	atcggccgcg	gcaagtgggtg	gcgacctagt	gggcccagct		3360
	tccgctgcat	ccccgaccgc	taccgcgcgc	agcgcgtgca	gctgctgtgt	cccgggtgtg		3420
	aggcgccgcg	cgcgcgcaag	gtgcgcctgg	tggcctcggtg	caagtgcagg	cgccctaccc		3480
	gcttccacaa	ccagtcggag	ctcaaggact	tgggaccga	ggcgcctcgg	ccgcagaagg		3540
50	gcccgaagcc	gcggccccgc	gcccggagcg	ccaaagccaa	ccaggccgag	ctggagaacg		3600
	cctactagag	cccgcgcgcg	cccctcccca	ccggcggggcg	ccccggccct	gaacccgcgc		3660
	cccacatttc	tgtcctctgc	gcgtgggttg	attgtttata	tttcattgta	aatgcctgca		3720
	accaggggca	gggggctgag	accttccagg	ccctgaggaa	tccggggcgc	cggaaggcc		3780
	cccctcagcc	cgccagctga	gggttcccac	ggggcagggg	aggaattga	gagtcacaga		3840
55	cactgagcca	cgcagccccg	cctctggggc	cgcctacctt	tgtgtgtccc	acttcagagg		3900

	aggcagaaat	ggaagcattt	tcaccgccct	ggggttttta	gggagcgggtg	tgggagtggtg	3960
	aaagtccagg	gactgggtta	gaaagttgga	taagattccc	ccttgccact	cgctgcccac	4020
	cagaaagcct	gaggcgtgcc	cagagcacaa	gactgggggc	aactgtagat	gtgggtttcta	4080
	gtcctggctc	tgccactaac	ttgctgtgta	accttgaact	acacaattct	ccttcgggac	4140
5	ctcaatttcc	actttgtaaa	atgaggggtg	aggtgggaat	aggatctcga	ggagactatt	4200
	ggcatatgat	tccaaggact	ccagtgcctt	ttgaatgggc	agaggtgaga	gagagagaga	4260
	gaaagagaga	gaatgaatgc	agttgcattg	attcagtgcc	aaggtcactt	ccagaattca	4320
	gagttgtgat	gctctcttct	gacagccaaa	gatgaaaaac	aaacagaaaa	aaaaaagtaa	4380
	agagtctatt	tatggctgac	atatttacgg	ctgacaaact	cctggaagaa	gctatgctgc	4440
10	ttcccagcct	ggcttccccg	gatgtttggc	tacctccacc	cctccatctc	aaagaaataa	4500
	catcatccat	tggggtagaa	aaggagaggg	tccgaggggtg	gtgggagggg	tagaaatcac	4560
	atccgcccc	acttcccaaa	gagcagcatc	cctccccga	cccatagcca	tgttttaag	4620
	tcaccttccg	aagagaagtg	aaaggttcaa	ggacactggc	cttgaggcc	cgaggggagca	4680
	gccatcacaa	actcacagac	cagcacatcc	cttttgagac	accgccttct	gcccaccact	4740
15	cacggacaca	tttctgccta	gaaaacagct	tcttactgct	cttacatgtg	atggcatatc	4800
	ttacactaaa	agaatattat	tgggggaaaa	actacaagtg	ctgtacatat	gctgagaaac	4860
	tgcagagcat	aatagctgcc	acccaaaaat	ctttttgaaa	atcatttcca	gacaacctct	4920
	tactttctgt	gtagttttta	attgttaaaa	aaaaaaagtt	ttaaacagaa	gcacatgaca	4980
	tatgaaagcc	tgcaggactg	gtcgtttttt	tggcaattct	tccacgtggg	acttgtccac	5040
20	aagaatgaaa	gtagtgggtt	ttaaagagtt	aagttacata	tttattttct	cacttaagtt	5100
	atztatgcaa	aagtttttct	tgtagagaat	gacaatgtta	atattgcttt	atgaattaac	5160
	agtctgttct	tccagagtcc	agagacattg	ttaataaaga	caatgaatca	tgaccgaaag	5220
	gatgtggtct	cattttgtca	accacacatg	acgtcatttc	tgtcaaagtt	gacacccttc	5280
	tcttggtcac	tagagctcca	accttgga	cacctttgac	tgctctctgg	tggcccttgt	5340
25	ggcaattatg	tcttcccttg	aaaagtcag	tttatccctt	cctttccaaa	cccagaccgc	5400
	atcttctcac	ccagggcatg	gtaataacct	cagccttgta	tctcttagc	agcctccctt	5460
	ccatgctggc	ttccaaaatg	ctgttctcat	tgtatcactc	ccctgctcaa	aagccttcca	5520
	tagctcccc	ttgcccagga	tcaagtgcag	tttccctatc	tgacatggga	ggccttctct	5580
	gcttgactcc	cacctcccac	tccaccaagc	ttcctactga	ctccaaatgg	tcatgcagat	5640
30	ccctgcttcc	ttagtttgcc	atccacactt	agcaccacca	ataactaatc	ctctttcttt	5700
	aggattcaca	ttacttgtca	tctcttcccc	taaccttcca	gagatgttcc	aatctcccat	5760
	gatccctctc	tccctctagg	ttccagcccc	ttttgtctac	accactactt	tgggttccaa	5820
	ttctgttttc	catttgacag	tcattcatgg	aggaccagcc	tggccaagtc	ctgcttagta	5880
	ctggcataga	caacacaaa	ccaagtacaa	ttcaggacca	gctcacagga	aacttcatct	5940
35	tcttcgaagt	gtggatttga	tgccctctgg	gtagaaatgt	aggatcttca	aaagtgggcc	6000
	agcctcctgc	acttctctca	aagtctcgcc	tccccagggt	gtcttaatag	tgtggtatgc	6060
	tagctgagtt	agcatcttca	gatgaagagt	aaccctaaag	ttactcttca	gttgccctaa	6120
	ggtgggatgg	tcaactggaa	agctttaaat	taagtccagc	ctaccttggg	ggaaccacc	6180
	cccacaaaga	aagctgaggt	ccctcctgat	gacttgtcag	tttaactacc	aataaccac	6240
40	ttgaattaat	catcatcatc	aagtctttga	taggtgtgag	tgggtatcag	tggccgggtcc	6300
	cttccctggg	ctccagcccc	cgaggaggcc	tcagttagcc	cctgcagaaa	atccatgcat	6360
	catgagtgtc	tcagggccca	gaatatgaga	gcaggtagga	aacagagaca	tcttccatcc	6420
	ctgagaggca	gtgcgggtcca	gtgggtgggg	acacgggctc	tgggtcaggt	ttgtgttgtt	6480
	tgtttgtttg	ttttgagaca	gagtctcgct	ctattgcccc	ggctggagtg	cagtgtcaca	6540
45	atctcggtct	actgcaactt	ctgccttccc	ggattcaagt	gattctcctg	cctcagcttc	6600
	cagagtagct	gggattacag	gtgcgtgcca	ccacgcctgg	ctaatttttg	tatttttgat	6660
	agagacgggg	tttcaccatg	ttggccaggc	tagtctcgaa	ctcttgacct	caagtgatct	6720
	gcctgcctcg	gcctcccaaa	gtgctgggat	tacaggcgtg	agccaccaca	cccagcccca	6780
	ggttggtgtt	tgaatctgag	gagactgaag	caccaagggg	ttaaagtgtt	tggccacagc	6840
50	catacttggg	ctcagttcct	tgccttcccc	ctcacttgag	ctgcttagaa	cctgggtgggc	6900
	acatgggcaa	taaccaggct	acactgtttt	gtaccaagtg	ttatgggaat	ccaagatagg	6960
	agtaatttgc	tctgtggagg	ggatgaggga	tagtggttag	ggaaagcttc	acaaagtggg	7020
	tgttgcttag	agattttcca	ggtggagaag	ggggcttcta	ggcagaaggc	atagcccaag	7080
	caaagactgc	aagtgcattg	ctgctcatgg	gtagaagaga	atccaccatt	cctcaacatg	7140
55	taccgagtcc	ttgccatgtg	caaggcaaca	tgggggtacc	aggaattcca	agcaatgtcc	7200

aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
 cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggtcggg ttagaggtta 7320
 tttatggaaa gttatatctt acctacatgg ggtctataag cctggcgcca atcagaaaag 7380
 gaacaaacaa cagacctagc tgggaggggc agcattttgt tgtagggggc ggggcacatg 7440
 5 tttctgggggt acagccagac tcagggcttg tattaatagt ctgagagtaa gacagacaga 7500
 gggatagaag gaaataggte cttttctctc tctctctctc tctctctctc actctctctc 7560
 tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
 gtacaaatca ggccacattt acacaaggag gtaagggaaa agaacgttgaggaggccaca 7680
 ggaccccaaa attccctgtt ttccttgaat caggcaggac ttacgcagct gggaggggtgg 7740
 10 agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaaagctg 7800
 gtgccatgtc ccacaccgc ccacctccca cctgctcctt gacacagccc tgtgctccac 7860
 aaccgggtc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat 7920
 cccacccca tttctggaac ctgccctctg tcttctccct tgtccaaggg caggcaaggg 7980
 ctcagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gatagtcagg 8040
 15 aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc cagggtgggc 8100
 tcgtttacac ctgtaggcca agcgtaatta ttaacagctc ccacttctac tctaaaaaat 8160
 gacccaatct gggcagtaaa ttatatggtg cccatgctat taagagctgc aacttgctgg 8220
 gcgtgggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
 gaggtcacga gttagagact ggccctggcca gcatggcaaa accccatctt tactaaaaat 8340
 20 acaaaaatta gcaaggcatg gtggcatgca cctgtaatcc cagggtactcg ggaggctgag 8400
 acaggagaat ggcttgaacc caggaggcag aggttgacgt gagccaagat tgtgccactg 8460
 cctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaaggat actgtcaatc 8520
 actgcaggaa gaaccaggt aatgaatgag yagaagagag gggctgagtc accatagtgg 8580
 cagcacccgac tctgcagga aaggcgagac actgggtcat ggggtactgae ggtgcccctg 8640
 25 aatgacgttc tgcttttagag accgaacctg agccctgaaa gtcgatgcct gttcatgggt 8700
 gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
 atgcccatt tccctacaat tgtctggggg gcctaagctt ctgcccacca agagggccag 8820
 agctggcagc gagcagctgc aggtaggaga gataggtag cataagggag gtgggaaaga 8880
 gagatggaag gagaggggtg cagagcacac acctccctg cctgacaact tctgagggc 8940
 30 tgggtcatgcc agcagattta aggcggaggg aggggagatg gggcgggaga ggaagtga 9000
 aaggagaggg tggggatgga gaggaagaga ggggtatcat tcattcattc cattgctact 9060
 gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt 9120
 ggagcctcat ggagctcaca gggagtgtct gcaaggagat ggataatgga cggataacaa 9180
 ataaacattt agtacaatgt ccgggaatgg aaagttctcg aaagaaaaat aaagctgggtg 9240
 35 agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggaggt ggcatttgag 9300
 c 9301

<210> 19

<211> 21

40 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

45

<400> 19

ccggagctgg agaacaacaa g

21

<210> 20

50 <211> 19

<212> DNA

<213> Artificial Sequence

<220>

55 <223> Primer for PCR

	<400> 20	
	gcactggccg gagcacacc	19
5	<210> 21	
	<211> 23	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Primer for PCR	
	<400> 21	
	aggccaaccg cgagaagatg acc	23
15	<210> 22	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Primer for PCR	
	<400> 22	
25	gaagtccagg gcgacgtagc a	21
	<210> 23	
	<211> 25	
	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<223> Primer for PCR	
35	<400> 23	
	aagcttggtta ccatgcagct cccac	25
	<210> 24	
	<211> 50	
40	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Primer for PCR	
45	<400> 24	
	aagcttctac ttgtcatcgt cgtccttgta gtcgtaggcg ttctccagct	50
	<210> 25	
50	<211> 19	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
55	<223> Primer for PCR	

<400> 25
 gcactggccg gagcacacc 19

5 <210> 26
 <211> 39
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Primer for PCR

<400> 26
 gtcgtcggat ccatgggggtg gcaggcggtc aagaatgat 39

15 <210> 27
 <211> 57
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Primer for PCR

<400> 27
 25 gtcgtcaagc ttctacttgt catcgctcctt gtagtcgtag gcgttctcca gtcggc 57

 <210> 28
 <211> 29
 <212> DNA
 30 <213> Artificial Sequence

 <220>
 <223> Primer for PCR

35 <400> 28
 gacttgatc ccaggggtgg caggcggtc 29

 <210> 29
 <211> 29
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer for PCR

45 <400> 29
 agcataagct tctagtaggc gttctccag 29

 <210> 30
 50 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 55 <223> Primer for PCR

	<400> 30	
	gacttggatc cgaagggaaa aagaaaggg	29
5	<210> 31	
	<211> 29	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Primer for PCR	
	<400> 31	
	agcataagct tttaatccaa atcgatgga	29
15	<210> 32	
	<211> 33	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Primer for PCR	
	<400> 32	
25	actacgagct cggccccacc acccatcaac aag	33
	<210> 33	
	<211> 34	
	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<223> Primer for PCR	
35	<400> 33	
	acttagaagc tttcagtcct cagcccccto ttcc	34
	<210> 34	
	<211> 66	
40	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Primer for PCR	
45	<400> 34	
	aatctggatc cataacttcg tatagcatatc attatacgaa gttatctgca ggattcgagg	60
	gccct	66
50	<210> 35	
	<211> 82	
	<212> DNA	
	<213> Artificial Sequence	
55	<220>	

<223> Primer for PCR

<400> 35
 5 aatctgaatt ccaccggtgt taattaaata acttcgtata atgtatgcta tacgaagtta 60
 tagatctaga gtcagcttct ga 82

<210> 36
 <211> 62
 <212> DNA
 10 <213> Artificial Sequence

<220>
 <223> Primer for PCR

15 <400> 36
 atttaggtga cactatagaa ctcgagcagc tgaagcttaa ccacatgggtg gtcacaacc 60
 at 62

<210> 37
 20 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 25 <223> Primer for PCR

<400> 37
 aacgacggcc agtgaatccg taatcatggt catgctgcc a ggtggaggag ggca 54

30 <210> 38
 <211> 31 <212> DNA
 <213> Artificial Sequence

<220>
 35 <223> Primer for PCR

<400> 38
 attaccaccg gtgacaccg cttcctgaca g 31

40 <210> 39
 <211> 61
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Primer for PCR

<400> 39
 50 attacttaat taaacatggc gcgccatat gccggcccct aattgcggcg catcgttaat 60
 t 61

<210> 40
 <211> 34
 <212> DNA
 55 <213> Artificial Sequence

<220>

<223> Primer for PCR

5

<400> 40

34

attacggccg gccgcaaagg aattcaagat ctga

<210> 41

<211> 34

10

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

15

<400> 41

34

attacggcgc gcccttcaca ggccgcaccc agct

20